<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:fb88bff5-eacd-4941-adf8-fd8ae012786c,g:07d605e7-adbe-4b08-8bef-e355af053dc0,d:2d1b55fadd3b49068baa4191851d4ddf--><meta http-equiv="Content-Type" content="text/html">


<title>pfe-20220403</title><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80L2ZyYWc6Nzk5YjY4MWY2MWI0NDYzMzhjYjM4NDA3MzRkNTMwNDUvdGFibGU6ZGQ2YjA3MjJjOWRhNDQxNTgzM2RjMjUzMTA1NDViNjUvdGFibGVyYW5nZTpkZDZiMDcyMmM5ZGE0NDE1ODMzZGMyNTMxMDU0NWI2NV8zLTEtMS0xLTI3NjcxMQ_861d88f9-337e-4ae9-8185-7ea2cebaa549">0000078003</ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80L2ZyYWc6Nzk5YjY4MWY2MWI0NDYzMzhjYjM4NDA3MzRkNTMwNDUvdGFibGU6ZGQ2YjA3MjJjOWRhNDQxNTgzM2RjMjUzMTA1NDViNjUvdGFibGVyYW5nZTpkZDZiMDcyMmM5ZGE0NDE1ODMzZGMyNTMxMDU0NWI2NV80LTEtMS0xLTI3NjcxMQ_63f0c0c9-e575-4221-883e-4a57566e799b">12/31</ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80L2ZyYWc6Nzk5YjY4MWY2MWI0NDYzMzhjYjM4NDA3MzRkNTMwNDUvdGFibGU6ZGQ2YjA3MjJjOWRhNDQxNTgzM2RjMjUzMTA1NDViNjUvdGFibGVyYW5nZTpkZDZiMDcyMmM5ZGE0NDE1ODMzZGMyNTMxMDU0NWI2NV81LTEtMS0xLTI3NjcxMQ_a64ca89a-d401-424d-a931-b4528aba1fc2">2022</ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80L2ZyYWc6Nzk5YjY4MWY2MWI0NDYzMzhjYjM4NDA3MzRkNTMwNDUvdGFibGU6ZGQ2YjA3MjJjOWRhNDQxNTgzM2RjMjUzMTA1NDViNjUvdGFibGVyYW5nZTpkZDZiMDcyMmM5ZGE0NDE1ODMzZGMyNTMxMDU0NWI2NV82LTEtMS0xLTI3NjcxMQ_12375af7-53a9-4342-bbca-2e59959556f4">Q1</ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80L2ZyYWc6Nzk5YjY4MWY2MWI0NDYzMzhjYjM4NDA3MzRkNTMwNDUvdGFibGU6ZGQ2YjA3MjJjOWRhNDQxNTgzM2RjMjUzMTA1NDViNjUvdGFibGVyYW5nZTpkZDZiMDcyMmM5ZGE0NDE1ODMzZGMyNTMxMDU0NWI2NV83LTEtMS0xLTI3NjcxMQ_c48b3562-93e8-43ac-9288-59c60d0eba20">false</ix:nonnumeric><ix:nonnumeric contextref="i1398ecf2c42643d5b2dd9bcf4fff0b09_I20220403" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xNzE3L2ZyYWc6MzBmNzYwODhkYzZjNDQyZGI4ZGY3ZmM5YWNmZWY1M2UvdGFibGU6ZmUxYWM0MTJlZTVmNDI4ZDllYTc5ZTZiYTlmZGRiODkvdGFibGVyYW5nZTpmZTFhYzQxMmVlNWY0MjhkOWVhNzllNmJhOWZkZGI4OV8yLTEtMS0xLTMzMjQ2Mg_0a991c04-6bf0-4771-8da7-660d402f5460">P9M</ix:nonnumeric><ix:nonnumeric contextref="i450d5b616e06425ebaaee6005832c8fc_I20220403" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xNzE3L2ZyYWc6MzBmNzYwODhkYzZjNDQyZGI4ZGY3ZmM5YWNmZWY1M2UvdGFibGU6ZmUxYWM0MTJlZTVmNDI4ZDllYTc5ZTZiYTlmZGRiODkvdGFibGVyYW5nZTpmZTFhYzQxMmVlNWY0MjhkOWVhNzllNmJhOWZkZGI4OV8zLTEtMS0xLTMzMjQ2MA_27089f32-847a-4637-a4e1-e91bd7e401e1">P1Y</ix:nonnumeric><ix:nonnumeric contextref="i5e9ce103164c49ccb09b4c678fcffc2d_I20220403" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xNzE3L2ZyYWc6MzBmNzYwODhkYzZjNDQyZGI4ZGY3ZmM5YWNmZWY1M2UvdGFibGU6ZmUxYWM0MTJlZTVmNDI4ZDllYTc5ZTZiYTlmZGRiODkvdGFibGVyYW5nZTpmZTFhYzQxMmVlNWY0MjhkOWVhNzllNmJhOWZkZGI4OV80LTEtMS0xLTMzMjQ2MA_7fe294f9-c1eb-430b-a394-96cf97edbeba">P1Y</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="pfe-20220403.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6bad63b428748a0834fa9a2e59c476f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i122e836787ac46bd93c33b8d47555aae_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24ea96b1525d41be8341ee5a131ff62e_I20220506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4e9531c688ae4b31893b5f87a304c2d9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie73edcb1d31e465f9103d2207066f5e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a4745cd5554d1eb8b1d79826aad315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a53ab8dd9143e6be8af5b147d6d71e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009eacb7c86e4007be20ca4b96113dc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8511b3061229447b8d673d4ed6657a87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13599ca943664af980623065c321dd7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b16103d299444aa2c0a72c19b99d16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6b7bd8b9124dbf83e22bd0622569dd_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie7bc679c8d654b3b92c0f11d31c2acb5_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2da06a72b434a938cbad5382ac9c5c1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i40cd2a56baa6486fb861a72bd0d777df_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icb85fc6d292248afa491676795094b05_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3d66469042d24d61aee64f79e5ebc4d8_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie80782db44a1440d8664ea8ab65de897_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibb8dbc4d15be490e815822eff9c60f03_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163f9f99a12342a0896b85733171bc90_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7824380bee3f49598b17671091055c0e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2f394b06174d1c85f8b8b89a0a9533_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee369d41246499390fcd23d443dc9e2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ed6f065a404dd683ecdc9c707769a8_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1abdf6353e2843e9b801379f10feb79f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8440a37a4494ed8be42223105528e13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7697515d3e4304a192f44ffcd35033_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603bb42954b34339a081e1b23751a898_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddfdbacf4fe84236adeb41ebd37549d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica0ea1ec52ad4c46b9d770c93afebb2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae6e41606a64b52b1ba264e3b858ab8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f7542c89b84f9c8eed5b8ae08c3b25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8af20d8086b440c8e34d1c7b297c77d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938e2f7b2f1e4fa895e67f30ada9c41f_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9039269f1207490282b0792e4917c741_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8a6e709faa664bee921de948064fc436_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i19096fc84ece474d801fc597dc47666a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d7f897933d548d98bf87110aaf1bec9_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f00a449e9674a358a30d89501ab7031_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1f0f568cb9864ad2bce94d853d87dfbb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13c34eec3902497ca2a0ef48303e2152_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba106cbd1d246e3908670cade753567_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9cc08a5833846f7b64c5ab42b042ae6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f1b96d7d1d4646a85f4e0fcfab00e3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b9cfd35dd344ae919c35379016730d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21f384aa3d24fe68143411f01dbd95e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc4170b088344bffab17c4cce8eac1f4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8524a5f7d441e9920a09b866380657_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatingsegment"><xbrli:measure>pfe:operatingSegment</xbrli:measure></xbrli:unit><xbrli:context id="i8c9b7c53ecb84f36a9040df3da6ae10e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12238265d1aa4e479cc4f7a3c2a6877a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94555cc427b04136be6b8eef46bd60cd_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603f28a8b8844abab7ee0491e1019632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dec1e006a3442f99a7d0dec8d60d874_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c5c90507e341c9b4342ba705adc4f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15468c66ef3641abb9d639d949cc97d1_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42315d643c849b194a9e9870cd9c000_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-03-11</xbrli:startdate><xbrli:enddate>2022-03-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1df79109b5e480892a961121084232d_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-03-11</xbrli:startdate><xbrli:enddate>2022-03-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9eb95056671943cc81072f3d6e3725dc_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6303bcbc1f416eaa7e6dbdd1161364_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id689b632ad7648e39340b4c4ecf7e7c5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a65ccb939e84c4dba5f3c3a4379e226_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad81607ed38143cb9d3235cb87296aaa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i382208453d554f3fb3da8caf335f8c1d_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9f5b419c0ed743538cdf1de741305959_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040295c1e7d942378f9fbcd2f5861c9f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e086e73918041fca5e1fb410bc4e687_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879a6d2e0cfd4ed994589944ca622816_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie10766bf0ae24289a930c0fcc615c947_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ff66ee3367f48d49bbf31222833091f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf907bd141547e19b74a026ba7f0134_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9449ddf354b403b9cf69f6f077bd1a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ia07d5ab3909a4980955e25483fd82b58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i39bbe12b10e2474a9db26d160b63a838_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9274520070475ca1f2161cd5dbf428_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674b1fff8a4b4219a4293016fe8c5466_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3105006d2547148f6cb559c3019e56_D20220104-20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-04</xbrli:startdate><xbrli:enddate>2022-01-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe020f44277e4451bc0f4ff8edbf0881_I20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b173b9f098a439191c3f825530bdf55_D20220104-20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:ResearchAndDevelopmentInProcessMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-04</xbrli:startdate><xbrli:enddate>2022-01-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i70b6a831bcc0470892350c70cf0f78e7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CorporateEnablingFunctionsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb9c7ff633e48efaba82fb171b6db9a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:GoToMarketModelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b20eb0b9e4d45da8ce4575d0fbe8876_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4e37c003dea455595ecad1c5558f769_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3e79252820bb4372bc5ba159b885f0b7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fb055b33a449afb47c4b9a9e9700f4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ae83a5d5594c108d70e5ba7679f49e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i549961d20ca8459a885500a5ff9919e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd6e951ae1fe486db8b6cb7e9b7a9b24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3c3c3969eee84bc8ad00958720166a04_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6764ff911980490d90a88335c9c244cf_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib7997f3c210e42e59fbf52fbd7f8225f_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied386218bb3c4c3b8d4fb4de5f0189f0_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idaee05a046b841ef8d7e6aefddcc8afc_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i61f95377cb5943d389feffc9f0841f5f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib8be90d4fa7d4c53b4bae11492692a69_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia28e9a23b0ed4ea08362cc89f563adcc_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b2b8f6094d14e579e10ac9083d0dd15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic350c30fdd434e918124f33a6867dab7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09931fa080534cb4a6b09d3324e26545_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if10d33e52d3442bcaaaaac234aecb668_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib52e1bff87a248e0b22e8ad724382bb3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0d8c3b6172ee44f8972b20b4b572c479_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idbe7e6276c1a4ec3a551624e7f1de9f1_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3978efe2842145f386795df734859f6c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a65e13457c493489ebc854aa0ee053_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7cf3f34d9c1402bb80ccb929ef82b9f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic08eaeb5343647d6a3de076ea1d335ab_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneAndBioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i96242ca8b97447f68763298df944081a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f81f90ccc9c420d8581eff30eeb192d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e21079a04843ccac94ff0193b25051_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80810fe7b1fb4e84ac1cdcf70d0251a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd22db8c38aa417981ad7a0e2adb8189_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6e5a93db534b438c8606c1f7937563_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6cff15f7abe44cf49e467a3297fab453_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i89c9124da14d4587b7cad1bc582c4951_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b73d6c111e444508e42f974c521096d_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1cf0746d1f7f4449a4bbe5dba43df7be_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516731bc71ea48fe8d48153c642aedab_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ea2ecde3c64d27999fbf67ea2b1427_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374a7b3695714592af18df30ab5e6735_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i367fc1c6e7b64b73a217ff29fda9d9f0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c07a699ef44298b841bf2c068bf51c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd924c84adf54e518c3e1d75cd69936e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia94a83f310e84ba4aa701380ba2edca2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f3def88b804499af53cf624612bf4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44a7c8fd9984ac28a7e2d7155a0847d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1023b68735d1408080ea06bff3ba9950_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c0d194acc94c2795747bf67459897d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9182925c87fd421b9a3ee71e067144da_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id93e24d58c7e43b58b6132641e42881a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce1c28205114c3b835fe5959d0fa198_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09ad8403c2f48ffa6768d5cb0c25dff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b8d860fd6b4952832cb789b371b3d4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6af5df56b84dd6b562218fa5add6a1_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab864c90b18646c4ae99b4a93fd52671_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3645413e985740eda0525681c093b00e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac9b309377d443e092ec47f072ae8917_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ad69d7dfb243d19c9b990d51361869_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6be370f501b4c01b623fd1a62663ae2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d4d7011fa9e426f83235daedfbc0d2b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e262309c1fa48079d1867ec5a658a7a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9c44e6d8fb4a709b48e7648b7a23e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1086a770a6af4910ab5e126d369ea8db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3f7158d6a44e7391143520201bad9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4155fa85584031b189ee801a6dc1d0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i899f8f926052420abb4e2b852a344789_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbd5be9a103f48e58baacf8c92602ca7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132528a30e7045eb8f6c246d64cf873a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70aeab5e7fb14a8b8e6ad8f076f52a1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6bd2a48b6742c0a3a49791feb6ee49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777f7d8b8dac411fa534243e37ef391b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i265d1ab5f2204789a03c901a23576f0f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3380e00e55b4fa8a65a2600c294edf2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6d637f8a7444503a4e6cf4de5380fa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ee17e41e72466b8fcf0845ac036899_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib345d23c234e46ff98d7f91c21cb82aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia606af2750074b6f92e3a1d980944cf2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7aac0a61606430e805b8d65b630d1d6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia86d7bc0c42142f6a114ddab32985469_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab4ec9706c88412ba8ce450b04555bfc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa6d26a6476a458881d852d3586cd5c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54352f1ccf2d448ca7264d501e48b8f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb87c734f7f347ddb27c69599af93d7d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541da0bebf1044f586fbc5deab12fdfd_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6a35176acb49c789c4bc2d7ca2bc1c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c26d1c2f7174d85aca8fe47b491fa6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7adbbe21ac41f0854cd160e5ee44db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484b8ae596c04bcd89a368b7a2e68298_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b27d4306b29494189af95f228ce9e9d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64feb9bb789644be90e0a3fb62415770_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3aca7059c60454d9dbd7882c92be026_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc9966961aa4a5eac7914b79fbb5de9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953ab40c38434820b511d8eae1e4f0f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083e2ed7f3074844ad343029b35a2f2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic844c100d4834aed866f277008b1d119_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb96f65c79e4e43a9b0f2ba8778da01_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ca6b12f388430abf8cc5a646e002a3_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a52fcde776142edb175b1102e0c7a0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79affbb0227f46e5b8193b279164f06e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefeb71ef3a024176a43e49c746f31e5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b55a96852094be28009c7eab13a9ad9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d273b96ee4c409bb5f4f8877c52d348_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aedb68827634218b6bb0e55c03538a9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8aaa4d14cf74e1aa03eebfa4b8718ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7490796ada7748128aa8d6bac9da74ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8277c08f9d904a77bc70208edc20943a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dacd2bb16c44f7fafc72fedcca37073_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e64d93f9ae4ba9b6e9871fb87b756e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e9c9c43dbc4ed6bed956603fbd59a6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4a0e30a6c343fbb4bc057f57758a01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id866d739037a40f399ffb04baa18b70a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1adbec93ff4152896ef3dbc266fe13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396fd3b33a1143059031b513c082f2aa_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie88a87477d86467e898ff362ffa2aa1e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec7cf6ce80c4d4799458ac9c7beab5a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0faa6c4d3af472faa12b8e11c63078e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27e6c6dba43a465bbd6ed102073943ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibde02c3ebcfe4f30b0ba0864e0956b5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1841bc47ec5849cb990c8e2fd67e0ceb_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0a252ab28d43a597fb4f9087606fbf_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd9e722697f43979694326c4506fc1d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c72b82f17544997a5bf97be6bd4e5dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb38c1d78e61439e9eeb9d60f7892ec4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd5c70a571b46aea9e14950eaa3a577_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic46d9886d139416099e1fe4e1c436cfc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fa62e7bd4584cacb0af7fb9e9a04dd9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib298875f836445ae8a6621e8d2dca823_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f5d26b1f0340bd9221e5289ffbcc08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937d9ad38d844977a86c316086936710_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecdc18a6c65448a7bf2bb84676aedf73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e7a3e26b1f4205a25688a89353b225_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id45f911275bc4aaab14275dd8cfe6095_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3237feda4c4489dbdc11b98eda3a5c0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia424a17af85d43a19699a8467ec27637_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ac2185b14e45618404196604b5111a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67bc35520f2a483cb6b9cdfa53bc64e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718ef01248f844da9cec0c790c09bb43_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f4fce547f7c4e05b2fd2b54f36b2f99_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980ed2156e2d46ebbaaac1fe61b299fd_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic970cf381542457eb1d31d8d05a944f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a92f46d466f4f0ea19618a069bc086f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88325aa4e3194b258b34676870fc5884_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e80bc24e5e4c6aae93be0b471eb98f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7477d180a840afa9c28f05c45db07d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1ecdb311a254f6d98d019c9fe38bdf0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24cf3e20cfab496184ca0a790855cfc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2092f8d599e4e11b19ac32005dfe23b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3805af9bb2814a7eb9b1cb8dc96bf885_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19cbdb5b38142acb2dcf9c0cb123ed0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id093ab2cce2548c29bd2e23e4b65c955_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7df2e8d36a4cff8704219305fa0bc2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad3f7d2bb3e4ecfa616ae5f1be4d97c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba54d9d67334d059112da451da77d20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9b249cb7b14accb08b47084b6eb3a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ba721cefcf41108731e9f656f2ac9c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f91e20641a5487e8960ffd765345898_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a9295e6baa49ac8c1971c3e2f49589_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d5c87710cb4cf6b2dcc21a22eee38e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b423cd5f8044aeebfa454f818203159_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559df6d8ac8b40abaccd506982c32750_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab549c119acd4314bd304269f3780fda_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029741954cac43309481482a59fa20ee_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215d247adb684998aa5d55f4dba4e4f5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3e0c38481b4b1e90caea4458c81e71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd33865dd9e149fc93d64b40cfde2f91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7fb214d9798460ea2ae1fd55eeb565c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19692c6f377647e7986f9362562da4e3_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5453ac09abb94063b45ec113cebe09ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3c2f2f374840e8a8a86086a4243ca6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0cf964e76614510b8932379c70dd5aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c47c001218d487792a980332f456adc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7a9e7252e6467a9d875689967e6b61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b1efc832b64c588a72817464d816f5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35cf5f9de62244cc8be4fcba4f7cd173_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7721b15b084a443f9c80866a92bffc81_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5daa53fe61464bb199949d6f116b3430_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6561ad527067439dac5114f8dd1472de_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i895ebe8dcdad4932a99763adef37fa6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba33fa09a0bb479986526c41985e2248_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ec0143ec854c2897cc4517221c9fd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e97e6292f19433898e6a4bb89ec456a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i287186eb6a974298a7425f7b06e010dd_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia091df0e14ae41eb852a4ff3e0d05bf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099e4c93c24442cea664ea3a40981096_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f5cb7438c644edbbef490f2b60c786_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48b94a8161f40a5a32b669f86d18f22_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79317728ed6542abaa35eedc73d7ee8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bcb394e9d4f4ec58625eac2ea7e53bb_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i468b1b161ad14b9d97c0f127846b153f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabfea622864b480896a73c7f050d548e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a18079dbef41d98ea4a6ab1cd9a190_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib568e9ca553c4320b3d05348eadd779c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i211fdae85534430ba6e76395bbfbbff3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1520d5b9360b4dccbc16aca3de72c6fa_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2060793d8a2b4589b4afe60d1c4124c8_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2cc927240ee49718a9da4c83c67c3f0_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i27d9dc24c3374f95a7196e54aed4d445_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if8bb7913d8c14e439bfef9e1f67ed399_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f29585765b5403ebfa7ac36c55ed8e3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9e0b582be5744723a93574247953ec62_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c18f829975a45c8b2772303aa6245c9_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69912f6e91cb4f54808b3e8f6d53582c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia005f37871144c8081897f52aee78eaf_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic79702f570114ca8aa26a3518fee3a60_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib4d035143a774fce8c1990d62a741fbb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98c5c9cd3d2644b3ae64e25bde3073fc_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id00e506e152345dfaca17bd236a853bd_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib574dd5d5f9a430289499455874d1ef1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie91268be5c3445fa978fbc2aa1e6509e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1b53d02b8c24768a1155d5c1b4dfff7_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f0f8441cb664a659b14b7508702ef4b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9323a1ccabfd4bd69e0ed1df96bcf347_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if40a973f4e744f1ea7561e3e8fb00fd8_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia12d191e668e411b9dfdb627695e3179_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d5076ab6d3647d3af23f0d5e94e2d8a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36f2b81121c4492694330f1d72200491_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80fac32edc9d4fe9b9fb1a6683a9e17f_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i675cd1e86ee94c82a4af543340567532_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ac4f5688687404498e8cb1412553fbf_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1b5682c5e4b467da08e6ed5d8a73d83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a79241f6454ff98bb9da3f918b54c1_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a48418dee947e18abd4864cc1d8ab4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib790556a844a4fb189d2de69ab2b2dac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64ccf7d575174b87877bde949d32ff1f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718b08327f864680b807c8f2f52d0d3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia837ea1226e943a79cc4e0d0d89dbf4a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6340c1c4b1144cae8226384c7015287d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e899807dd6a48b7a219649935f38539_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7380a325d8e64496b74a1606b3b2807c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2827e89952bb45e6a54899f79588fb37_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f5fec3ee294b9eb970e707b988f13e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea9c9bc1c7f45ceaff3818ebd6058de_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a35527a5038472e98fdfbbaad2dafd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4450eb2cfd8b48bda1906bc9fd2d49ce_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4a2976439c41d5ad62263cf59d8f1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2d5298a36045ac8ee86c89abe1c074_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610663b8b97f44e9948c1891c2e2900f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df1f5f5701e4199915b8bca1ad078fe_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5266d51fc0514f5394a4cbb10ea6f081_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98cb0e0e3bcd4d53803bacded9c4b4d9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-01-01</xbrli:startdate><xbrli:enddate>2017-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:context id="i4cf0bc1683994dabae0b09e4f4334795_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i013e5218ec03476580132ca96892fc10_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:OtherPatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i613377f8a86046149d6da3e3e6cb4bfa_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-01-01</xbrli:startdate><xbrli:enddate>2017-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>pfe:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i2621d6730855458f959b341448de9e27_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-01-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>pfe:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i9e43302017e04b1393a21ba82c9623e3_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2013-01-01</xbrli:startdate><xbrli:enddate>2013-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="lagoon"><xbrli:measure>pfe:lagoon</xbrli:measure></xbrli:unit><xbrli:context id="i107c540186ef402d97fd5639a25a37dc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-01-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8b7898a9cd2641bfbff7d24c6dfad2f4_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30a2c68c78884fae86e646356d6b9a41_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icaaf0596d764452bbcbac24bd260f815_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ida5befccee2e4efa94c1a66b4baf2890_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic8bd686116ea4dac90aeec1d623a28e0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iabc0f5e5976a4081820401402186fd35_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3c110eebdbb45e1a79a4c17192b29b7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i40ed83f9e549484e847fe007ec997de8_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c95d9722a724dfcb3d5eb05d4e5a3da_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3ccec203f4144a0fb669d187f4377351_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3152374dfa25418595a1c0308ecc6a23_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i41270b758c1d46fcbedebcbb44055380_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e7af85b3e4a4f98ad9b33d523f739d5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00164188d3ab4ba0a6525f0333129fd3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i43cf026e4ceb4512aeca1360388ccd6c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i11e19e5bb8cc49a6b0070c913874a10c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if5b9e8ab6e0d4cd1a5f8c0a2743cefd4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i87530cb66c58474f807cb29294dbcd86_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2d629aca7a2449a96eeb492739ebc60_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c07ff391c6949e49366878bf9642489_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i29a3b2c8b1c7462d9fa379cbb7056d6a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id921a82c38464bd88b73da3115bf2b7c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8a707be866f14de18ce2230a729d8119_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i374d2afe98284addbca9020d145b8a8e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e75354e487a4dc8af572674dfc8737a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5e80a0ae2b3a4bb58d29d5a14a0e3758_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i68a8d6e882a7477db4bdef5ada229a8a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i23b05a2dee4141d8aafbaece3b0f2a9e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i26c29fc52df0492d8adf588dd23eacd3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3c98ee0bda8749e4bb5bc3deb581e80f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib200840a55b74a4ba250410b4d846b8d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2da31f898f4d467bacc0fb123da37640_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20d0a20745c14c1281a88f27d679e887_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id3f74c09f5f0465f90b6c2736b56e403_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3622ef3f518d42449c5e4f3423f0bd86_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f203f618b4944d3928f406d4d9b3c09_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8e0583d1d904a65afac1e36a704af68_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i03bff54ac3e3492b941cf2880c0b04a1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i480524826e154d858ceed97bf478569b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia79b5ae25b904f9c9489c79a05f8ac5e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie1572b96b6bd44e18e5b7de528a81eef_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i56b6f4110e334aaca34cf65b91803525_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4aa8e10486f14cc9929e3f515e497185_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5761dda6d0904083928fc3e4dd368990_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa747d7722c0451cbf43d5994c727bd2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20367294350841ff8f8d103f66b27128_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic6f25f2250e04c79959c22e7d8dd40b7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a7e1209b9654b42884a80f3cbc035b6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa38542696af49449bec808dec503c3e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22329063ffca434184f5e54477c37d27_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibfc2f94d96c6497186ed529e92425b1b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13c3eeafa900479da2138733992b2636_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i464f59429cf449a1ab096ee576bda4ba_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4247fd55c65047fa90eb67e8ca54f06e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3825cc8f059a48539bf52a46a8495f99_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibbc4e0bd2ad1456c9f2a7fad2803084b_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6e4a1b1e4c04856a3682021abfdb171_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i67bb24f4746c4b9c8c51bb10c4620be7_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifd4ce5f051904dbf9441d4269e7cef9c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iea5e5c69dedf462fb8e78af7eef609f1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b6086c49fc047a19b337a5f6904926b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1a9cfec816743ccae7e7ddee1817fd7_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1180d8a0bb09417bbf62af96856e9382_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d35a5f7d57744e4913402ae016b2d68_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38b77cd344ef43889d191a17740ccf7c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i312153f7ba1f479ab467c39b2c5d2ff9_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i858b30e3471f40f3b0715d2260ee4fc3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22b45f70d46c44fab93b6cb968fde7d6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i167c294d808a4baea160301675828860_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2edaf2e90e324125ba42d8cdb377ddb7_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibf1e8f7edde548a1a8c88f472551ca96_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82bd332b07504350a19fb5ca2c765f9b_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i07167b12cbf3406b95c38cb9916a2809_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i73e290283edb4f8abb2b3dd3fa118093_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i763e39ccea79436fb64fa76bdcf1a286_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if6c58f343d9e4021b80feae0e6071b8c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if4db19eac381483a93032d162775f7c0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id4f5a7ba34e2472f801d20af2cc481dd_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa09128622de4a3ba3052989631fee82_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d34083b3baf463c820a2523f4b71ffa_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icfeea77fd8044250b9a58e054b46d17e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0002a141088e488aae7dc3008321793f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i88ff63e57253422498c526a43b85c2e1_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9831594f3d4d47f5a86f5fd43c2d2dc9_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i644e06c55f674618a3cf4b635f1b8793_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i17e1cf89c4ca4291b45b31f62c95dbd3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i75ed4cf33ca34e4a9bc6aa4d73178459_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b793d79c5ed44c38384530e981002e6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibc838b33cbd049e3866a6be07c55b9ef_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i730e7608c5d041de8a09917c7ea6b1b0_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i069a55b784a5444facc987514dfcbf0e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92eccd20d0d240fdba4fdcc076a3bd8e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic1ebbc94721f4b3d9729bb2e84e63849_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id80bcaaa63c94b439df9c4d2c987d05d_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6c258487c37448c7a5f7865c46dd6667_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i94b27e5834be4ed095ab7e46579bc9f6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iecde536e0bdc4a9298033ca562d335bb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2390737b19a14f2394dd4c7d06346f87_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ec1c6f5bd01474ca2851d3875cc2812_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i946d879e581c4bd98bb69c1c12d158bf_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if91945f6ed7240bfb57ae5a7c3c3eb2c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b33eb0b0c274277a6b11939ae2f5e4e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id7f9aa1074494b13b06bf4e30d1eab74_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7cbfaeeefa6743e6bd89506f62c4f5ba_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa5f87e4a8144775961301d9c4da571c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22eb186593d943b0a83b5a158a5c4bbf_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7647ea6b84924a64a6d35398e085a719_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13fdcef05287493ab8780f56121b4a9f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i75ac7c13b90b4b42b2f32593d8f144ea_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i131c61a3ac5f4e1fa3614c3292ba145e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia73c1afe171e45c883095fc4903b9d02_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf6831f047364b47a19a28060648adc1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i17ec224b285a408aab25ad7aa49baa92_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9331f572dca54312812dab029d25d4b6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80f8caf5dc454967b79771f3ed2a1a1c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i84f7316209254d369b391702633ea27d_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9e387a17a3e4284b4330917883bb632_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i933eefba8db34a6fb618d8eba93c2999_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9adaa23531147e385a170b2f139531d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iee7ae2a9acec4754a261164669b76ae9_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b63f86bb6a74083bf90380872a01bd7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib7ad61ebd0f7420ca92d477dbc2f9b9c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6734edd6cb5f4663a2779a9e64e461b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16409719261f43008f5bbaf2c0fa7843_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i893dd0e0ba9b4b7e9ba0fbb6cb8c0ab6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6e5f91c4c4c493986eda62f0c5b60a9_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia128c50ff4df4ed894d90e14461dab94_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8483472faf6c4201a992e4609257452d_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i63e93084b61840a29a027fd45290e750_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0956b534d13549b39a4f4c82c07de287_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0b1b7d3d21084227bad2e6d857b8691f_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib44fa39bb6d5456caeb94fff03f512b2_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc9f8478410041109d88625f91cf1fdd_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7d61326b704944419cce3fce1cebfeb6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia27c207acad449e7a064045a163e1d07_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5a7505f413e4b6b87c5d8d59c07cc8c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id8b4a02c10854ad0a881ad1c41403bbf_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic6bf0e1bdd7b4de695e41c0d1403502a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0ec0d207102a4ba3a04c43550b49d460_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c4fd02f8da94946bbd28441ccf00831_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6540f0b3a8d347bb8a81e0000e47d62d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i522df390299349d98c16cb7286a06a1e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1398ecf2c42643d5b2dd9bcf4fff0b09_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedmember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain>2022-04-01</us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain></xbrldi:typedmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i450d5b616e06425ebaaee6005832c8fc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedmember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain>2023-01-01</us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain></xbrldi:typedmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9ce103164c49ccb09b4c678fcffc2d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedmember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain>2024-01-01</us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain></xbrldi:typedmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f04f53b93c4f7d85d0d00977069a9e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d528d42f6414b6dae3a8bb680aeb22c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af3306ed56345c389e398557df7f547_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475612619a5342b28380c77a81b499d6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMTItMS0xLTI3NjcxMQ_19171ce3-7eac-44de-88e1-442fb4c70bab" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMTItMS0xLTI3NjcxMQ_19171ce3-7eac-44de-88e1-442fb4c70bab" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctMTItMS0xLTI3NjcxMQ_1138f874-8e41-4f4d-9d7d-a28c1b10695a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctMTItMS0xLTI3NjcxMQ_1138f874-8e41-4f4d-9d7d-a28c1b10695a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS04LTEtMS0yNzY3MTE_ae4f5815-c0a6-4920-8785-273dba4fe0bd" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS04LTEtMS0yNzY3MTE_ae4f5815-c0a6-4920-8785-273dba4fe0bd" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMA_06d8a0b1-c451-4c72-b22b-9033aeb116a0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtNi0xLTEtMjgxNTEz_b209faca-c8e6-4dd7-bf6c-55eac7390da5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjM_f33ccbd5-f25a-4a5c-bb0c-010a137a6a45" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtNi0xLTEtMjgxNTEz_b209faca-c8e6-4dd7-bf6c-55eac7390da5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjE_c2ea381b-8d9b-4370-9a21-42877e9195e9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctOC0xLTEtMjc2NzEx_61d8ddcb-3a39-4324-a806-487f6e354835" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctOC0xLTEtMjc2NzEx_61d8ddcb-3a39-4324-a806-487f6e354835" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi04LTEtMS0yODE1MTc_72029c23-6b87-4987-b96e-5041cc95eebf" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjI_c1290e3a-ff0c-42b1-9bca-82654dd4b085" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi04LTEtMS0yODE1MTc_72029c23-6b87-4987-b96e-5041cc95eebf" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjE_c2ea381b-8d9b-4370-9a21-42877e9195e9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtMTItMS0xLTI3NjcxMQ_4b4fbe88-3cb2-4640-9f1a-8ac1706c2b90" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtMTItMS0xLTI3NjcxMQ_4b4fbe88-3cb2-4640-9f1a-8ac1706c2b90" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtMTItMS0xLTI3NjcxMQ_5a3233be-5d0b-45ab-8135-98caad13d316" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtMTItMS0xLTI3NjcxMQ_5a3233be-5d0b-45ab-8135-98caad13d316" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtOC0xLTEtMjc2NzEx_b4727dc9-c3b1-4b38-83d3-b80d702f38fa" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtOC0xLTEtMjc2NzEx_b4727dc9-c3b1-4b38-83d3-b80d702f38fa" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi04LTEtMS0yNzY3MTE_5525066e-7044-4bf4-980a-6d148b9fd246" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi04LTEtMS0yNzY3MTE_5525066e-7044-4bf4-980a-6d148b9fd246" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtNi0xLTEtMjc2NzEx_23129a37-ce81-4831-af96-dea7200334d7" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtNi0xLTEtMjc2NzEx_23129a37-ce81-4831-af96-dea7200334d7" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMTAtMS0xLTI3NjcxMQ_ea4dc684-c14f-4225-9b3b-fa5fd712bb40" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMTAtMS0xLTI3NjcxMQ_ea4dc684-c14f-4225-9b3b-fa5fd712bb40" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtMTAtMS0xLTI3NjcxMQ_b4be2a4c-5a7c-4b6b-8119-dcd4822b159a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtMTAtMS0xLTI3NjcxMQ_b4be2a4c-5a7c-4b6b-8119-dcd4822b159a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi0xMi0xLTEtMjc2NzEx_45ca419e-09c7-41a0-bde5-030aa098e917" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi0xMi0xLTEtMjc2NzEx_45ca419e-09c7-41a0-bde5-030aa098e917" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi02LTEtMS0yNzY3MTE_7f904f59-2b94-4cfa-8098-6974d7eff8d9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi02LTEtMS0yNzY3MTE_7f904f59-2b94-4cfa-8098-6974d7eff8d9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctNi0xLTEtMjc2NzEx_e3b05536-3587-44ae-9465-b97957d12fe5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctNi0xLTEtMjc2NzEx_e3b05536-3587-44ae-9465-b97957d12fe5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS02LTEtMS0yNzY3MTE_d746bb0f-57d5-496a-9af0-7105665fca23" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS02LTEtMS0yNzY3MTE_d746bb0f-57d5-496a-9af0-7105665fca23" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMA_06d8a0b1-c451-4c72-b22b-9033aeb116a0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi02LTEtMS0yODE1MTM_571efee2-2bbb-4760-8e1b-9226c0cbde5e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjE_c2ea381b-8d9b-4370-9a21-42877e9195e9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi02LTEtMS0yODE1MTM_571efee2-2bbb-4760-8e1b-9226c0cbde5e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjI_c1290e3a-ff0c-42b1-9bca-82654dd4b085" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctMTAtMS0xLTI3NjcxMQ_e7ddecf5-5458-4f1d-aaa7-7270d87bad80" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctMTAtMS0xLTI3NjcxMQ_e7ddecf5-5458-4f1d-aaa7-7270d87bad80" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS0xMi0xLTEtMjc2NzEx_c623093e-c8b4-4007-8d99-1f123c5c0f7b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS0xMi0xLTEtMjc2NzEx_c623093e-c8b4-4007-8d99-1f123c5c0f7b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMA_06d8a0b1-c451-4c72-b22b-9033aeb116a0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy02LTEtMS0yODUyMTU_ea296c5f-91bd-4fcd-b3bd-c9370e55bbbb" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTk_0f0d2b9f-4fc4-408d-b35b-92f657ae7162" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy02LTEtMS0yODUyMTU_ea296c5f-91bd-4fcd-b3bd-c9370e55bbbb" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTc_c165efd6-604d-44b8-9c0a-9003848351e6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtOC0xLTEtMjgxNTE3_edd5351b-a558-4a8b-ba0c-bdffaa44eb26" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjE_c2ea381b-8d9b-4370-9a21-42877e9195e9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtOC0xLTEtMjgxNTE3_edd5351b-a558-4a8b-ba0c-bdffaa44eb26" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjM_f33ccbd5-f25a-4a5c-bb0c-010a137a6a45" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfNC0xMC0xLTEtMjk2ODE0_c155a9e6-d1bf-498e-b414-dababf4ce19d" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjc_ac3cedf0-3f46-414c-88bb-b1fd7293873b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfNC0xMC0xLTEtMjk2ODE0_c155a9e6-d1bf-498e-b414-dababf4ce19d" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjk_b5d9c432-b3cf-4071-a16c-c114a3f72b6e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtNi0xLTEtMjc2NzEx_d0a75abd-9211-4a4e-903a-073095a2fc3f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtNi0xLTEtMjc2NzEx_d0a75abd-9211-4a4e-903a-073095a2fc3f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtMTAtMS0xLTI3NjcxMQ_013d88bf-e477-40bf-838e-46267f8d960a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtMTAtMS0xLTI3NjcxMQ_013d88bf-e477-40bf-838e-46267f8d960a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy00LTEtMS0yODUyMTI_c7677d98-5c35-43dd-9e2e-5976d93ff2df" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTk_0f0d2b9f-4fc4-408d-b35b-92f657ae7162" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy00LTEtMS0yODUyMTI_c7677d98-5c35-43dd-9e2e-5976d93ff2df" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTc_c165efd6-604d-44b8-9c0a-9003848351e6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtOC0xLTEtMjc2NzEx_9f08e456-f873-4076-a796-696009468804" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtOC0xLTEtMjc2NzEx_9f08e456-f873-4076-a796-696009468804" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMi0xLTEtMjc2NzEx_28ad7b25-cb80-4844-a6f1-748ce587ea0e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMi0xLTEtMjc2NzEx_28ad7b25-cb80-4844-a6f1-748ce587ea0e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi0xMC0xLTEtMjc2NzEx_447a5f64-809c-4911-b062-6052094465ca" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi0xMC0xLTEtMjc2NzEx_447a5f64-809c-4911-b062-6052094465ca" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfMy0xMC0xLTEtMjk2ODE0_c5cb44ab-24e5-4fc4-92dc-4eb4fc8cae09" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjc_ac3cedf0-3f46-414c-88bb-b1fd7293873b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfMy0xMC0xLTEtMjk2ODE0_c5cb44ab-24e5-4fc4-92dc-4eb4fc8cae09" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjg_70bfd400-a281-47c2-9d4b-cc1ed4bbd4c0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtNC0xLTEtMjc2NzEx_59f8d36d-0eb5-4f57-a7ee-c63f86380885" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtNC0xLTEtMjc2NzEx_59f8d36d-0eb5-4f57-a7ee-c63f86380885" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtNi0xLTEtMjc2NzEx_06cd7ec5-8532-404c-bc84-8690df805a28" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtNi0xLTEtMjc2NzEx_06cd7ec5-8532-404c-bc84-8690df805a28" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtOC0xLTEtMjc2NzEx_9f6fdf61-98b0-4030-879c-b2ad74a5fa35" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtOC0xLTEtMjc2NzEx_9f6fdf61-98b0-4030-879c-b2ad74a5fa35" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS0xMC0xLTEtMjc2NzEx_3cd8b7e1-4ad1-4175-b44c-e32d35500eb6" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS0xMC0xLTEtMjc2NzEx_3cd8b7e1-4ad1-4175-b44c-e32d35500eb6" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMA_06d8a0b1-c451-4c72-b22b-9033aeb116a0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTktOC0xLTEtMjc2NzEx_dcd2ac17-a868-492e-a22a-e4de35e649a1 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTgtOC0xLTEtMjc2NzEx_3320bbfb-12f1-4bbf-a9d1-0603b98a8eba id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTktNi0xLTEtMjc2NzEx_d418b89e-6512-438b-a053-9a1119c71c5e id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMjItNi0xLTEtMjc2NzEx_7436a958-d57a-42fb-863b-f4abb026ee45 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTgtNi0xLTEtMjc2NzEx_3ae80567-f959-47b8-b366-bd58af307786 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMjItOC0xLTEtMjc2NzEx_fbcc7043-4355-47ba-a81b-77da6c2237d5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMyOA_3fec174c-cf24-4175-8265-d49416dc2686" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTEtOC0xLTEtMjgxNTE3_2812be2c-3fc6-457e-994a-cd2246c8d472 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOC04LTEtMS0yODE1MTc_f3182c25-9f3e-43cc-9b64-8459f9742e59 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTEtNi0xLTEtMjgxNTEz_87fda6a1-5675-47b9-ad80-de0956176f71 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOC02LTEtMS0yODE1MTM_7eb5963e-14fe-4480-9f88-675ff727c31e id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNS02LTEtMS0yODE1MTM_82670197-e57c-44b2-ab10-dbb1282dc5c3 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNS04LTEtMS0yODE1MTc_c9eefef7-e981-429f-bc44-d3c2c87ffc81 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOS04LTEtMS0yODE1MTc_4975ff5c-321c-4afc-9d7e-2c4a3a3436c1 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOS02LTEtMS0yODE1MTM_67508b3c-d02a-4fec-9005-02cf354f360b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjE_c2ea381b-8d9b-4370-9a21-42877e9195e9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNy02LTEtMS0yNzY3MTE_5c7e31d5-580b-475f-8ff9-77bd3b5e9bbb id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNy04LTEtMS0yNzY3MTE_b4714f00-d863-44e9-87d3-17834b4e02cd" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMxMw_c73b5615-0036-48ea-b33d-cda250629053" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfNS04LTEtMS0yNzY3MTE_8b3c45b7-cedf-4f13-ae73-475321ece20e id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfNS02LTEtMS0yNzY3MTE_19054934-6604-406a-985a-c159e856f10e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzUz_03a8e262-3f2e-437e-96c4-a4f5d4fcf932" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNy04LTEtMS0zMTk5MDA_e48f801d-db53-4f35-b551-cae032c9b50b id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNy02LTEtMS0zMTk4OTM_4250241b-aa0d-46cd-8fe3-fc9e0399fb77" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RleHRyZWdpb246NTMzNDlhY2U1YTM0NGM5Mzk1ZGZmMmQ3OTY0YjA2ZGFfMTY0OTI2NzQ0MTgxODU_27cebdc3-244c-410e-84ff-421e8d4c79dc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMy00LTEtMS0yNzY3MTE_95f4daf6-14f1-476d-94fc-e7cd3aed2aa2 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMy0yLTEtMS0yNzY3MTE_85ae3aae-07b3-4a24-8f16-3277bfbc5e39" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzc3_7e5667d7-4f1d-4a81-8095-ef63a3345b55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOC04LTEtMS0yNzY3MTE_92804a6e-7ffc-4ba7-a2b2-28978bdff81f id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOC02LTEtMS0yNzY3MTE_ac0c3825-2dc7-4645-8115-597a9f66b60b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzI4Mg_6756ee43-1095-4a17-8861-455db1f58311" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNi0xLTEtMzI2Mzcw_167b2ce4-4354-4d76-b319-f853d63a4b84 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNC0xLTEtMzI2Mzcw_16435377-2cfa-4aaf-a4e4-cc6f4f7dfa2c" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTg_ac6803fb-ec6d-447e-b765-42254754a809" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi0yLTEtMS0yODE0NDA_ac2af997-b672-4707-8eee-66132d114f36 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi00LTEtMS0yODE1MTA_cfe87283-5ddd-462a-beea-7b055c8801ab" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjI_c1290e3a-ff0c-42b1-9bca-82654dd4b085" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC00LTEtMS0yNzY3MTE_6c4fb955-37e5-45da-a6e0-c9549d36034e id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC02LTEtMS0yNzY3MTE_fb76c241-7501-4ced-8b51-ce685514d8a6 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC0xMi0xLTEtMjc2NzEx_f4626249-ba42-40f4-a656-5a8ea1c87df4 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC0yLTEtMS0yNzY3MTE_f2e69915-d6b8-4db4-94dd-f75ff2ad3579 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC0xMC0xLTEtMjc2NzEx_038ffe18-8497-4a2c-beef-ce6f274507ea" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RleHRyZWdpb246OTQ3Mzk5YjEzNWZlNDcwNzgyYjQ1ZWYyYjQ0N2U5NDFfNDM4_7eaa69a0-dadf-4575-a953-f6a33fbb79e2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMi02LTEtMS0yNzY3MTE_7e1e8b5a-5ea4-4ad6-973e-b65316f17d96 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMi00LTEtMS0yNzY3MTE_855e2e97-d90a-4fcd-ab23-213c92d6eaef id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTAtNC0xLTEtMzI2Mzcw_f7f369f9-1f89-4ae7-bfe1-c338d38308cf id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTAtNi0xLTEtMzI2Mzcw_688175bf-d067-49fa-abe6-e27106330922" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTk_0f0d2b9f-4fc4-408d-b35b-92f657ae7162" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtMTItMS0xLTI3NjcxMQ_8a9aa773-db98-4c1e-8086-12db606fc14c id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtOC0xLTEtMjc2NzEx_b78f4ec6-698f-46ca-aba7-6e5954e408e5 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtNi0xLTEtMjc2NzEx_e1c1c997-b2bb-4ae9-9267-044f4d906683 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtMTItMS0xLTI3NjcxMQ_9b6f4495-e341-4efb-9903-69c328112172 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtNi0xLTEtMjc2NzEx_179d4b0a-534e-4fea-a0be-5f228e91e836 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtMTAtMS0xLTI3NjcxMQ_33ba152c-7823-4329-b3f2-3d404d6d9548 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtMTAtMS0xLTI3NjcxMQ_087dfb94-7c6f-4e9b-900f-67ff5c378c54 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTktMi0xLTEtMjc2NzEx_beeba019-39f0-465c-b959-944171c879ed id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtMi0xLTEtMjc2NzEx_b07022ad-18f2-4c55-868f-cdf4c887aeaf id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOS0yLTEtMS0yNzY3MTE_018309f0-7a11-4ed6-a151-a51cfee5df72 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtOC0xLTEtMjc2NzEx_4a29e1b9-3a58-4c48-b534-aedc1c22623c id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOS00LTEtMS0yNzY3MTE_fad73cc1-1fea-42aa-891d-111d3d0b3ab3 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOC0yLTEtMS0yNzY3MTE_f4b961e6-8642-4342-be72-9e24e9a7aab9 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtNC0xLTEtMjc2NzEx_8c3a1a3f-f874-458c-b251-00c79bfd6628 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOC00LTEtMS0yNzY3MTE_80d7ee16-c896-4ba5-81a4-c487b104ae86 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTktNC0xLTEtMjc2NzEx_19d46b75-cd4d-43cf-8262-f512c092a96c" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC04LTEtMS0yNzY3MTE_7e0b284d-3912-4c48-b9d9-cb3a314fccfd id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC0yLTEtMS0yNzY3MTE_0d9b45c5-8f47-43f7-ae3e-4ee8228134a4 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC00LTEtMS0yNzY3MTE_7ddfd518-ab9a-40cb-b50e-75c9144adc65 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC02LTEtMS0yNzY3MTE_9c863ff0-df81-47e0-9353-ad38d1182c06" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzI4OQ_1a61c783-e703-413d-8352-d4238e74ecaa" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTEtNi0xLTEtMjc2NzEx_2ee6aaaf-f7e8-4fec-85c8-628513b4e6dc id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTEtOC0xLTEtMjc2NzEx_28ab9b07-0518-42b4-a14a-7015f10862b4" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RleHRyZWdpb246MjA5NjIzM2QyNjUwNGIwOGJkZTBiMjViZWYzM2Q1NmVfMjY4_dabf21b7-d37c-4a41-9d8e-58efc178ea1b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMy04LTEtMS0yNzY3MTE_5c3b7097-6c4d-46bd-b0b3-090fd368b19a id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMy02LTEtMS0yNzY3MTE_36d83234-c8c3-4408-aaea-d973af7823b9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMzEzNQ_678dec91-ae9c-4a98-8277-e47d087a1892" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOS04LTEtMS0yNzY3MTE_ff27b6a5-982f-43bc-8996-69855833dc2d id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOS02LTEtMS0yNzY3MTE_052bbe79-4b0d-4b5b-8fbc-8b2cc269b555" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU3Nw_63b28fd3-0799-4eba-a4aa-844531357200" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMTItMS0xLTI5OTE0Ng_2910f94a-d330-45c5-9b42-4b629e61ea5f id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItOC0xLTEtMjk5MTQ2_ba0e3fdc-d854-43e7-b081-7bfe6944c08a id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMTAtMS0xLTI5OTE0Ng_ffce3647-e8e8-4863-b194-25c81b01386c id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItNi0xLTEtMjk5MTQ2_1bf0ce7a-51b4-419a-b94d-3f53b64e624a id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItNC0xLTEtMjk5MTQ2_f0eaaf7d-927c-443a-a01f-e53a47ef2358 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMi0xLTEtMjk5MTQ2_d6acc190-843f-4473-8d30-c3187a1c63a5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfMTAxMQ_cdc7731d-756a-495b-a584-62d272f41c75" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS00LTEtMS0yNzY3MTE_abc1ff6a-38f5-4dfd-9e91-8f449d1110e3 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS02LTEtMS0yNzY3MTE_a6282636-1540-47ab-a95f-adeec336a91b id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS0yLTEtMS0yNzY3MTE_3f7fe3a5-46e3-4100-a87d-5dfeab97bc8d id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS04LTEtMS0yNzY3MTE_b48ae1be-01d5-47fe-bde0-63f6150b4ce1" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzM2Mg_edc25c48-81c3-4be7-a0ac-8889c9442212" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOC02LTEtMS0yNzY3MTE_f4f651cd-5131-441b-87e6-99be1a15ec71 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOC04LTEtMS0yNzY3MTE_c564b312-299e-4d8a-ae5b-e9a85e91e012" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU4OQ_60d31938-9d8b-4d11-a712-cf95cc0ffe74" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi04LTEtMS0yNzY3MTE_20ba2f94-737b-4555-b063-ccd2d40a7306 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC0yLTEtMS0yNzY3MTE_99bd3141-c260-4d8e-811d-7fbc73e08628 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi0yLTEtMS0yNzY3MTE_3818c13b-e690-40b9-8d2f-3eac330e4eb6 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC04LTEtMS0yNzY3MTE_1c3bf326-9b92-422c-ad6c-58f7a9707883" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg2Nw_3d62db41-e8eb-42cc-a2d5-9efbe697b2b6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNS00LTEtMS0yNzY3MTE_35f91b9a-90bb-48b6-bcc2-6cd42a933320 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNS0yLTEtMS0yNzY3MTE_c5b139c5-b094-4883-afe0-c5694e09282a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjA1_fa57e0b8-bc58-4643-be68-d1b5479baf10" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNi0xLTEtMjg1MjI5_c4a96786-467c-4aef-9742-15f3f32e11de id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNC0xLTEtMjg1MjI2_7e11c141-ce07-44b3-9ab4-13794adb9c23" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTc_c165efd6-604d-44b8-9c0a-9003848351e6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtMi0xLTEtMjgxNDQw_d34711e7-1382-42a5-8d3c-bd024d407ca0 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtNC0xLTEtMjgxNTEw_6276ccc6-46a6-45c7-8189-6ed1694f8907" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjM_f33ccbd5-f25a-4a5c-bb0c-010a137a6a45" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTMtMi0xLTEtMjc2NzEx_2bd8ed9a-1a0e-4a96-a303-b988e3951abf id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTMtNC0xLTEtMjc2NzEx_caacd079-b7fb-4dad-bb39-2db7c0de1be7" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzY3_c76ff992-e94e-4d84-bf6e-7b85e7360234" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNC0yLTEtMS0yNzY3MTE_4b5017aa-9144-4c9b-bee6-e1c6563fee7c id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNC00LTEtMS0yNzY3MTE_a7e81a59-90a1-4278-a818-49211405c72e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RleHRyZWdpb246NGE0ZGQ1ODkzOTIwNDA0NGE0MWQ2ZDQxNWJkNGVkYzhfNzY_e0081be1-6aaa-449b-9c2c-2220fefb210c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItNi0xLTEtMjc2NzEx_5a660e0c-8cc4-4031-9236-f18e7e39fcd7 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMTQtMS0xLTI3NjcxMQ_a6207a6d-7400-4f2d-a597-c9c1a160927c id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItNC0xLTEtMjc2NzEx_85928fcd-63d7-47f7-9a31-8a50ff87b0ea id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMi0xLTEtMjc2NzEx_038534ce-0fdf-4af2-869c-ffc3554969e6 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMTAtMS0xLTI3NjcxMQ_626aa49f-8659-4432-bdc5-b2b85f5e2012 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMTItMS0xLTI3NjcxMQ_2c1eb10e-ac65-43b2-8aa2-442a2ab4e165" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMTIyMg_046435b5-0147-49d5-964f-7cfac17b9050" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTQtMi0xLTEtMjc2NzEx_66860d4f-bf90-4777-b536-82fc8a9398c0 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfNS0xMC0xLTEtMjk2ODE0_66860d4f-bf90-4777-b536-82fc8a9398c0 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTQtNC0xLTEtMjc2NzEx_eecc232e-7edc-461a-a089-519f5a37633b id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfMi0xMC0xLTEtMjk2ODE0_eecc232e-7edc-461a-a089-519f5a37633b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjc_ac3cedf0-3f46-414c-88bb-b1fd7293873b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTgtNC0xLTEtMjc2NzEx_1e62bc50-a0e6-41c4-b80a-09b474ff7476 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjItNC0xLTEtMzI2MTQ4_d751a480-5b26-4783-96ae-3684cefc9fda id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTgtNi0xLTEtMjc2NzEx_3ac30c5b-00f8-4696-a5ee-b42e244d9a76 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjMtNC0xLTEtMzI0OTE3_ce72a88a-cf8a-42fa-a0f7-4354d39e5389 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTctNC0xLTEtMjc2NzEx_d00f9623-48c1-480d-be2e-93a7718416ec id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjMtNi0xLTEtMzI0OTI0_5cd81174-83bf-484e-a172-9439d0f07e61 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNC0xLTEtMzI0ODM3_45b0a2bd-e97e-48b8-b21a-7c6bc37f33da id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTctNi0xLTEtMjc2NzEx_52203469-5687-4bd4-9249-d6233cfb6e81 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNi0xLTEtMjc2NzEx_668dca05-7cd7-4aff-bd62-a96c7ab4f45b id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjItNi0xLTEtMzI2MTQ4_d9a0d048-174c-40e8-af5c-323e1e691b49 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNC0xLTEtMjc2NzEx_24622a70-1c32-4753-8e56-b3766a257cff id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNi0xLTEtMzI0ODM3_efa2a47f-256b-4dcc-b7a4-96c2504a45d6" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMyNw_be1a8271-a2c8-4eec-93a2-3001ad08e395" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfOC02LTEtMS0yNzY3MTE_db3b93fe-0347-443f-b16a-83ec45151ad7 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfOC04LTEtMS0yNzY3MTE_2799de80-9dc3-4d1f-9ec3-163e155e0bad" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RleHRyZWdpb246MjA5NjIzM2QyNjUwNGIwOGJkZTBiMjViZWYzM2Q1NmVfMjY3_5281c62b-bf4c-4797-bd95-95f9b0b5c0c7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS0xMi0xLTEtMjc2NzEx_c67ac17e-5db8-40b5-9ad7-f1c3d95e81c0 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS04LTEtMS0yNzY3MTE_6ed6b336-4e2d-40f6-9122-d28d69facdc6 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5NzQ1NA_117a8570-fa54-4982-88d3-d6756d781e6a id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS0yLTEtMS0yNzY3MTE_e8e0ef2a-2561-4721-875a-9ad1ead4317c id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS02LTEtMS0yNzY3MTE_daf78c02-2ecf-4cfd-ad5e-f48f0e03531a id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS0xMC0xLTEtMjc2NzEx_7f83554d-ab47-412a-88c4-614b6892d3e2 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5NzQ1OA_1f669da2-6027-4185-8855-dce9a5c48ba0 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS00LTEtMS0yNzY3MTE_fcb0d532-e28c-4f1f-8592-5360ccedfbb5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMg_9f5db33d-320f-436a-9103-2cb6eff909db" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNS00LTEtMS0yNzY3MTE_803a47fb-7358-49c3-ac1a-82abccf579d7 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNS02LTEtMS0yNzY3MTE_197965ee-9a64-4a8a-b9a2-93d7276c1e25" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMzMQ_7c368f4b-d77c-42ed-920c-158e8df2d670" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMTItMS0xLTI3NjcxMQ_a21913a4-997d-4ca8-b133-e70674d929a5 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktNi0xLTEtMjc2NzEx_ad1b98a9-6051-482d-bf7c-1bcc271e0d9f id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktNC0xLTEtMjc2NzEx_b65b4566-138a-47c4-b24d-be27ddde9841 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMTAtMS0xLTI3NjcxMQ_559d0b56-8d4e-4026-92bc-ae9cec9d7332 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMTQtMS0xLTI3NjcxMQ_5b06c9d6-b5ca-4c74-95f2-ceeb3407384d id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMi0xLTEtMjc2NzEx_2205dcd7-ee08-4153-b3d3-9105035fbef6" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMTIxMQ_a8d1e4eb-8630-4877-b3c9-875daa4462a2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNi0yLTEtMS0yNzY3MTE_ab37ad5c-8b7c-4f00-8098-b65bad65f863 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNi00LTEtMS0yNzY3MTE_25e1ff8b-0c44-4915-8906-a36216b441bc" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjE2_a813c330-4403-4a34-a080-62b4556c97b8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfMy02LTEtMS0yNzY3MTE_85bf167d-2617-49a4-9930-f7d14f5d58b3 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfMy04LTEtMS0yNzY3MTE_134a22de-b232-4005-a750-d2cf6cca8ef0" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzYz_154b00ab-1e97-4774-add4-c86b8358f3e0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi04LTEtMS0yNzY3MTE_22d1db9b-7e5b-4aa7-8cfd-fd7d43e08dc5 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi02LTEtMS0yNzY3MTE_739511f4-c963-4ada-9086-92f84fd114a1 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi00LTEtMS0yNzY3MTE_97ee3fcb-af53-4f1f-90a2-fad1d8d02767 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi0yLTEtMS0yNzY3MTE_5c12f0ca-81a6-41db-b277-5097a60dc6cb" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMyNA_b8c06b30-d95f-47ac-b79a-f39e34322ae6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOS04LTEtMS0yNzY3MTE_d1b1c5b6-3b2c-4717-a68c-b4094f5e42bc id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOS02LTEtMS0yNzY3MTE_5701b7ca-9019-4502-92c2-440d87214ffe" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMwMQ_3b2655fa-b2d8-4ac0-9b23-85f366110ca0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTYtOC0xLTEtMjc2NzEx_b8a79dc3-a3ba-401b-8608-8c0704512110 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTYtNi0xLTEtMjc2NzEx_6abb5122-1461-477e-b93f-b9ccf2d62639" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMxNA_dadd1793-8807-4149-8ae8-090e6c8cf72c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNC02LTEtMS0yNzY3MTE_2c57d765-f827-4f15-a9e8-787a87af0585 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNS04LTEtMS0yNzY3MTE_4de626f1-4eae-42b5-ac3f-60b3cb6a5f6d id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNC04LTEtMS0yNzY3MTE_f79bcad1-6f66-41a8-a88f-eb8ab43af4f1 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNi04LTEtMS0yNzY3MTE_66600840-6073-42fe-a33f-9f3df94d37ff id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNS02LTEtMS0yNzY3MTE_8aecbe76-d43d-4ba2-b117-f34f86fdfc91 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNi02LTEtMS0yNzY3MTE_9d71f124-7628-4b82-8a15-1e3089160b25" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RleHRyZWdpb246NTMzNDlhY2U1YTM0NGM5Mzk1ZGZmMmQ3OTY0YjA2ZGFfMTY0OTI2NzQ0MTg1NzE_cfe8e9f3-7ad3-4d78-8df5-3213796bf562" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItOC0xLTEtMjc2NzEx_c4db10eb-dea2-42bd-a100-c51b0ebccec3 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtMi0xLTEtMjc2NzEx_8b9ae502-9216-4a1a-85ef-2136794acefb id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItMTItMS0xLTI3NjcxMQ_b8133fd6-78e0-4498-bdd9-a8e64b0045ee id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtOC0xLTEtMjc2NzEx_fa3d4dc0-9267-421b-9644-385db98051ff id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtNi0xLTEtMjc2NzEx_cbcc2ad1-94b8-4653-9771-a9f022a67f71 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItMi0xLTEtMjc2NzEx_a48688c4-b6c2-4fdf-a2fa-de3f2d607e61 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtMTItMS0xLTI3NjcxMQ_400c5f95-e44f-48f3-a893-19e26c9b7992 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItNi0xLTEtMjc2NzEx_65964656-ccae-4029-8e77-65a9e8a2cd41" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjQtNi0xLTEtMjc2NzEx_1e1c035a-9a27-420b-9fe1-55b2e791b25b id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjQtNC0xLTEtMjc2NzEx_6e353de4-2668-43b8-bd03-bbedc389d306" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMwNw_95743234-3c54-4c2b-ac3c-691f38de9eec" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTMtNi0xLTEtMjc2NzEx_034771d1-a296-4669-8609-d55e8a066216 id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTMtOC0xLTEtMjc2NzEx_ca263689-3166-4d00-8e49-e515a82eba8a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU4Mw_a5ef37ab-7e53-4d47-81bd-b84e6a4de43b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTktNi0xLTEtMjc2NzEx_fd615c2a-d6b7-49fa-9c6c-93f59cbd386f id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTktOC0xLTEtMjc2NzEx_ebecca67-12a5-4b67-ac35-1dfd4c01b804" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RleHRyZWdpb246YzBlNjg4N2M4YzVmNDZiMmJlYTQ5MDRiZmFkOGY3NThfMjQx_f4db10cf-819e-4685-a854-6257df518b15" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_1"></div><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">FORM <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF84Mg_1093b621-92b0-4994-b086-7bce0fc00feb">10-Q</ix:nonnumeric> </span></div><div><span><br></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF84Nw_fbc300bd-4f4b-4ce6-91c6-64c3db7ed6ea">☒</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8yMTE_71d1efd7-caaf-49a5-a177-86bffb2d6c11">April&nbsp;3, 2022</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8yMjA_d80ade94-0de8-4a52-9315-6a227ea3b04c">☐</ix:nonnumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the transition period from _______ to _______</span></div><div><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8zOTI_838e1099-6287-4100-aea9-974a880a5877">1-3619</ix:nonnumeric></span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">----</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF80MDI_05064da5-8d29-4f9c-bb3b-edbd834564d2">PFIZER INC</ix:nonnumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6ZjVkYmNlZTVhNGFhNDNmMTgwZmUxZDFiNWE3Mzc1NjgvdGFibGVyYW5nZTpmNWRiY2VlNWE0YWE0M2YxODBmZTFkMWI1YTczNzU2OF8wLTAtMS0xLTI3NjcxMQ_57f42cc7-6073-4ef3-8f99-1f11bfc81976">Delaware</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6ZjVkYmNlZTVhNGFhNDNmMTgwZmUxZDFiNWE3Mzc1NjgvdGFibGVyYW5nZTpmNWRiY2VlNWE0YWE0M2YxODBmZTFkMWI1YTczNzU2OF8wLTEtMS0xLTI3NjcxMQ_fe62cff3-26d2-4fe9-a9a7-a2e46eed1c45">13-5315170</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></tbody></table></div><div><span><br></span></div><div style="text-align:center"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8yMTkz_fd3633bd-958e-464c-99e9-3818ae5bbbdf" continuedat="i30f83cff02784dba987712d8be7b91e5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">235 East 42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">nd</span></ix:nonnumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i30f83cff02784dba987712d8be7b91e5"> Street</ix:continuation>, <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF80ODc_ef9ac0eb-66fd-4c1b-828e-13ba509b07ac">New York</ix:nonnumeric>, <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF80OTE_0e2bf037-3b76-44c9-b382-c4426f6d8c29">New York</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF80OTU_fdd7731f-137f-40b8-9d2f-144ac2c7238e">10017</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)&nbsp;&nbsp;(zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF81NTM_0ab4402b-a687-48f9-a099-8c2f02795dfa">212</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">) <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF81NTc_88f099ea-a563-43c0-a5c1-b58c76371958">733-2323</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant’s telephone number)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie6bad63b428748a0834fa9a2e59c476f_D20220101-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6N2I2ODkwNzQ3ZDlmNGM3OGJmZTQ5NTI5ZmZhY2Q5N2UvdGFibGVyYW5nZTo3YjY4OTA3NDdkOWY0Yzc4YmZlNDk1MjlmZmFjZDk3ZV8zLTAtMS0xLTI3NjcxMQ_9cf0327f-be0d-46ab-8942-4bbeb813d76d">Common Stock, $.05 par value</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie6bad63b428748a0834fa9a2e59c476f_D20220101-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6N2I2ODkwNzQ3ZDlmNGM3OGJmZTQ5NTI5ZmZhY2Q5N2UvdGFibGVyYW5nZTo3YjY4OTA3NDdkOWY0Yzc4YmZlNDk1MjlmZmFjZDk3ZV8zLTItMS0xLTI3NjcxMQ_0c98ce1d-a9c7-4346-bed3-c037576ec1c7">PFE</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie6bad63b428748a0834fa9a2e59c476f_D20220101-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6N2I2ODkwNzQ3ZDlmNGM3OGJmZTQ5NTI5ZmZhY2Q5N2UvdGFibGVyYW5nZTo3YjY4OTA3NDdkOWY0Yzc4YmZlNDk1MjlmZmFjZDk3ZV8zLTQtMS0xLTI3NjcxMQ_15b7e9c7-a329-416e-b76c-a99a737b9569">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i122e836787ac46bd93c33b8d47555aae_D20220101-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6N2I2ODkwNzQ3ZDlmNGM3OGJmZTQ5NTI5ZmZhY2Q5N2UvdGFibGVyYW5nZTo3YjY4OTA3NDdkOWY0Yzc4YmZlNDk1MjlmZmFjZDk3ZV81LTAtMS0xLTI3NjcxMQ_7302e4a9-b222-40ca-9e3f-cf021c60b87e">1.000% Notes due 2027</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i122e836787ac46bd93c33b8d47555aae_D20220101-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6N2I2ODkwNzQ3ZDlmNGM3OGJmZTQ5NTI5ZmZhY2Q5N2UvdGFibGVyYW5nZTo3YjY4OTA3NDdkOWY0Yzc4YmZlNDk1MjlmZmFjZDk3ZV81LTItMS0xLTI3NjcxMQ_060d0ea5-601c-4b6f-8ded-3f5ddabde557">PFE27</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i122e836787ac46bd93c33b8d47555aae_D20220101-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6N2I2ODkwNzQ3ZDlmNGM3OGJmZTQ5NTI5ZmZhY2Q5N2UvdGFibGVyYW5nZTo3YjY4OTA3NDdkOWY0Yzc4YmZlNDk1MjlmZmFjZDk3ZV81LTQtMS0xLTI3NjcxMQ_4fb8834f-90da-452b-8511-0adc50ddd573">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6YThiZjM0MjY1Y2U5NDhhM2JlM2FkMjk5Zjg2MTliZGMvdGFibGVyYW5nZTphOGJmMzQyNjVjZTk0OGEzYmUzYWQyOTlmODYxOWJkY18wLTAtMS0xLTI3NjcxMQ_f3c06d21-9e92-4bb6-b6b9-6f90673aa3aa">Yes</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6ODIyNTU1NTczYTIzNDk1ZDgxMzllZWE2NWI1ZGQ3YWIvdGFibGVyYW5nZTo4MjI1NTU1NzNhMjM0OTVkODEzOWVlYTY1YjVkZDdhYl8wLTAtMS0xLTI3NjcxMQ_9e9a4dac-4438-4fb7-bd69-e5d3cdacbdb3">Yes</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8xNjA0_f6c5926b-19c6-44ef-958b-cc230ca8a0eb">Large Accelerated filer</ix:nonnumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Smaller reporting company&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8xNzIx_9f691fc4-b73b-4908-9ac6-3d23d920604a">☐</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8xNzQ5_110ddc44-2f57-45a7-967f-fde88252ad98">☐</ix:nonnumeric> </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGFibGU6MTBiMmI0NGI1OGFmNGNhOTg5MDEwM2YyMGVkYWI5MWIvdGFibGVyYW5nZToxMGIyYjQ0YjU4YWY0Y2E5ODkwMTAzZjIwZWRhYjkxYl8wLTEtMS0xLTI3NjcxMQ_bd1beb78-f24e-4891-ae36-b4cbefed12c3">☐</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At May&nbsp;6, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="i24ea96b1525d41be8341ee5a131ff62e_I20220506" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xL2ZyYWc6YTYyYmFiZmY3NTRmNGNjMzk3YTU4Y2IwMzc0NTdmZGQvdGV4dHJlZ2lvbjphNjJiYWJmZjc1NGY0Y2MzOTdhNThjYjAzNzQ1N2ZkZF8yMTMx_ef107fe7-ea1e-4046-b45a-52a734dae496">5,610,895,801</ix:nonfraction> shares of the issuer’s voting common stock were outstanding.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_7"></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr></tbody></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tbody><tr><td style="width:1.0%"></td><td style="width:92.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_13">PART I.&nbsp;&nbsp;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_19">Condensed Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_19">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_22">Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_22">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_25">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_25">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_28">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_28">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_31">9</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_34">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management’<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_94">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_94">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_136">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_136">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_136">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_139">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_139">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_139">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_142">PART II.&nbsp;&nbsp;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_145">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_145">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_145">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_148">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_148">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_148">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_151">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_151">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_151">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_163">Item </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_163">6</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_163">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_163">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_163">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d1b55fadd3b49068baa4191851d4ddf_166">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1b55fadd3b49068baa4191851d4ddf_166">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A = Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_10"></div><div style="text-align:center"><span><br></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEFINED TERMS </span></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&nbsp;27, 2022 and February&nbsp;28, 2021, and for U.S. subsidiaries is as of and for the three months ended April&nbsp;3, 2022 and April&nbsp;4, 2021. References to “Notes” in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2021 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the fiscal year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ACIP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ALK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenues</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Arena</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arena Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Astellas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ATTR-CM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Biohaven</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and BioShin Limited. (collectively, Biohaven)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BioNTech</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer Biopharmaceuticals Group</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biologics License Application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BNT162b2*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer-BioNTech COVID-19 Vaccine, also known as Comirnaty</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BOD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CDC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CGRP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">calcitonin gene-related peptide</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">conditional marketing authorisation</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Comirnaty*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer-BioNTech COVID-19 Vaccine, also known as BNT162b2</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Western Europe, Scandinavian countries and Finland</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: U.S., Developed Europe, Japan, Canada, South Korea, Australia and New Zealand</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Japan, Canada, South Korea, Australia and New Zealand</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Commission</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FFDCA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Federal Food, Drug and Cosmetic Act</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This Quarterly Report on Form 10-Q for the quarterly period ended April 3, 2022</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally Accepted Accounting Principles</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GIST</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">gastrointestinal stromal tumors</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GPD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Product Development organization</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GlaxoSmithKline plc</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">HIPAA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act of 1996 </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hospira</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JAK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janus kinase</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">King</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">London Interbank Offered Rate</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LOE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">loss of exclusivity</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCSPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></tbody></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meridian</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mRNA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">messenger ribonucleic acid</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MSA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Manufacturing Supply Agreement</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan-Japan collaboration</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020, which fell in Pfizer’s international first quarter of 2021</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Myovant</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Myovant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">nmCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OPKO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Paxlovid*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PC1</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer CentreOne</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PGS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer Global Supply</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pharmacia</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacia Corporation</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PRAC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacovigilance Risk Assessment Committee</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PsA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RCC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ReViral</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ReViral Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sandoz</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sandoz, Inc., a division of Novartis AG</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">sNDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">supplemental new drug application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">TSAs</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transition service arrangements</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">UC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Upjohn Business</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer’s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Viatris</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ViiV Healthcare Limited</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">WRDM</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide Research, Development and Medical</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">This Form 10-Q includes discussion of the COVID-19 vaccine that Pfizer has co-developed with BioNTech (BNT162b2) and our oral COVID-19 treatment (Paxlovid). The vaccine may be referred to by its brand name, Comirnaty (approved under a BLA), or as BNT162b2 (authorized under EUA). The vaccine is FDA-approved to prevent COVID-19 in individuals 16 years of age and older. The vaccine is authorized by the FDA to prevent COVID-19 in individuals 5 years of age and older. In addition, Comirnaty/BNT162b2 is authorized by the FDA for a third dose for certain immunocompromised individuals 5 years of age and older, as a booster dose for individuals 12 years of age and older and as a second booster dose for individuals 50 years of age and older and for certain immunocompromised individuals 12 years of age and older. Paxlovid has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. The FDA has issued EUAs to certain other companies for products intended for the prevention or treatment of COVID-19 and may continue to do so during the duration of the Declaration. See the EUA Fact Sheets at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">www.cvdvaccine-us.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">www.covid19oralrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_13"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.222%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART I.&nbsp; FINANCIAL INFORMATION</span></td></tr></tbody></table></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_16"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_19"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMi02LTEtMS0yNzY3MTE_4be8f326-8d5d-4753-8a7f-7ba173442c96">25,661</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMi04LTEtMS0yNzY3MTE_e2d50d1c-7b04-46ac-a0f3-5b99661c1e9e">14,516</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNC02LTEtMS0yNzY3MTE_2c57d765-f827-4f15-a9e8-787a87af0585">9,984</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNC04LTEtMS0yNzY3MTE_f79bcad1-6f66-41a8-a88f-eb8ab43af4f1">4,157</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNS02LTEtMS0yNzY3MTE_8aecbe76-d43d-4ba2-b117-f34f86fdfc91">2,593</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNS04LTEtMS0yNzY3MTE_4de626f1-4eae-42b5-ac3f-60b3cb6a5f6d">2,777</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNi02LTEtMS0yNzY3MTE_9d71f124-7628-4b82-8a15-1e3089160b25">2,301</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNi04LTEtMS0yNzY3MTE_66600840-6073-42fe-a33f-9f3df94d37ff">1,994</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNy02LTEtMS0zMTk4OTM_4250241b-aa0d-46cd-8fe3-fc9e0399fb77">355</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNy04LTEtMS0zMTk5MDA_e48f801d-db53-4f35-b551-cae032c9b50b">19</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNy02LTEtMS0yNzY3MTE_fbb6d090-d4d7-41dd-bf6f-ed303197cc25">835</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfNy04LTEtMS0yNzY3MTE_e61e6944-2e01-4ade-8a47-40ea2649df85">858</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfOC02LTEtMS0yNzY3MTE_efc3b70b-70be-4fda-9d65-a1da809c8879">192</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfOC04LTEtMS0yNzY3MTE_b5722167-9310-49c1-a157-b6c29ff875ea">22</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions––net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTAtNi0xLTEtMjc2NzEx_3ce45104-4a77-432c-87ba-615b0e5d94a5">350</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTAtOC0xLTEtMjc2NzEx_e503bbd9-94f0-4f90-84fa-1cfb8623a23b">1,004</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTEtNi0xLTEtMjc2NzEx_4081e1a0-b258-46d5-994a-57712bb1a0af">9,050</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTEtOC0xLTEtMjc2NzEx_39f0da42-789d-47af-a12a-0fffd2b6ef03">5,692</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTItNi0xLTEtMjc2NzEx_5c5329b0-431e-419b-b239-ad2129b4bc32">1,172</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTItOC0xLTEtMjc2NzEx_c57ebac2-0e98-4a20-bb54-3441216cae59">808</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTMtNi0xLTEtMjc2NzEx_56524059-93c6-49cc-9bdc-4dbca8193a03">7,879</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTMtOC0xLTEtMjc2NzEx_16bf1368-1144-4157-9b93-10fb5428ed9b">4,885</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTUtNi0xLTEtMjc2NzEx_bcc3de07-419e-4f4d-ac6f-ee59ff0b4b9e">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTUtOC0xLTEtMjc2NzEx_437f3f3e-2f06-49fe-b798-0e9655702455">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTgtNi0xLTEtMjc2NzEx_e565048b-51ca-465e-b7ae-8a239e9be3f3">7,870</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTgtOC0xLTEtMjc2NzEx_cd3f26d6-d9c1-43ed-849b-af99c01de306">4,886</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTktNi0xLTEtMjc2NzEx_c2b5160b-6659-44a0-a45c-cb2ff4d38006">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMTktOC0xLTEtMjc2NzEx_426d6e53-edaf-4c8e-ac40-e310c98ea937">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjAtNi0xLTEtMjc2NzEx_7fa06a7f-b895-46b0-a244-dc2d38c9fe62">7,864</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjAtOC0xLTEtMjc2NzEx_47b27d4a-d545-4ef3-af44-808c63bad66b">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share––basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjMtNi0xLTEtMjc2NzEx_757af0f3-7325-4496-ac8f-70a532255676">1.40</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjMtOC0xLTEtMjc2NzEx_275aa026-8ea5-4a6b-8c48-2fce75bf702f">0.87</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjQtNi0xLTEtMjc2NzEx_48bba931-76b3-4352-aff6-58e2933fa219">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjQtOC0xLTEtMjc2NzEx_0e395c97-27f4-4ca0-99e8-5124e17ba980">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjUtNi0xLTEtMjc2NzEx_a2b0613f-a400-4ed2-94cd-aa6f5bc346fc">1.40</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjUtOC0xLTEtMjc2NzEx_ecf21ed4-a7b1-44b1-9282-f52873d92d29">0.87</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share––diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjgtNi0xLTEtMjc2NzEx_b8267fb6-6404-4b9c-b581-25396d43c312">1.37</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjgtOC0xLTEtMjc2NzEx_17c57c03-c9c0-4303-8574-d4a0d1010924">0.86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjktNi0xLTEtMjc2NzEx_1c6cf679-e81f-41ab-aad7-ccd56f44924c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMjktOC0xLTEtMjc2NzEx_9f891dd0-634c-4f75-9184-1f3706ee4336">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMzAtNi0xLTEtMjc2NzEx_98469c82-6db1-423f-9b3d-cb498a060fe0">1.37</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMzAtOC0xLTEtMjc2NzEx_e4147a04-9f2b-4172-b5cd-98143e40e949">0.86</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares––basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMzItNi0xLTEtMjc2NzEx_674379d7-a510-4d9a-973d-7bca5dcb49ca">5,617</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMzItOC0xLTEtMjc2NzEx_2e8e5d71-e136-4997-90db-e78dcbfd9008">5,584</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares––diluted</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMzMtNi0xLTEtMjc2NzEx_f1a4c814-b4ca-40f6-9f00-321816d31a41">5,758</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RhYmxlOmYxNGYyMzJkMDdiMDRhM2E5ZmQwNTUyZjdhODIxNTg1L3RhYmxlcmFuZ2U6ZjE0ZjIzMmQwN2IwNGEzYTlmZDA1NTJmN2E4MjE1ODVfMzMtOC0xLTEtMjc2NzEx_0fe4208c-22ab-4028-a894-1ab6c3a8e1bf">5,662</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RleHRyZWdpb246NTMzNDlhY2U1YTM0NGM5Mzk1ZGZmMmQ3OTY0YjA2ZGFfMTY0OTI2NzQ0MTg1NzE_cfe8e9f3-7ad3-4d78-8df5-3213796bf562" footnoterole="http://www.xbrl.org/2003/role/footnote">Exclusive of amortization of intangible assets.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8xOS9mcmFnOjUzMzQ5YWNlNWEzNDRjOTM5NWRmZjJkNzk2NGIwNmRhL3RleHRyZWdpb246NTMzNDlhY2U1YTM0NGM5Mzk1ZGZmMmQ3OTY0YjA2ZGFfMTY0OTI2NzQ0MTgxODU_27cebdc3-244c-410e-84ff-421e8d4c79dc" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></ix:footnote></div><div style="margin-top:135pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_22"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER&nbsp;INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMi02LTEtMS0yNzY3MTE_e565048b-51ca-465e-b7ae-8a239e9be3f3">7,870</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMi04LTEtMS0yNzY3MTE_cd3f26d6-d9c1-43ed-849b-af99c01de306">4,886</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfNC02LTEtMS0yNzY3MTE_c744f7b3-cb48-4c64-aecf-16bd68ab9c3d">363</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfNC04LTEtMS0yNzY3MTE_7b1362f1-60f1-48cf-90e3-69410fd6a7d6">465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfNy02LTEtMS0yNzY3MTE_ef2f3aef-a0d8-4f55-a890-736914aafda2">203</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfNy04LTEtMS0yNzY3MTE_236e01b5-3f61-4b95-a850-e9a6868cbce7">214</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfOC02LTEtMS0yNzY3MTE_db3b93fe-0347-443f-b16a-83ec45151ad7">213</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfOC04LTEtMS0yNzY3MTE_2799de80-9dc3-4d1f-9ec3-163e155e0bad">259</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfOS02LTEtMS0yNzY3MTE_bc5f5947-290e-49cc-8500-673d82f12278">10</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfOS04LTEtMS0yNzY3MTE_0052fb1c-616e-4028-810c-6a8517405ebf">473</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTAtNi0xLTEtMjc2NzEx_7cfc634c-af26-498d-bb2a-add7a74451fe">133</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTAtOC0xLTEtMjc2NzEx_bd4f8af7-f32a-4428-acf1-673f51a8726c">79</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTEtNi0xLTEtMjc2NzEx_2ee6aaaf-f7e8-4fec-85c8-628513b4e6dc">233</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTEtOC0xLTEtMjc2NzEx_28ab9b07-0518-42b4-a14a-7015f10862b4">242</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTMtNi0xLTEtMjc2NzEx_a6d56885-edf7-413c-ac83-13b23349da9a">99</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTMtOC0xLTEtMjc2NzEx_9e367b52-d081-462b-9337-8bbf660459eb">163</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTUtNi0xLTEtMjc2NzEx_2abe387f-0d22-44ec-ad67-7fb4ca512057">36</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTUtOC0xLTEtMjc2NzEx_7fa4e9fd-81c9-4628-9901-dc65ccfd4d79">40</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTYtNi0xLTEtMjc2NzEx_80210c1c-4fff-493f-959e-aa660ae459cd">10</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTYtOC0xLTEtMjc2NzEx_a48dbbb8-f333-4b67-b0c5-8b0776451810">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTctNi0xLTEtMjc2NzEx_d6889f1d-c368-491c-876b-98ff98b10268">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTctOC0xLTEtMjc2NzEx_d7a2d1b4-a734-42cd-9c62-74d3ac6ac1ea">3</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTgtNi0xLTEtMjc2NzEx_8c34a147-8960-47e3-80f4-a4ffee2e2d8d">47</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTgtOC0xLTEtMjc2NzEx_d025e59c-724e-479c-b8fd-a9f5b56993cc">43</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTktNi0xLTEtMjc2NzEx_b50f9ae5-8fa8-4143-99cc-43b57d7efb6e">321</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMTktOC0xLTEtMjc2NzEx_1fe6b712-ec2f-487e-a6ba-5b65f3bdc960">732</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjAtNi0xLTEtMjc2NzEx_d8ab5889-1ea4-4120-ba18-27cd3b07a369">60</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjAtOC0xLTEtMjc2NzEx_d86887b8-2714-4254-b04a-4d066d3c27a5">84</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjEtNi0xLTEtMjc2NzEx_f7ef6d5b-42c7-4de5-99ed-f1a9da6eda03">260</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjEtOC0xLTEtMjc2NzEx_f37bb4ff-ff40-403e-9078-035bedfc320c">647</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjMtNi0xLTEtMjc2NzEx_2bca82f4-beae-47ea-ae9d-bcbf2fb0d2bb">7,610</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjMtOC0xLTEtMjc2NzEx_e7736009-314b-43d1-ade4-ac71ee1443eb">5,533</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjQtNi0xLTEtMjc2NzEx_83d77f69-8047-4c59-b092-13a81b9f989f">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjQtOC0xLTEtMjc2NzEx_78128cf1-4720-4843-bfaa-e69b74e0cdb6">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjUtNi0xLTEtMjc2NzEx_a7a9a6e5-a2a8-454d-a97c-b2ebdbabd8fc">7,604</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RhYmxlOjg3NDcwNmM4YTJlZDRhMWI4YjFlM2ZiNmI1OGNhZTI1L3RhYmxlcmFuZ2U6ODc0NzA2YzhhMmVkNGExYjhiMWUzZmI2YjU4Y2FlMjVfMjUtOC0xLTEtMjc2NzEx_984ba182-adf1-4ff8-9b0b-d86e84123fe6">5,523</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RleHRyZWdpb246MjA5NjIzM2QyNjUwNGIwOGJkZTBiMjViZWYzM2Q1NmVfMjY3_5281c62b-bf4c-4797-bd95-95f9b0b5c0c7" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yMi9mcmFnOjIwOTYyMzNkMjY1MDRiMDhiZGUwYjI1YmVmMzNkNTZlL3RleHRyZWdpb246MjA5NjIzM2QyNjUwNGIwOGJkZTBiMjViZWYzM2Q1NmVfMjY4_dabf21b7-d37c-4a41-9d8e-58efc178ea1b" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net.</span></ix:footnote></div><div style="margin-top:300pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_25"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMy0yLTEtMS0yNzY3MTE_e2e94467-874d-4615-99ea-2be5ff357e90">2,470</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMy00LTEtMS0yNzY3MTE_429a9e01-7559-44a9-b4c5-c2f64c90c0d1">1,944</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNC0yLTEtMS0yNzY3MTE_04243e36-2b41-424b-8b1e-254be905913e">21,427</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNC00LTEtMS0yNzY3MTE_e2bf1bc2-2518-4136-8309-db0ac70424d5">29,125</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts: 2022—$<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNS0wLTEtMS0yNzY3MTEvdGV4dHJlZ2lvbjozY2E0NjE1NmM4MmI0M2M1OGM3ZjY5YjNkNDhiMjYyN183NA_69ebfaf9-bfed-4657-a354-e45a9fd4b0d3">492</ix:nonfraction>; 2021—$<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNS0wLTEtMS0yNzY3MTEvdGV4dHJlZ2lvbjozY2E0NjE1NmM4MmI0M2M1OGM3ZjY5YjNkNDhiMjYyN184Mw_7747a9d2-2b79-46f6-9bb9-ff5754d2e6b6">492</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNS0yLTEtMS0yNzY3MTE_af15570a-8f5d-47b9-93d7-20c7f1f8b27c">13,225</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNS00LTEtMS0yNzY3MTE_201b2e5b-f0b4-40e2-b4c9-c510bc4afcc6">11,479</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNi0yLTEtMS0yNzY3MTE_23b7a7e1-7a44-4c70-8193-d660eecccb9a">9,979</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNi00LTEtMS0yNzY3MTE_d89f2df9-bdf1-4e7c-a60a-5f6b486516ae">9,059</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNy0yLTEtMS0yNzY3MTE_e270d241-216f-46d9-bab8-d864c2fee3fe">3,117</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNy00LTEtMS0yNzY3MTE_8044a4ca-41bd-48ea-b5e4-6d879b57bf09">4,266</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfOC0yLTEtMS0yNzY3MTE_bd66c6ae-14d2-4afa-a630-01fa32711dae">4,202</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfOC00LTEtMS0yNzY3MTE_9bc0eea3-4d32-4564-8e0b-dafb22ea1a2e">3,820</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfOS0yLTEtMS0yNzY3MTE_6db79280-41c9-486c-8429-d11f1d0775ef">54,420</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfOS00LTEtMS0yNzY3MTE_da34a205-2a50-484a-a336-a9355904fb3d">59,693</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTAtMi0xLTEtMjc2NzEx_0f17970b-36f6-4dc1-815f-25c55b3fb5fb">15,995</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTAtNC0xLTEtMjc2NzEx_7edb83f1-3633-4236-b533-ec066ab7f446">16,472</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTEtMi0xLTEtMjc2NzEx_59af1eee-412d-4499-8e7e-75870ead56bf">4,742</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTEtNC0xLTEtMjc2NzEx_2aec19ce-572b-42ba-8ba9-6d50af8b0376">5,054</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation: 2022—$<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTItMC0xLTEtMjc2NzExL3RleHRyZWdpb246NzMwYjBlNWRlYzAzNDY4ZTgxOWNkZWY4ZDdhODdiNjVfNzE_ecec283c-14fd-4602-9d6d-4f94c8b78bf2">15,358</ix:nonfraction>; 2021—$<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTItMC0xLTEtMjc2NzExL3RleHRyZWdpb246NzMwYjBlNWRlYzAzNDY4ZTgxOWNkZWY4ZDdhODdiNjVfODA_e6d6b53e-d0a1-457d-8af5-d8922cf0d9b9">15,074</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTItMi0xLTEtMjc2NzEx_fcb78d30-631d-4632-bf71-390123f89d1e">15,109</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTItNC0xLTEtMjc2NzEx_89a36a90-4cf0-45b0-9bd4-e7f842c5c3e4">14,882</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTMtMi0xLTEtMjc2NzEx_6beb3375-c357-4f8b-9865-c04a6e59f679">29,816</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTMtNC0xLTEtMjc2NzEx_9b8b0d90-7a8a-447e-8bf2-86e66e33747d">25,146</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTQtMi0xLTEtMjc2NzEx_66860d4f-bf90-4777-b536-82fc8a9398c0">50,211</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTQtNC0xLTEtMjc2NzEx_eecc232e-7edc-461a-a089-519f5a37633b">49,208</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTUtMi0xLTEtMjc2NzEx_1862611a-8366-4cb2-afb6-3e2d8cedd7d7">5,668</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTUtNC0xLTEtMjc2NzEx_2abca546-e898-4202-bb5c-5321951065d2">3,341</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTYtMi0xLTEtMjc2NzEx_161103b5-612a-44ef-9073-9512dbf13217">7,879</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTYtNC0xLTEtMjc2NzEx_095161a8-2af7-457f-8128-392f718f985c">7,679</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTgtMi0xLTEtMjc2NzEx_ef8040bb-42ff-444f-9d73-00829167d1cb">183,841</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMTgtNC0xLTEtMjc2NzEx_e57043b5-aaf6-4846-983c-5eda16761774">181,476</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt: 2022—$<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjEtMC0xLTEtMjc2NzExL3RleHRyZWdpb246ZTJlNTgxYjkyNDE3NGJlNTllY2FhOTBjNjg0OTU4ZTVfNzc_dbf5982e-2fbb-40b5-8454-6a04206cae8b">260</ix:nonfraction>; 2021—$<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjEtMC0xLTEtMjc2NzExL3RleHRyZWdpb246ZTJlNTgxYjkyNDE3NGJlNTllY2FhOTBjNjg0OTU4ZTVfODY_0ddd3bb0-cbbe-400a-bdea-fbbdadbb3c17">1,636</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjEtMi0xLTEtMjc2NzEx_4b2fd9d7-9f66-4636-b442-df834ef2bbf5">645</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjEtNC0xLTEtMjc2NzEx_a7d176d9-2f95-422f-92e4-67b2b0bdad14">2,241</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjItMi0xLTEtMjc2NzEx_dfadfe70-f0a1-4568-9856-23b0c25577d7">5,506</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjItNC0xLTEtMjc2NzEx_f1e10e8a-1795-47d9-9480-35295dbf7438">5,578</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjMtMi0xLTEtMjc2NzEx_407e15de-f905-42f6-8f88-594b92f8136d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjMtNC0xLTEtMjc2NzEx_363d9ff2-ed04-4f91-bf60-50b091fef1d2">2,249</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjQtMi0xLTEtMjc2NzEx_676f234d-538e-48d9-aaaa-2929be93a260">3,177</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjQtNC0xLTEtMjc2NzEx_d5e10a98-b046-4155-8dd1-47dae4c3189e">1,266</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjUtMi0xLTEtMjc2NzEx_cd4b182c-3f0c-4f0f-9da1-df88bb0b9498">2,249</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjUtNC0xLTEtMjc2NzEx_fa3c02e3-d258-4b73-8a6c-dc091a1f32a6">3,332</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjYtMi0xLTEtMjc2NzEx_ed31dac7-7307-46ae-8741-0777064ee99e">3,108</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjYtNC0xLTEtMjc2NzEx_edb07439-fa3c-4d4e-a985-25f102575ba5">3,067</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjctMi0xLTEtMjc2NzEx_35dae8ed-f01a-4c6a-ac43-dd69dcd51c84">24,583</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjctNC0xLTEtMjc2NzEx_d1534b4c-2563-4b7a-b0f3-8e2d90f96873">24,939</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjktMi0xLTEtMjc2NzEx_f4ece646-0451-44c8-8538-07fc27ad1d72">39,268</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMjktNC0xLTEtMjc2NzEx_726f624f-072c-493a-bd2c-3ead6845d3c7">42,671</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzEtMi0xLTEtMjc2NzEx_7cb5f4ce-2990-4518-8cb5-cb5a91168fc9">35,656</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzEtNC0xLTEtMjc2NzEx_6d8d8c8f-e315-4428-91fc-2e3b5058d302">36,195</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzItMi0xLTEtMjc2NzEx_d3d6d76c-5768-421e-abe7-bada074bcb24">3,261</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzItNC0xLTEtMjc2NzEx_3b897649-fa55-4765-9238-37d8d5240432">3,489</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzMtMi0xLTEtMjc2NzEx_a2098f70-619f-4054-b3ef-1d277984319d">233</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzMtNC0xLTEtMjc2NzEx_7af8596c-1210-4f0f-bfdd-bea4f2425761">235</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzQtMi0xLTEtMjc2NzEx_d3470e02-47bb-47ae-a8e3-62d675843554">655</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzQtNC0xLTEtMjc2NzEx_90a58a41-f16b-47bb-bc92-52c2ef39a037">349</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzUtMi0xLTEtMjc2NzEx_4602262d-4556-4e24-a1de-f4a55e35e305">11,574</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzUtNC0xLTEtMjc2NzEx_e526da17-43b1-464f-b995-349aa670365e">11,331</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzYtMi0xLTEtMjc2NzEx_3562c42e-0de7-4ca6-bf07-e2667f3f6ea3">10,508</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzYtNC0xLTEtMjc2NzEx_150a541e-31d4-4bc1-abf2-48511b91f80b">9,743</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzctMi0xLTEtMjc2NzEx_7ae94269-388d-48ad-9899-a5b2f3389b0a">101,155</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzctNC0xLTEtMjc2NzEx_45a23f2e-8cd4-431a-9690-4f4ab669e21d">104,013</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzktMi0xLTEtMjc2NzEx_b059815e-d696-458a-84df-4ff6849fe915"></ix:nonfraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfMzktNC0xLTEtMjc2NzEx_ba3f8124-a9eb-4b42-b348-499fdf01ec3b"></ix:nonfraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDItMi0xLTEtMjc2NzEx_9d4477dc-58e3-4e3d-b806-af6f7b827172">476</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDItNC0xLTEtMjc2NzEx_e27cd73c-b4fb-4578-b7b5-54f5ed0e966f">473</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDMtMi0xLTEtMjc2NzEx_69c9d173-da45-4773-b2b1-a69cd7de0dc1">90,844</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDMtNC0xLTEtMjc2NzEx_0a690cb2-7c3b-4729-9666-2d255168588c">90,591</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDUtMi0xLTEtMjc2NzEx_efbcc457-9900-43c1-a5e4-24d503bf5b97">113,931</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDUtNC0xLTEtMjc2NzEx_3d9023ea-c042-4992-9f64-b8dbf685250b">111,361</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDYtMi0xLTEtMjc2NzEx_44407ad9-a689-4234-8f3c-12faf6e5784a">111,193</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDYtNC0xLTEtMjc2NzEx_dfdc69a0-ed77-4ca1-bc80-331834b3984f">103,394</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDctMi0xLTEtMjc2NzEx_f3228bab-b5cf-4288-b3a1-35b78437a663">6,157</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDctNC0xLTEtMjc2NzEx_2caa36c1-bcf8-4ef1-a080-c43603364067">5,897</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pfizer Inc. shareholders’ equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDgtMi0xLTEtMjc2NzEx_6ec33915-8a06-44ca-b331-3e454c4746bc">82,424</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDgtNC0xLTEtMjc2NzEx_48ebb45d-17bb-4008-abcc-b591f99d9a11">77,201</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDktMi0xLTEtMjc2NzEx_fcf718cd-d6d4-47e3-8749-68cd28355b55">261</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNDktNC0xLTEtMjc2NzEx_cee75dd2-d683-4bd0-9a49-038689abac95">262</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNTAtMi0xLTEtMjc2NzEx_3092d768-dbbb-4a17-92ad-ff764c67cb7f">82,685</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNTAtNC0xLTEtMjc2NzEx_daea8414-ae06-40dd-9ea1-b5c49bf72b7e">77,462</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNTEtMi0xLTEtMjc2NzEx_e13cbc4c-a6c1-4557-8bb1-234c99a14174">183,841</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yNS9mcmFnOmEzNzM3ZmM1N2RkODQzNzZhNDYyMDRhZTFkNWRlYWY1L3RhYmxlOmZjMDhhZDBiYjk1NTRiZDc4MGZlNTBlOWY0MWViN2FiL3RhYmxlcmFuZ2U6ZmMwOGFkMGJiOTU1NGJkNzgwZmU1MGU5ZjQxZWI3YWJfNTEtNC0xLTEtMjc2NzEx_6c39c08b-9bd2-44b8-814f-51218846a83a">181,476</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:70pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_28"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="75" style="padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.305%"><tbody><tr><td style="width:1.0%"></td><td style="width:26.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:3.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add’l<br>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br>holders’ Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, January&nbsp;1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie73edcb1d31e465f9103d2207066f5e1_I20211231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy02LTEtMS0yNzY3MTE_fc19903e-de00-4fee-8614-f383efb96ced">9,471</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie73edcb1d31e465f9103d2207066f5e1_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy04LTEtMS0yNzY3MTE_42ef93f7-df2a-431e-ba02-6f5ce92c84db">473</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92a4745cd5554d1eb8b1d79826aad315_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0xMC0xLTEtMjc2NzEx_636e87f6-ab94-434d-a06d-9db7e7542fe2">90,591</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i51a53ab8dd9143e6be8af5b147d6d71e_I20211231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0xMi0xLTEtMjc2NzEx_104f671c-db55-46bf-aa95-99e9cb808203">3,851</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i51a53ab8dd9143e6be8af5b147d6d71e_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0xNC0xLTEtMjc2NzEx_45af28b1-e603-4812-b1fe-80266886850d">111,361</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i009eacb7c86e4007be20ca4b96113dc7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0xNi0xLTEtMjc2NzEx_7305d977-d4b8-4ab2-b64b-59ea330c39f4">103,394</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8511b3061229447b8d673d4ed6657a87_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0xOC0xLTEtMjc2NzEx_ed6ff549-6b5c-4114-b55c-76deb89fa2f5">5,897</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13599ca943664af980623065c321dd7c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0yMC0xLTEtMjc2NzEx_dcc9222d-aa26-4d9a-8c9a-881cf0d103ad">77,201</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i68b16103d299444aa2c0a72c19b99d16_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0yMi0xLTEtMjc2NzEx_9074b608-2048-46d0-b2fb-778c67bad9f1">262</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMy0yNC0xLTEtMjc2NzEx_b140f2e7-2fe7-4bcd-b4d3-3fe49887cac7">77,462</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf6b7bd8b9124dbf83e22bd0622569dd_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNC0xNi0xLTEtMjc2NzEx_70d9c550-ef95-4e86-b6ca-dfb5a1217553">7,864</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7bc679c8d654b3b92c0f11d31c2acb5_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNC0yMC0xLTEtMjc2NzEx_efb9b28c-a669-4012-87a9-dfeeafface94">7,864</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2da06a72b434a938cbad5382ac9c5c1_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNC0yMi0xLTEtMjc2NzEx_565fb74d-4070-436f-bab3-924d2200a9ea">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNC0yNC0xLTEtMjc2NzEx_300a81b8-8e49-40d9-960d-7baece9d79f2">7,870</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&nbsp;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40cd2a56baa6486fb861a72bd0d777df_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNS0xOC0xLTEtMjc2NzEx_738d7d41-3ede-4489-83eb-84cdc29f1278">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie7bc679c8d654b3b92c0f11d31c2acb5_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNS0yMC0xLTEtMjc2NzEx_7239dcdd-0f18-49d8-ac17-3c0da551ae23">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNS0yNC0xLTEtMjc2NzEx_8d09ba7c-c85a-4633-8dac-c81a2e2ee562">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNi0wLTEtMS0yNzY3MTEvdGV4dHJlZ2lvbjo2ODJhZDAzNTkzNGM0NDJmYjE4NjZkZjBkZTM3MTZlYV85MzQ1ODQ4ODM2MTM5_cd53154a-d9fc-41ac-8fe6-e1c1d5b038e0">—</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfNy0yNC0xLTEtMjc2NzEx_6bcbf8ff-27c8-4154-8ba2-55b489089cd6">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="icb85fc6d292248afa491676795094b05_D20220101-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtNi0xLTEtMjc2NzEx_f689fb57-a2f4-4ad0-b106-0fdcb4370780">23</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb85fc6d292248afa491676795094b05_D20220101-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtOC0xLTEtMjc2NzEx_369d8796-71f4-4f0c-bb1b-7733d5337d2b">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d66469042d24d61aee64f79e5ebc4d8_D20220101-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtMTAtMS0xLTI3NjcxMQ_35c3a9fb-842c-40d4-91ec-2b3b53a39338">249</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="ie80782db44a1440d8664ea8ab65de897_D20220101-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtMTItMS0xLTI3NjcxMQ_3d3cedb6-36fd-45f6-b207-519dcb7dbad7">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie80782db44a1440d8664ea8ab65de897_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtMTQtMS0xLTI3NjcxMQ_69805420-3934-4fdc-a51a-d81b45daed75">570</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icf6b7bd8b9124dbf83e22bd0622569dd_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtMTYtMS0xLTI3NjcxMQ_ae771c2a-f7ad-4e15-b4cb-45f9db629bb1">65</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie7bc679c8d654b3b92c0f11d31c2acb5_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtMjAtMS0xLTI3NjcxMQ_c6bb511f-5f24-43dd-9cd0-cc3fe5638705">383</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTAtMjQtMS0xLTI3NjcxMQ_d80e787c-d268-4aff-a98b-8312efe8c50f">383</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="ie80782db44a1440d8664ea8ab65de897_D20220101-20220403" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTEtMTItMS0xLTI3NjcxMQ_af6ca97c-6a2a-432c-b192-92f81ff79907">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie80782db44a1440d8664ea8ab65de897_D20220101-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTEtMTQtMS0xLTI3NjcxMQ_8a794044-1bba-4275-bb59-3628ff37f5ae">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie7bc679c8d654b3b92c0f11d31c2acb5_D20220101-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTEtMjAtMS0xLTI3NjcxMQ_5ea4467b-74bd-4fd0-8085-4549b2ad1405">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTEtMjQtMS0xLTI3NjcxMQ_ccc631ba-403c-4460-a931-0e8210e5b93c">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d66469042d24d61aee64f79e5ebc4d8_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTMtMTAtMS0xLTI3NjcxMQ_291c968c-8a31-423b-8317-10fa64e90a64">3</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7bc679c8d654b3b92c0f11d31c2acb5_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTMtMjAtMS0xLTI3NjcxMQ_e69781cb-603c-432b-b843-250f2fdf23ff">3</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if2da06a72b434a938cbad5382ac9c5c1_D20220101-20220403" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTMtMjItMS0xLTI3NjcxMQ_0fd42ea7-520a-42f2-8829-7dd4d500a167">7</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTMtMjQtMS0xLTI3NjcxMQ_13fb64de-340f-44f6-b2a3-fa489c10af9b">4</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, April&nbsp;3, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibb8dbc4d15be490e815822eff9c60f03_I20220403" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtNi0xLTEtMjc2NzEx_26cb3a9a-039a-49f5-9161-441bcae31ecb">9,494</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibb8dbc4d15be490e815822eff9c60f03_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtOC0xLTEtMjc2NzEx_1ca8c7d2-fe69-4f9a-b73c-907b944ff241">476</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i163f9f99a12342a0896b85733171bc90_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMTAtMS0xLTI3NjcxMQ_d43b1060-05c9-4de7-bde4-1ca6f53ea458">90,844</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i7824380bee3f49598b17671091055c0e_I20220403" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMTItMS0xLTI3NjcxMQ_eeefaf4b-4e33-4d25-9dd0-cba071a7ed6a">3,903</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7824380bee3f49598b17671091055c0e_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMTQtMS0xLTI3NjcxMQ_93d327e3-8807-4c5b-bab6-181a386e85f7">113,931</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f2f394b06174d1c85f8b8b89a0a9533_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMTYtMS0xLTI3NjcxMQ_443a2ba4-6204-447c-9420-d549dbe9c8a0">111,193</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifee369d41246499390fcd23d443dc9e2_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMTgtMS0xLTI3NjcxMQ_a6b5238d-9704-46c7-b419-7f5e2d88fa40">6,157</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34ed6f065a404dd683ecdc9c707769a8_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMjAtMS0xLTI3NjcxMQ_399b41b0-2acb-412a-8d1e-4818140bc150">82,424</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1abdf6353e2843e9b801379f10feb79f_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMjItMS0xLTI3NjcxMQ_11c2dc6f-e4db-4639-8aa8-02f31c3d92aa">261</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTQtMjQtMS0xLTI3NjcxMQ_ee65fafc-52fe-4fc3-9716-d5802de8456e">82,685</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="63" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add’l<br>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br>holders’ Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, January&nbsp;1, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="id8440a37a4494ed8be42223105528e13_I20201231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktNi0xLTEtMjc2NzEx_60edbbde-cfdc-4323-9d5b-6a9bf27f2b32">9,407</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8440a37a4494ed8be42223105528e13_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktOC0xLTEtMjc2NzEx_999bcdcd-2042-42ae-aaac-216e709e59fe">470</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5a7697515d3e4304a192f44ffcd35033_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMTAtMS0xLTI3NjcxMQ_3d7b46a8-cd24-49a7-90da-61d2119c1ee5">88,674</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i603bb42954b34339a081e1b23751a898_I20201231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMTItMS0xLTI3NjcxMQ_fca15c95-97e4-4576-be25-b1fe33203b7e">3,840</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i603bb42954b34339a081e1b23751a898_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMTQtMS0xLTI3NjcxMQ_218a8714-3cda-497c-863b-ad205c14c778">110,988</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iddfdbacf4fe84236adeb41ebd37549d6_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMTYtMS0xLTI3NjcxMQ_1227ddb1-8175-477e-9282-696b0bd1d34d">90,392</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ica0ea1ec52ad4c46b9d770c93afebb2e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMTgtMS0xLTI3NjcxMQ_b04617bd-68a6-41c4-aba2-fcc3a1746aa0">5,310</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifae6e41606a64b52b1ba264e3b858ab8_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMjAtMS0xLTI3NjcxMQ_13e5eb02-9d25-4325-81fe-66b8aa1b7e36">63,238</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i03f7542c89b84f9c8eed5b8ae08c3b25_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMjItMS0xLTI3NjcxMQ_5132748f-598b-47dc-809f-d709208b5d96">235</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie8af20d8086b440c8e34d1c7b297c77d_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMTktMjQtMS0xLTI3NjcxMQ_2288d9ae-0f0d-4bcf-909d-8804c5eb0c74">63,473</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i938e2f7b2f1e4fa895e67f30ada9c41f_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjAtMTYtMS0xLTI3NjcxMQ_3fa091b1-e66b-4587-8395-8d097e8d11b3">4,877</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9039269f1207490282b0792e4917c741_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjAtMjAtMS0xLTI3NjcxMQ_7028bd04-bf44-4832-b039-11d05f56a64e">4,877</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a6e709faa664bee921de948064fc436_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjAtMjItMS0xLTI3NjcxMQ_c7209c69-6210-4d72-a9cd-192732ebf5e1">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjAtMjQtMS0xLTI3NjcxMQ_ae757d99-ddd9-45ce-8618-a3e5a8667510">4,886</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&nbsp;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i19096fc84ece474d801fc597dc47666a_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjEtMTgtMS0xLTI3NjcxMQ_daecb398-2391-479a-889a-e5683357e943">646</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9039269f1207490282b0792e4917c741_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjEtMjAtMS0xLTI3NjcxMQ_176ed652-3c7a-4640-bb59-f366c9c783e1">646</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a6e709faa664bee921de948064fc436_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjEtMjItMS0xLTI3NjcxMQ_666dc990-57fe-41e3-abd6-c26f8173bf91">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjEtMjQtMS0xLTI3NjcxMQ_68e67155-1cca-4d7f-8608-a361a3869f6b">647</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjItMC0xLTEtMjc2NzExL3RleHRyZWdpb246ZTMyNWMxMjUwMGJkNDFlNmE4MjhkYTEyZTg1ZGZiODVfOTM0NTg0ODgzNjEzOQ_84b900eb-f3dc-4722-8cc6-e7c6a8e9a776">—</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i938e2f7b2f1e4fa895e67f30ada9c41f_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjMtMTYtMS0xLTI3NjcxMQ_1ee10ca9-3365-44fd-802a-ad9a12d16adc">84</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9039269f1207490282b0792e4917c741_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjMtMjAtMS0xLTI3NjcxMQ_6a5a9924-a659-4bad-bf2a-71120aff8b96">84</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjMtMjQtMS0xLTI3NjcxMQ_9aafee29-dd49-420f-a72e-11e09cf6aabd">84</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i1d7f897933d548d98bf87110aaf1bec9_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtNi0xLTEtMjc2NzEx_d677e457-9c4b-4783-a7ae-d004bdbe5ed6">38</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d7f897933d548d98bf87110aaf1bec9_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtOC0xLTEtMjc2NzEx_a44ae8a0-ef93-4764-b7df-8e5e9c960fe2">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f00a449e9674a358a30d89501ab7031_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtMTAtMS0xLTI3NjcxMQ_5ffdfffb-b465-4cad-b1e7-32d7070f6e8f">329</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i1f0f568cb9864ad2bce94d853d87dfbb_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtMTItMS0xLTI3NjcxMQ_13928a6b-cbd0-4b05-bcfd-19d6d8381cf7">11</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1f0f568cb9864ad2bce94d853d87dfbb_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtMTQtMS0xLTI3NjcxMQ_1abc93a9-ab14-482a-9537-452b2568ec93">361</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9039269f1207490282b0792e4917c741_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtMjAtMS0xLTI3NjcxMQ_32e9e051-a5ef-41c8-90dc-d02079b5548a">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjYtMjQtMS0xLTI3NjcxMQ_43386ade-afef-4395-994e-379c539187c0">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjctMjQtMS0xLTI3NjcxMQ_90cbac2e-c0eb-459c-889c-da5f185741fd">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i938e2f7b2f1e4fa895e67f30ada9c41f_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjktMTYtMS0xLTI3NjcxMQ_5f6cff22-06a7-4184-a885-c3767eb7c20e">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9039269f1207490282b0792e4917c741_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjktMjAtMS0xLTI3NjcxMQ_2eb8b908-2e94-45a5-a680-1f424659caeb">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMjktMjQtMS0xLTI3NjcxMQ_a15f9209-951a-44a8-a268-7845dfa02b81">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i13c34eec3902497ca2a0ef48303e2152_I20210404" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtNi0xLTEtMjc2NzEx_139b3b4d-5922-4614-908a-2580199899f0">9,445</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13c34eec3902497ca2a0ef48303e2152_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtOC0xLTEtMjc2NzEx_7d825806-9961-4caa-a813-f904d4e930f7">472</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibba106cbd1d246e3908670cade753567_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMTAtMS0xLTI3NjcxMQ_eb2273b2-d742-456b-99c8-0a8214677e85">89,002</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="ie9cc08a5833846f7b64c5ab42b042ae6_I20210404" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMTItMS0xLTI3NjcxMQ_47e9b1d3-c886-4115-bc9a-03e7df7c8699">3,851</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie9cc08a5833846f7b64c5ab42b042ae6_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMTQtMS0xLTI3NjcxMQ_1924a13a-91a2-46d7-ba48-6049dd9fad6b">111,349</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35f1b96d7d1d4646a85f4e0fcfab00e3_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMTYtMS0xLTI3NjcxMQ_b518ad76-bd2d-4de3-9570-03c437f4d12c">95,158</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id5b9cfd35dd344ae919c35379016730d_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMTgtMS0xLTI3NjcxMQ_d964ad6f-c223-4eec-97e3-ef2a2c152ca4">4,664</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia21f384aa3d24fe68143411f01dbd95e_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMjAtMS0xLTI3NjcxMQ_f7ac4a5a-6975-410e-b758-6f454fb676e4">68,620</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc4170b088344bffab17c4cce8eac1f4_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMjItMS0xLTI3NjcxMQ_d65a8a46-5c0e-4762-943d-1dccaf2aaca6">245</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f8524a5f7d441e9920a09b866380657_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8yOC9mcmFnOjk1YWM1MGM3YzJiODRiZTA5MzRiNTBhNzEwYzVkMGM4L3RhYmxlOjQ5YjFlNWYyZTdiNjQ0YzQ4OTkyNWI5ODY5ZDNjOTljL3RhYmxlcmFuZ2U6NDliMWU1ZjJlN2I2NDRjNDg5OTI1Yjk4NjlkM2M5OWNfMzAtMjQtMS0xLTI3NjcxMQ_e330fbe5-db50-4a92-816b-f472b5a6f549">68,865</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:280pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_31"></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMy0yLTEtMS0yNzY3MTE_e565048b-51ca-465e-b7ae-8a239e9be3f3">7,870</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMy00LTEtMS0yNzY3MTE_cd3f26d6-d9c1-43ed-849b-af99c01de306">4,886</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued operations—net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNC0yLTEtMS0yNzY3MTE_99e695c0-7b1b-4cb9-9bca-a74f4ddc61a5">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNC00LTEtMS0yNzY3MTE_e2be63c9-66f2-462d-b21b-8c2ed77abafd">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNS0yLTEtMS0yNzY3MTE_dec5f92f-a459-4675-b8f3-ccad2074d523">7,879</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNS00LTEtMS0yNzY3MTE_75e51e2d-030d-43af-aab0-f7cf3ea5ce7f">4,885</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNy0yLTEtMS0yNzY3MTE_bab5d003-1e99-449f-b632-163aeb956ddc">1,187</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNy00LTEtMS0yNzY3MTE_ad07a5cb-2c17-4356-8b01-8d28959c8267">1,207</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfOC0yLTEtMS0yNzY3MTE_3bcda98f-b13e-43e7-b27b-141a5f009b4e">31</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfOC00LTEtMS0yNzY3MTE_88f215ef-821e-4b4f-b84e-cc49e3ba3eaa">24</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTAtMi0xLTEtMjc2NzEx_a19d027a-e59d-4253-8c7d-56aee9e70dfd">2,321</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTAtNC0xLTEtMjc2NzEx_3dd7e464-0462-4e31-b467-92b79e81d2f1">203</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTItMi0xLTEtMjc2NzEx_9e83c92d-cefd-40a1-96ea-cc50ad776830">86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTItNC0xLTEtMjc2NzEx_e9c9a79d-8e05-43f0-bf8e-9d3e01d1713d">172</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTMtMi0xLTEtMjc2NzEx_621f54da-4207-4db5-8d9c-0f380dca91ef">404</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTMtNC0xLTEtMjc2NzEx_a2f4c7af-9ed6-4c9c-91f3-2f61c0b71bbd">373</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTQtMi0xLTEtMjc2NzEx_0f66fc08-79e8-42cc-9271-336e2d55e5d5">815</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTQtNC0xLTEtMjc2NzEx_406c1c6f-a565-4457-aaa8-9fe5ac80b800">291</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other changes in assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTUtMi0xLTEtMjc2NzEx_e61c03d7-25fa-44a5-9b09-04b42963123a">730</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTUtNC0xLTEtMjc2NzEx_04f20ac6-99db-4e31-a98f-7f585bb87b39">1,281</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTYtMi0xLTEtMjc2NzEx_bb4f6964-2f7e-4579-8013-1cc24d929ed1">6,541</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTYtNC0xLTEtMjc2NzEx_d9eb1b92-b5f6-4e2f-bbc5-67f12ade5603">4,546</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTctMi0xLTEtMjc2NzEx_23fab228-9693-464f-a9ac-ee874fb63618">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTctNC0xLTEtMjc2NzEx_a4fb775e-9d68-4d5a-b52e-67bd5ba0c2d3">8</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTgtMi0xLTEtMjc2NzEx_3f949b76-a6df-4144-add6-9c94ffb220f1">6,541</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMTgtNC0xLTEtMjc2NzEx_7c114c04-a1cb-4558-8398-ade3f3f728d6">4,538</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjEtMi0xLTEtMjc2NzEx_3f007851-e965-4e97-b943-753c7681ceda">643</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjEtNC0xLTEtMjc2NzEx_01bfac02-41ce-47c3-9340-96a9269887ca">554</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjItMi0xLTEtMjc2NzEx_ebce565b-5965-49ba-9f0d-ea91ea2a92fe">8,758</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjItNC0xLTEtMjc2NzEx_19c71ce6-0890-4624-88cf-445643f9efd4">6,054</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjMtMi0xLTEtMjc2NzEx_580bddc0-9ff0-48a5-996b-a8042147422e">13,421</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjMtNC0xLTEtMjc2NzEx_50a5ec15-84b2-47ad-bd73-f62380b13f9b">5,465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjQtMi0xLTEtMjc2NzEx_84a27af7-3c2e-429c-868b-90f8c5f392c1">3,409</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjQtNC0xLTEtMjc2NzEx_259f68f8-6497-4671-bb2d-2b649b33cf63">996</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjUtMi0xLTEtMjc2NzEx_9e9e20ea-5a4c-4649-aee4-6778a7a5d1c9">676</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjUtNC0xLTEtMjc2NzEx_3494b6a7-a700-430d-ab41-9cff96490505">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjYtMi0xLTEtMjc2NzEx_4bddeb18-7f07-4b31-8522-1ce995f52b43">52</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjYtNC0xLTEtMjc2NzEx_9febd206-6d78-4282-b6b9-a897744e720c">256</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjctMi0xLTEtMjc2NzEx_5b59339b-6b62-4c7d-8b07-7c46da5f2938">6,225</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjctNC0xLTEtMjc2NzEx_d10e0c50-7a33-4c0a-8afa-9f8133167304">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjgtMi0xLTEtMjc2NzEx_12ee6962-379f-492c-8023-851646bcae43">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjgtNC0xLTEtMjc2NzEx_132ed6bf-d436-46df-a303-3c5dab173494">163</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjktMi0xLTEtMjc2NzEx_dfc12a0d-bff9-4a51-b2f3-e947664ed743">567</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMjktNC0xLTEtMjc2NzEx_c3a3a444-b80c-4447-bd72-c1b1d638169d">1,746</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzAtMi0xLTEtMjc2NzEx_7a03e303-86d1-40b4-8c0a-ec69b3fbe563">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzAtNC0xLTEtMjc2NzEx_305062a5-0a6d-49ac-b5a2-16cc815a4902">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzEtMi0xLTEtMjc2NzEx_275b7a33-3b64-4efe-87cd-0ca1b71b8f10">567</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzEtNC0xLTEtMjc2NzEx_d9798829-1221-4f53-b92e-88af6b0d4cf8">1,747</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzYtMi0xLTEtMjc2NzEx_c58b5fce-2734-4082-bd0e-b8f3611ceab6">220</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzYtNC0xLTEtMjc2NzEx_44ca03fd-6aef-487a-910e-65f422d0e47e">25</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzgtMi0xLTEtMjc2NzEx_efba3979-9e28-4116-a5ec-3d030bfbe5d0">1,609</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzgtNC0xLTEtMjc2NzEx_42c12ef0-73cb-472e-a7a4-a1a54bd4deb2">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzktMi0xLTEtMjc2NzEx_0e820fa6-cf57-4af3-a7c1-6f2ba58c4f09">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfMzktNC0xLTEtMjc2NzEx_98c9f59a-5fb5-4aab-808e-8f936224e012">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDAtMi0xLTEtMjc2NzEx_6f6596ee-fce6-40bf-a735-4efc599f80b8">2,249</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDAtNC0xLTEtMjc2NzEx_fb68f5d0-e453-47b1-b907-b86248cc4ddf">2,172</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDEtMi0xLTEtMjc2NzEx_7a4e1e2d-52c1-4b6c-8c5d-584b2ae14956">501</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDEtNC0xLTEtMjc2NzEx_4ad4f231-f29a-4e18-bcd9-230e00575867">610</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDQtMi0xLTEtMjc2NzEx_bb25b406-9c9b-4a04-9631-de5986ebe912">6,578</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDQtNC0xLTEtMjc2NzEx_b8fed2c4-6138-4d0e-a04d-192f21ca2a1a">2,807</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDUtMi0xLTEtMjc2NzEx_0b0e406d-52ea-4c9b-abc8-0e942d00bd1d">1</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDUtNC0xLTEtMjc2NzEx_c691af1b-79d4-4d63-82bd-3127eadc473f">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDYtMi0xLTEtMjc2NzEx_1268f452-5000-48d2-bb23-b31a84c77496">529</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDYtNC0xLTEtMjc2NzEx_93b5f5ac-5b38-406a-826a-f4ad89d3dee5">15</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDctMi0xLTEtMjc2NzEx_fc3ec2e4-b976-4f2e-b2e9-96692fc62f9b">1,983</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie8af20d8086b440c8e34d1c7b297c77d_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDctNC0xLTEtMjc2NzEx_e201e230-edcc-465e-817b-8ace0fc01cab">1,825</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDgtMi0xLTEtMjc2NzEx_cbc6933a-d2bc-46c9-95fd-1001cb991797">2,513</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f8524a5f7d441e9920a09b866380657_I20210404" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNDgtNC0xLTEtMjc2NzEx_45d9b381-08a4-40f6-941f-1c8a26a215df">1,809</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNTQtMi0xLTEtMjc2NzEx_3b595511-32e2-4d8e-b66d-63ea5f57440d">354</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNTQtNC0xLTEtMjc2NzEx_8488d721-f811-495a-b513-5e767458379f">394</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest paid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNTUtMi0xLTEtMjc2NzEx_56a68153-e82e-407e-b0ba-ca75e1577492">453</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNTUtNC0xLTEtMjc2NzEx_678ea6b5-d602-4e64-95f0-322f455cf9cb">445</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest rate hedges</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNTYtMi0xLTEtMjc2NzEx_e1f56039-3254-4d60-938f-b1050d54bb92">26</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zMS9mcmFnOmYyZDE3NDg0ZmJhNzRhMjY5YzIxZDgxOThlYzhkMzNkL3RhYmxlOmRjYjdjOTI5NjJkNzQ1YWI4MjhlNjEwNTM5OTk4MWQyL3RhYmxlcmFuZ2U6ZGNiN2M5Mjk2MmQ3NDVhYjgyOGU2MTA1Mzk5OTgxZDJfNTYtNC0xLTEtMjc2NzEx_e4c5399d-05ec-4ee8-adc3-12ada66326ef">10</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:75pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_34"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span><br></span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_37"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfNjk4Mw_b1e47829-b7f1-4e5f-8293-f45e2c7ade54" continuedat="i57956835033d4b8f811c9e3afedc4135" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonnumeric></span></div><div><span><br></span></div><ix:continuation id="i57956835033d4b8f811c9e3afedc4135" continuedat="i1215347c742240de9f8f5d91fab22791"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfNjk4NA_6da8192e-2a15-4077-bd74-a1b735789a73" continuedat="ib0c86a44e6b04c7fbebadb27541e6db1" escape="true">Basis of Presentation</ix:nonnumeric></span></div><div><span><br></span></div><ix:continuation id="ib0c86a44e6b04c7fbebadb27541e6db1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&nbsp;27, 2022 and February&nbsp;28, 2021, and for U.S. subsidiaries is as of and for the three months ended April&nbsp;3, 2022 and April&nbsp;4, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of <ix:nonfraction unitref="operatingsegment" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfMTA5OTUxMTY0NTQ4OQ_9ddc39c5-5d88-4532-9a22-d0e65f316fb2">two</ix:nonfraction> operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is the only reportable segment. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities completed in 2022 and 2021 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary, Mylan-Japan collaboration and Upjohn Business. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below.</span></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations and segment reporting.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfMTY0OTI2NzQ0NjA2ODE_0a4f7084-cd7d-495d-9d0d-d8494dd6f004" continuedat="ie29d2d8315834c94abe81cc35373ad4c" escape="true">New Accounting Standard Adopted in 2022</ix:nonnumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie29d2d8315834c94abe81cc35373ad4c">On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.</ix:continuation></span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfNjk5Mw_5124bf18-46b9-4ed3-8eae-122e951d2e6e" continuedat="i3b7b12a4c0a7430698635b718d4a1225" escape="true">Revenues and Trade Accounts Receivable</ix:nonnumeric></span></div><ix:continuation id="i3b7b12a4c0a7430698635b718d4a1225" continuedat="i03a276b67ebf41a3b1f0d168b03a3a34"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i1215347c742240de9f8f5d91fab22791"><ix:continuation id="i03a276b67ebf41a3b1f0d168b03a3a34"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfNjk4Ng_ce5427b3-0203-4655-ae42-3ffbf9269c4c" continuedat="id5be0344109a420791f1aa1134e5dda1" escape="true">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</ix:nonnumeric></span></div><div><ix:continuation id="id5be0344109a420791f1aa1134e5dda1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c9b7c53ecb84f36a9040df3da6ae10e_I20220403" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfMS0yLTEtMS0yNzY3MTE_1dd68159-b6a3-434c-94c1-ae9fb1b59dbc">933</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12238265d1aa4e479cc4f7a3c2a6877a_I20211231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfMS00LTEtMS0yNzY3MTE_297f2a9a-aaf5-40b6-a0b3-6d03902f7b23">1,077</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94555cc427b04136be6b8eef46bd60cd_I20220403" decimals="-6" name="pfe:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfMy0yLTEtMS0yNzY3MTE_dc5a58e5-73c8-4829-80cd-73d9c31c9577">3,858</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i603f28a8b8844abab7ee0491e1019632_I20211231" decimals="-6" name="pfe:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfMy00LTEtMS0yNzY3MTE_a33c85e5-0414-4343-813a-99aeab434f5f">3,811</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94555cc427b04136be6b8eef46bd60cd_I20220403" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfNC0yLTEtMS0yNzY3MTE_3e95e31c-32c8-49e5-9d1e-727b5d034971">440</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i603f28a8b8844abab7ee0491e1019632_I20211231" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfNC00LTEtMS0yNzY3MTE_4e4a20a5-75cc-4e30-915c-39721d353d27">528</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8dec1e006a3442f99a7d0dec8d60d874_I20220403" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfNS0yLTEtMS0yNzY3MTE_9435076f-f5bc-4dc9-b964-919ed7d05480">299</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib2c5c90507e341c9b4342ba705adc4f1_I20211231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfNS00LTEtMS0yNzY3MTE_3f2ee142-9494-4b68-84c8-2cb5b445cb16">433</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfNi0yLTEtMS0yNzY3MTE_8086b740-10da-444f-84cc-90ad1b96426a">5,530</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RhYmxlOmU4NzgyMTA4NjU1OTQwZThiYTcyMjFlMjIyMWI0ZGY5L3RhYmxlcmFuZ2U6ZTg3ODIxMDg2NTU5NDBlOGJhNzIyMWUyMjIxYjRkZjlfNi00LTEtMS0yNzY3MTE_e06a104c-519c-41c9-a549-e3f8e40400de">5,850</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&nbsp;3, 2022 and April&nbsp;4, 2021, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">D. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl8zNy9mcmFnOjM0N2NhZmNiZDE0MjQyMmQ4MmU3YjE2OTNhZmQwZDQ5L3RleHRyZWdpb246MzQ3Y2FmY2JkMTQyNDIyZDgyZTdiMTY5M2FmZDBkNDlfMTY0OTI2NzQ0NjA2ODI_5e4c0548-275e-4f48-97b6-e0ebc73d3fd9" continuedat="i7c5407d3cb554e5f90438fb62fff9df7" escape="true">Acquired In-Process Research and Development Expenses</ix:nonnumeric></span></div><div><span><br></span></div><div><ix:continuation id="i7c5407d3cb554e5f90438fb62fff9df7" continuedat="i7d87bac73ad149c898af47eb5b5178a8"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we began reporting acquired IPR&amp;D expense as a separate line item in our consolidated statements of income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;D. These costs were previously recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Prior periods have been revised to conform to the current period presentation. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. The fair value of IPR&amp;D acquired in connection with a business combination is recorded on the balance sheet as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i7d87bac73ad149c898af47eb5b5178a8">.</ix:continuation> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Notes 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_40"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfNjUxMQ_2bb59162-90b0-4f4c-8b72-11ec1e41f0e0" continuedat="iac052a5d66e14e39a34388f9db3fd3ac" escape="true">Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</ix:nonnumeric></span></div><ix:continuation id="iac052a5d66e14e39a34388f9db3fd3ac" continuedat="i8438ae49b2cd4a32807a4cd5ee4acfcf"><div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Arena––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2022, we acquired Arena, a clinical stage company, for $<ix:nonfraction unitref="usdPerShare" contextref="i15468c66ef3641abb9d639d949cc97d1_I20220311" decimals="0" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY0MTMzNw_ef117d7d-61b7-45b1-85be-2e1c2088ad89">100</ix:nonfraction> per share in cash. The total fair value of the consideration transferred was $<ix:nonfraction unitref="usd" contextref="ie42315d643c849b194a9e9870cd9c000_D20220311-20220311" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDI2OQ_e8a441b3-15b4-48e2-8559-b2d155a67160">6.6</ix:nonfraction>&nbsp;billion ($<ix:nonfraction unitref="usd" contextref="ie42315d643c849b194a9e9870cd9c000_D20220311-20220311" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDI3Nw_5cce3b9b-b5dd-42eb-901e-052e97d96560">6.2</ix:nonfraction> billion, net of cash acquired). In addition, $<ix:nonfraction unitref="usd" contextref="ia1df79109b5e480892a961121084232d_D20220311-20220311" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY1NTEwMA_3de0693a-2b6a-4569-b87c-e01f9fb3e0db">138</ix:nonfraction> million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Arena’s portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including UC, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In connection with this acquisition, we provisionally recorded: (i) $<ix:nonfraction unitref="usd" contextref="i15468c66ef3641abb9d639d949cc97d1_I20220311" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDE2OA_663f06a4-493d-44c6-bfd3-a8dd3f81abed">5.5</ix:nonfraction> billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, consisting of $<ix:nonfraction unitref="usd" contextref="i9eb95056671943cc81072f3d6e3725dc_I20220311" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDE4OA_1238760a-c153-4233-823a-237ec0890bb5">5.0</ix:nonfraction> billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">IPR&amp;D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and $<ix:nonfraction unitref="usd" contextref="i8b6303bcbc1f416eaa7e6dbdd1161364_I20220311" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDIwNg_ef0998cc-e729-4d5d-b1df-5b21268d6349">460</ix:nonfraction> million of indefinite-lived </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Licensing agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ii) $<ix:nonfraction unitref="usd" contextref="i15468c66ef3641abb9d639d949cc97d1_I20220311" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDIyNw_4738634f-b989-4a52-bc0a-9b3da5a784a8">1.0</ix:nonfraction> billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and (iii) $<ix:nonfraction unitref="usd" contextref="i15468c66ef3641abb9d639d949cc97d1_I20220311" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY3NDI0Nw_c29916b6-2083-4f82-b7e6-7de779da1aee">510</ix:nonfraction> million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i8438ae49b2cd4a32807a4cd5ee4acfcf" continuedat="ie29f401830e24de09dd7b37b228f878d"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Discontinued Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Meridian––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, we completed the sale of our Meridian subsidiary. In the three months ended April&nbsp;3, 2022, the amounts recorded under the interim TSAs and MSA were not material.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upjohn Separation and Combination with Mylan––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&nbsp;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination and to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The amounts recorded under these agreements were not material to our consolidated results of operations in the three months ended April&nbsp;3, 2022 and April&nbsp;4, 2021. Net amounts due from Viatris under the agreements were approximately $<ix:nonfraction unitref="usd" contextref="id689b632ad7648e39340b4c4ecf7e7c5_I20220403" decimals="-6" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTIwNw_b161173b-34dd-4a28-812c-079adece5580">133</ix:nonfraction> million as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="i4a65ccb939e84c4dba5f3c3a4379e226_I20211231" decimals="-6" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTIyMw_97ba1537-647a-4c6a-b883-f14f4ef97e2f">53</ix:nonfraction> million as of December 31, 2021. The cash flows associated with the agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $<ix:nonfraction unitref="usd" contextref="iad81607ed38143cb9d3235cb87296aaa_D20210101-20210404" decimals="-6" name="pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTQwMg_7c1f0e21-88fa-42f3-b74c-63966e67479b">277</ix:nonfraction> million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financing activities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer Healthcare JV––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&nbsp;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a <ix:nonfraction unitref="number" contextref="i382208453d554f3fb3da8caf335f8c1d_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMzUyNg_0f121ee2-82c9-409f-9f1f-a0359229f18c">32</ix:nonfraction>% equity stake in the new company and GSK owns the remaining <ix:nonfraction unitref="number" contextref="i9f5b419c0ed743538cdf1de741305959_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMzU4OA_c0b4ce2a-f071-48c7-802a-f66e8d68b8a8">68</ix:nonfraction>%. We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in the Consumer Healthcare JV is $<ix:nonfraction unitref="usd" contextref="i040295c1e7d942378f9fbcd2f5861c9f_I20220403" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMzc1OQ_5f8f0ab4-9e7e-4e10-92c2-ebe929c1c8fd">15.8</ix:nonfraction> billion as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="i1e086e73918041fca5e1fb410bc4e687_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMzc3NQ_05e29c89-21a1-4a9c-9a39-6137182421d6">16.3</ix:nonfraction> billion as of December 31, 2021 and is reported as a private equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of April&nbsp;3, 2022 and December 31, 2021. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2021 is primarily due to $<ix:nonfraction unitref="usd" contextref="i879a6d2e0cfd4ed994589944ca622816_D20220101-20220403" decimals="-6" sign="-" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfNDI1Mw_42b7f586-55cb-4529-b5fa-c99a7e8da188">508</ix:nonfraction> million in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as well as dividends totaling approximately $<ix:nonfraction unitref="usd" contextref="i879a6d2e0cfd4ed994589944ca622816_D20220101-20220403" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfNDM2Ng_5002f25f-1535-4b08-9651-b8322738b171">177</ix:nonfraction> million, partially offset by our share of the JV’s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of the JV’s earnings generated in the fourth quarter of 2021, which we recorded in our operating results in the first quarter of 2022, was $<ix:nonfraction unitref="usd" contextref="i879a6d2e0cfd4ed994589944ca622816_D20220101-20220403" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfNDcwNQ_29bb5a98-bb3b-470f-b9de-c3fe805dfa82">185</ix:nonfraction> million. Our total share of the JV’s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in first quarter 2021, was $<ix:nonfraction unitref="usd" contextref="ie10766bf0ae24289a930c0fcc615c947_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY2MzQ3Mg_dbd910a5-e317-4f16-96b8-09585e63667a">71</ix:nonfraction>&nbsp;million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was not material to our results of operations in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-top:3pt;padding-right:9pt"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfNjUwNw_50ed642c-f134-481c-903a-894c274fbd10" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tbody><tr><td style="width:1.0%"></td><td style="width:53.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:21.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2021, the most recent period available, and for the three months ending December 31, 2020, is as follows:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNC02LTEtMS0yNzY3MTE_1f7c3ab7-8e83-43d0-b317-1a192f78b2cc">3,420</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNC04LTEtMS0yNzY3MTE_013d3bd8-dd82-4a22-b6ab-1c254141c31a">3,096</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNS02LTEtMS0yNzY3MTE_9452409d-6e6e-45d4-9b43-4eb828270a05">1,312</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNS04LTEtMS0yNzY3MTE_f86f567f-c98a-44da-9a9a-bdf82b3c0eba">1,188</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNi02LTEtMS0yNzY3MTE_7930d251-44a4-4950-8b81-1983b9bec108">2,108</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNi04LTEtMS0yNzY3MTE_7fd8515c-12dc-4ac9-bd81-8b9a16778e54">1,908</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNy02LTEtMS0yNzY3MTE_273e0b92-ec82-4a0a-9da4-a10c1b92a2d3">590</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfNy04LTEtMS0yNzY3MTE_5df8d140-0089-4a38-8365-fec3be930bc9">233</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfOC02LTEtMS0yNzY3MTE_ebe44bf5-73b8-4956-819d-8b22b5905adf">590</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfOC04LTEtMS0yNzY3MTE_9960b556-7471-47de-ac27-c7c7cf92f19e">233</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i707d72e8b3f74ce6b0b7d42573842a20_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfOS02LTEtMS0yNzY3MTE_ed07bf18-d284-45fc-be91-a3d049899e24">578</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4779c8f575c46699927280d4a8ed93b_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RhYmxlOmJiZDQwMTRlMjhmNTQ4NThiM2M2YTdjYWM0NWNkYTI5L3RhYmxlcmFuZ2U6YmJkNDAxNGUyOGY1NDg1OGIzYzZhN2NhYzQ1Y2RhMjlfOS04LTEtMS0yNzY3MTE_13a7c8e7-5cdd-496b-9456-c0ceabdcac9a">221</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></div><div style="padding-right:9pt"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with GSK’s previously announced planned demerger of at least <ix:nonfraction unitref="number" contextref="i9ff66ee3367f48d49bbf31222833091f_I20220331" decimals="2" name="pfe:DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzM1NA_65e480a6-a986-411e-82ce-206ed95bbda0">80</ix:nonfraction>% of GSK’s <ix:nonfraction unitref="number" contextref="i9f5b419c0ed743538cdf1de741305959_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY5MTI3Mg_9f97c9e6-44c0-41ac-b493-b69b87ff20b8">68</ix:nonfraction>% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $<ix:nonfraction unitref="usd" contextref="ifaf907bd141547e19b74a026ba7f0134_I20220331" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzM2Mg_464e695a-f0ec-45b0-83ea-ea99712c3ee9">8.75</ix:nonfraction> billion in U.S. dollar-denominated senior notes of various maturities, €<ix:nonfraction unitref="eur" contextref="if9449ddf354b403b9cf69f6f077bd1a9_I20220331" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzM4MQ_17a6aa6d-c2ca-4973-9c83-0f69d7ca9afe">2.35</ix:nonfraction> billion in euro-denominated senior notes of various maturities and £<ix:nonfraction unitref="gbp" contextref="ia07d5ab3909a4980955e25483fd82b58_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzQwMA_b1605b05-6d73-466f-881c-f7280466bbeb">700</ix:nonfraction> million in U.K. pound-denominated senior notes of various maturities (collectively, the “notes”). The notes are guaranteed by GSK generally up to and excluding the date of the demerger (the “Guarantee Assumption Date”). We have agreed to indemnify GSK for <ix:nonfraction unitref="number" contextref="i39bbe12b10e2474a9db26d160b63a838_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzQxNw_19713787-04bc-4024-960f-c67471646c95">32</ix:nonfraction>% (representing our pro rata equity interest in the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity is provided solely for the benefit of GSK and will terminate automatically as of the Guarantee Assumption date. Neither we nor any of our subsidiaries is an issuer or guarantor of any of the notes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ie29f401830e24de09dd7b37b228f878d"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following its issuance of the notes in March 2022, in our fiscal second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of £<ix:nonfraction unitref="gbp" contextref="icf9274520070475ca1f2161cd5dbf428_I20220703" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzQyOQ_cb0e2f42-d7e9-47b8-a6a8-e374fd5c81b0">2.9</ix:nonfraction> billion, at an interest rate of <ix:nonfraction unitref="number" contextref="icf9274520070475ca1f2161cd5dbf428_I20220703" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzQ0Nw_f99de500-c4db-4b23-a1bd-5448b6986da9">1.365</ix:nonfraction>% per annum payable semi-annually in arrears. The loan will mature and be repaid upon the earlier of two business days after approval of the demerger transaction by GSK’s shareholders or two business days after the occurrence of a mandatory redemption event with respect to the notes. In conjunction with the demerger, we will receive our <ix:nonfraction unitref="number" contextref="i674b1fff8a4b4219a4293016fe8c5466_I20220703" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NzQ1Ng_4369f13d-b745-4b7f-94f9-a73ac6d2f682">32</ix:nonfraction>% share of the proceeds repaid by us and GSK as a dividend from the Consumer Healthcare JV.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Collaboration Arrangement</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Biohaven––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Biohaven will continue to lead R&amp;D globally and we have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January&nbsp;4, 2022, we paid Biohaven $<ix:nonfraction unitref="usd" contextref="ied3105006d2547148f6cb559c3019e56_D20220104-20220104" decimals="-6" name="pfe:PrepaymentsAndPaymentsToCollaboratorsCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NjkyNA_90c34cc0-7f80-4ddd-92b5-fbcd02fd1a7c">500</ix:nonfraction> million, including an upfront payment of $<ix:nonfraction unitref="usd" contextref="ied3105006d2547148f6cb559c3019e56_D20220104-20220104" decimals="-6" name="pfe:PaymentsToCollaboratorsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NjkzMA_a0364eb3-ec62-48ee-af77-de18f9dd6771">150</ix:nonfraction> million and an equity investment of $<ix:nonfraction unitref="usd" contextref="ibe020f44277e4451bc0f4ff8edbf0881_I20220104" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4NjkzNQ_8dae2c0d-8a50-470f-8810-c85a027ac7d8">350</ix:nonfraction> million. We recognized $<ix:nonfraction unitref="usd" contextref="i0b173b9f098a439191c3f825530bdf55_D20220104-20220104" decimals="-6" name="pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4Njk0MA_17118673-0d66-479b-956d-4f5d0116bb71">263</ix:nonfraction>&nbsp;million for the upfront payment and premium paid on our equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Biohaven is also eligible to receive up to $<ix:nonfraction unitref="usd" contextref="ied3105006d2547148f6cb559c3019e56_D20220104-20220104" decimals="-6" name="pfe:CollaborativeArrangementMilestonePaymentUponCommercializing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80MC9mcmFnOjk3MWY4Zjg3YjNiZjRmNjNhN2M0ZTZmMTJjMmEzYWY0L3RleHRyZWdpb246OTcxZjhmODdiM2JmNGY2M2E3YzRlNmYxMmMyYTNhZjRfMTA5OTUxMTY4Njk0OA_27cfdc05-e55d-49bc-b31f-1630b409558c">740</ix:nonfraction> million in non-U.S. commercialization milestone payments, in addition to tiered double-digit royalties on net sales outside of the U.S. In addition to the milestone payments and royalties above, we will also reimburse Biohaven for the portion of certain additional milestone payments and royalties due to third parties in accordance with preexisting Biohaven agreements, which are attributed to ex-U.S. sales.</span></div></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_43"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzM2NA_4e10f05d-a8c4-48c7-ba1a-a0ff5919594e" continuedat="i8e10040da3354ee690ec90c6bb3a6614" escape="true">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonnumeric></span></div><ix:continuation id="i8e10040da3354ee690ec90c6bb3a6614" continuedat="iefe8e4d4fd8540d3b66aab452c363c68"><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV, and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $<ix:nonfraction unitref="usd" contextref="i70b6a831bcc0470892350c70cf0f78e7_I20220403" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5Nzk0OQ_f433d93a-8110-4800-ad3a-447d33e98c50">1.8</ix:nonfraction>&nbsp;billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $<ix:nonfraction unitref="usd" contextref="i0cb9c7ff633e48efaba82fb171b6db9a_I20220403" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5Nzk1Ng_b1e23121-09a8-45e8-ac51-4fabfa18df36">1.1</ix:nonfraction>&nbsp;billion, with substantially all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $<ix:nonfraction unitref="usd" contextref="i7b20eb0b9e4d45da8ce4575d0fbe8876_I20220403" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5Nzk2NA_b558cf91-9339-4442-bf4c-18c305f3a601">800</ix:nonfraction>&nbsp;million, with approximately <ix:nonfraction unitref="number" contextref="ib4e37c003dea455595ecad1c5558f769_D20220101-20220403" decimals="2" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5Nzk3OA_2c85a898-494d-4d9d-8873-330042c3b57f">25</ix:nonfraction>% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through April&nbsp;3, 2022, we incurred costs of $<ix:nonfraction unitref="usd" contextref="i3e79252820bb4372bc5ba159b885f0b7_I20220403" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5Nzk4Mw_aab83ee5-26ae-4ede-8dee-be4f88de7fc7">2.3</ix:nonfraction>&nbsp;billion, of which $<ix:nonfraction unitref="usd" contextref="i79fb055b33a449afb47c4b9a9e9700f4_I20220403" decimals="-6" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5ODIzNg_61774e3c-4e66-41e2-87f1-32a452de9caf">875</ix:nonfraction> million is associated with Biopharma ($<ix:nonfraction unitref="usd" contextref="if4ae83a5d5594c108d70e5ba7679f49e_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5ODI0Ng_578890b5-4113-417a-9eb1-e51de1ce4be5">20</ix:nonfraction> million in 2022, $<ix:nonfraction unitref="usd" contextref="i549961d20ca8459a885500a5ff9919e8_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5ODI2MQ_93e34d54-bfa3-4bc5-8c94-930bad4479b6">712</ix:nonfraction> million in 2021, $<ix:nonfraction unitref="usd" contextref="ibd6e951ae1fe486db8b6cb7e9b7a9b24_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5ODE2Mg_977004da-2d8f-4146-96ba-c3b80aa09dce">79</ix:nonfraction> million in 2020 and $<ix:nonfraction unitref="usd" contextref="i3c3c3969eee84bc8ad00958720166a04_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5ODE3OA_4014265d-2f38-4196-abe4-59bedf79c4a8">64</ix:nonfraction> million in 2019).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="iefe8e4d4fd8540d3b66aab452c363c68"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMxMg_b62f5574-3907-4bfd-bcf4-362252f91412" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNC02LTEtMS0yNzY3MTE_5bfe86c3-8c39-4512-9236-54bc8acad028">25</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNC04LTEtMS0yNzY3MTE_7b61c3af-0b29-4625-a989-414eb46545db">22</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNS02LTEtMS0yNzY3MTE_f0d1dd59-3362-4923-8ab1-bc6564d47653">8</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNS04LTEtMS0yNzY3MTE_7604b5bb-f8af-4b0b-abcb-93de4c7ea907">5</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNi02LTEtMS0yNzY3MTE_8ce44501-faf2-408f-91ec-2055b2b3ebd0">11</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNi04LTEtMS0yNzY3MTE_5f1c7d40-53d9-47fb-a982-30b208667a70">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNy02LTEtMS0yNzY3MTE_5c7e31d5-580b-475f-8ff9-77bd3b5e9bbb">43</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfNy04LTEtMS0yNzY3MTE_b4714f00-d863-44e9-87d3-17834b4e02cd">17</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOC02LTEtMS0yNzY3MTE_ac0c3825-2dc7-4645-8115-597a9f66b60b">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOC04LTEtMS0yNzY3MTE_92804a6e-7ffc-4ba7-a2b2-28978bdff81f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOS02LTEtMS0yNzY3MTE_5701b7ca-9019-4502-92c2-440d87214ffe">142</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfOS04LTEtMS0yNzY3MTE_d1b1c5b6-3b2c-4717-a68c-b4094f5e42bc">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTAtNi0xLTEtMjc2NzEx_efc3b70b-70be-4fda-9d65-a1da809c8879">192</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTAtOC0xLTEtMjc2NzEx_b5722167-9310-49c1-a157-b6c29ff875ea">22</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6764ff911980490d90a88335c9c244cf_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTEtNi0xLTEtMjc2NzEx_0a847a98-9f7a-4e16-b24b-d3164bf6dc9a">6</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7997f3c210e42e59fbf52fbd7f8225f_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTEtOC0xLTEtMjc2NzEx_ab5c117f-1fb4-44fe-bfad-aecf11362e62">8</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation––asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income, mainly in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTYtNi0xLTEtMjc2NzEx_6abb5122-1461-477e-b93f-b9ccf2d62639">9</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTYtOC0xLTEtMjc2NzEx_b8a79dc3-a3ba-401b-8608-8c0704512110">6</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied386218bb3c4c3b8d4fb4de5f0189f0_D20220101-20220403" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTgtNi0xLTEtMjc2NzEx_3ae80567-f959-47b8-b366-bd58af307786">12</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idaee05a046b841ef8d7e6aefddcc8afc_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTgtOC0xLTEtMjc2NzEx_3320bbfb-12f1-4bbf-a9d1-0603b98a8eba">11</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i61f95377cb5943d389feffc9f0841f5f_D20220101-20220403" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTktNi0xLTEtMjc2NzEx_d418b89e-6512-438b-a053-9a1119c71c5e">74</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib8be90d4fa7d4c53b4bae11492692a69_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMTktOC0xLTEtMjc2NzEx_dcd2ac17-a868-492e-a22a-e4de35e649a1">64</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMjItNi0xLTEtMjc2NzEx_7436a958-d57a-42fb-863b-f4abb026ee45">85</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMjItOC0xLTEtMjc2NzEx_fbcc7043-4355-47ba-a81b-77da6c2237d5">75</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMjMtNi0xLTEtMjc2NzEx_4ff259ea-1c75-4921-bb0b-ef4595ea5725">280</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmYyNDg0MGFjY2U0ZjQ5NGY5N2U2NjFkNmJiMjAxMjFlL3RhYmxlcmFuZ2U6ZjI0ODQwYWNjZTRmNDk0Zjk3ZTY2MWQ2YmIyMDEyMWVfMjMtOC0xLTEtMjc2NzEx_ffa70a0b-6cb4-4e79-8b13-7c930fd58321">111</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMxMw_c73b5615-0036-48ea-b33d-cda250629053" footnoterole="http://www.xbrl.org/2003/role/footnote">Primarily represents cost reduction initiatives.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzI4Mg_6756ee43-1095-4a17-8861-455db1f58311" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents external costs for banking, legal, accounting and other similar services.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMwMQ_3b2655fa-b2d8-4ac0-9b23-85f366110ca0" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $<ix:nonfraction unitref="usd" contextref="ia28e9a23b0ed4ea08362cc89f563adcc_D20220101-20220403" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfNzY5NjU4MTM5OTc5MQ_b4a74f99-83b7-4e69-8ce0-6da6abc25f2b">138</ix:nonfraction> million in payments to Arena employees for the fair value of previously unvested long-term incentive awards. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMxNA_dadd1793-8807-4149-8ae8-090e6c8cf72c" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMyOA_3fec174c-cf24-4175-8265-d49416dc2686" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMwNg_976d6477-4e5a-49c8-a976-e431bf72cd98" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br>Termination<br>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br>Impairment<br>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b2b8f6094d14e579e10ac9083d0dd15_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi0yLTEtMS0yNzY3MTE_5c12f0ca-81a6-41db-b277-5097a60dc6cb">1,014</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic350c30fdd434e918124f33a6867dab7_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi00LTEtMS0yNzY3MTE_97ee3fcb-af53-4f1f-90a2-fad1d8d02767">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09931fa080534cb4a6b09d3324e26545_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi02LTEtMS0yNzY3MTE_739511f4-c963-4ada-9086-92f84fd114a1">57</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMi04LTEtMS0yNzY3MTE_22d1db9b-7e5b-4aa7-8cfd-fd7d43e08dc5">1,071</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if10d33e52d3442bcaaaaac234aecb668_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMy0yLTEtMS0yNzY3MTE_5b8d5a73-a0dc-47c3-8515-f87506f15e2b">25</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib52e1bff87a248e0b22e8ad724382bb3_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMy00LTEtMS0yNzY3MTE_c31d4da9-04fb-4503-b5cc-a41239fddeab">8</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0d8c3b6172ee44f8972b20b4b572c479_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMy02LTEtMS0yNzY3MTE_081fd619-a015-4f76-ab45-3120cb6f5acd">11</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfMy04LTEtMS0yNzY3MTE_a5254ba8-9a34-44a3-b2db-c803b2e75d15">43</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if10d33e52d3442bcaaaaac234aecb668_D20220101-20220403" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC0yLTEtMS0yNzY3MTE_0d9b45c5-8f47-43f7-ae3e-4ee8228134a4">95</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib52e1bff87a248e0b22e8ad724382bb3_D20220101-20220403" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC00LTEtMS0yNzY3MTE_7ddfd518-ab9a-40cb-b50e-75c9144adc65">8</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0d8c3b6172ee44f8972b20b4b572c479_D20220101-20220403" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC02LTEtMS0yNzY3MTE_9c863ff0-df81-47e0-9353-ad38d1182c06">59</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNC04LTEtMS0yNzY3MTE_7e0b284d-3912-4c48-b9d9-cb3a314fccfd">163</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, April&nbsp;3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idbe7e6276c1a4ec3a551624e7f1de9f1_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS0yLTEtMS0yNzY3MTE_3f7fe3a5-46e3-4100-a87d-5dfeab97bc8d">943</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3978efe2842145f386795df734859f6c_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS00LTEtMS0yNzY3MTE_abc1ff6a-38f5-4dfd-9e91-8f449d1110e3">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18a65e13457c493489ebc854aa0ee053_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS02LTEtMS0yNzY3MTE_a6282636-1540-47ab-a95f-adeec336a91b">9</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RhYmxlOmUxM2ZkNmYzMWU1NjRlNWM4YThmOWRmYzFjNGIzZGMxL3RhYmxlcmFuZ2U6ZTEzZmQ2ZjMxZTU2NGU1YzhhOGY5ZGZjMWM0YjNkYzFfNS04LTEtMS0yNzY3MTE_b48ae1be-01d5-47fe-bde0-63f6150b4ce1">952</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzMyNA_b8c06b30-d95f-47ac-b79a-f39e34322ae6" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonfraction unitref="usd" contextref="i603f28a8b8844abab7ee0491e1019632_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzEwMw_9686174e-1f9b-4927-a74d-60bb25f868f2">816</ix:nonfraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonfraction unitref="usd" contextref="ib2c5c90507e341c9b4342ba705adc4f1_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzE0MQ_6253914b-1145-4ffa-8b93-e97374fcc512">255</ix:nonfraction> million).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzI4OQ_1a61c783-e703-413d-8352-d4238e74ecaa" footnoterole="http://www.xbrl.org/2003/role/footnote">Includes adjustments for foreign currency translation.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzM2Mg_edc25c48-81c3-4be7-a0ac-8889c9442212" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonfraction unitref="usd" contextref="i94555cc427b04136be6b8eef46bd60cd_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzI0MA_0fef830f-bbf1-4d17-a52a-4656e0009043">812</ix:nonfraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonfraction unitref="usd" contextref="i8dec1e006a3442f99a7d0dec8d60d874_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80My9mcmFnOjMxMWEwYzk1NjU0YTRjYmZiNTFjNTExYzlhYmIzNDRlL3RleHRyZWdpb246MzExYTBjOTU2NTRhNGNiZmI1MWM1MTFjOWFiYjM0NGVfMzI3OA_f568b432-382d-432f-a3b5-408929ba3338">140</ix:nonfraction> million).</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_46"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU2OA_7a48f9d4-2d9b-4333-af79-1f7db00f2e68" continuedat="ia23cf60b58f54917b065b04afd68098c" escape="true">Other (Income)/Deductions—Net</ix:nonnumeric></span></div><ix:continuation id="ia23cf60b58f54917b065b04afd68098c"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU3Ng_9797a22b-9258-432a-89d5-0953f31eaae3" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMy02LTEtMS0yNzY3MTE_69aa1be4-cfb2-456f-9382-39edfcd44c0e">14</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:InvestmentIncomeInterest" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMy04LTEtMS0yNzY3MTE_869d2436-c604-467f-a961-dcd3633a9951">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNC02LTEtMS0yNzY3MTE_bffb1076-4cfb-4ba0-995e-25eff83b224c">322</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNC04LTEtMS0yNzY3MTE_709d8f83-cce1-4d42-8844-99c1249374aa">336</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNS02LTEtMS0yNzY3MTE_7d17abf1-fe33-4eba-878b-0489ca3c2418">308</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNS04LTEtMS0yNzY3MTE_d832248e-a925-4f74-93a9-429b0adcbcda">336</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNi02LTEtMS0yNzY3MTE_b35fb59c-2d5b-4c99-b7e6-3b05ce958cb0">173</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNi04LTEtMS0yNzY3MTE_d27e6088-3a5c-4aa8-872f-b6859a7a08d5">176</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNy02LTEtMS0yNzY3MTE_518ead7f-fe44-430c-9e7e-12b7d00a467c">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfNy04LTEtMS0yNzY3MTE_a7024ebd-e6a3-4c70-a39f-20789b8158a8">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOC02LTEtMS0yNzY3MTE_f4f651cd-5131-441b-87e6-99be1a15ec71">699</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOC04LTEtMS0yNzY3MTE_c564b312-299e-4d8a-ae5b-e9a85e91e012">401</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOS02LTEtMS0yNzY3MTE_052bbe79-4b0d-4b5b-8fbc-8b2cc269b555">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfOS04LTEtMS0yNzY3MTE_ff27b6a5-982f-43bc-8996-69855833dc2d">231</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTAtNi0xLTEtMjc2NzEx_fe44c92a-1824-4d52-81ae-3c35ec56013d">283</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTAtOC0xLTEtMjc2NzEx_896b76a3-80a9-4e49-9987-0384e9f1399b">266</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTEtNi0xLTEtMjc2NzEx_97fbb1eb-0a2a-4990-a007-44e64d2971e9">79</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTEtOC0xLTEtMjc2NzEx_b6178811-31a9-4c3c-b68a-3a04fb52de3f">51</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTMtNi0xLTEtMjc2NzEx_034771d1-a296-4669-8609-d55e8a066216">184</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTMtOC0xLTEtMjc2NzEx_ca263689-3166-4d00-8e49-e515a82eba8a">62</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTQtNi0xLTEtMjc2NzEx_64e168ed-0459-4abd-9f3c-429359f88971">88</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTQtOC0xLTEtMjc2NzEx_a47d0a36-650e-4353-a685-0355ae063ee7">216</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTUtNi0xLTEtMjc2NzEx_3ce45104-4a77-432c-87ba-615b0e5d94a5">350</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RhYmxlOjY3ZDJiN2M1YzA2NzRlYmY4ZTc5NTA5ZDExZGFiOGMwL3RhYmxlcmFuZ2U6NjdkMmI3YzVjMDY3NGViZjhlNzk1MDlkMTFkYWI4YzBfMTUtOC0xLTEtMjc2NzEx_e503bbd9-94f0-4f90-84fa-1cfb8623a23b">1,004</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU4OQ_60d31938-9d8b-4d11-a712-cf95cc0ffe74" footnoterole="http://www.xbrl.org/2003/role/footnote">The losses in the first quarter of 2022 include, among other things, unrealized losses of $<ix:nonfraction unitref="usd" contextref="ib7cf3f34d9c1402bb80ccb929ef82b9f_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfNzY5NjU4MTQwMDY3Nw_33ddaed6-992b-46b4-a5f4-206cff5fa4dd">473</ix:nonfraction>&nbsp;million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $<ix:nonfraction unitref="usd" contextref="ic08eaeb5343647d6a3de076ea1d335ab_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfNzY5NjU4MTM5NjA2NQ_8e2fc606-2a38-4115-a35d-9d37ea579de7">409</ix:nonfraction>&nbsp;million related to investments in Allogene Therapeutics, Inc. and BioNTech.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU3Nw_63b28fd3-0799-4eba-a4aa-844531357200" footnoterole="http://www.xbrl.org/2003/role/footnote">The first quarter of 2021 included, among other things, $<ix:nonfraction unitref="usd" contextref="i96242ca8b97447f68763298df944081a_D20220101-20220403" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfNDc4_ee97e679-5a34-4aa5-b95a-9404bb552ae3">188</ix:nonfraction>&nbsp;million of net collaboration income from BioNTech related to Comirnaty.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80Ni9mcmFnOjUxOWEwNWM5YWFiYjQ4NjlhNmY0OTIwYjFiOTEzYmFiL3RleHRyZWdpb246NTE5YTA1YzlhYWJiNDg2OWE2ZjQ5MjBiMWI5MTNiYWJfMTU4Mw_a5ef37ab-7e53-4d47-81bd-b84e6a4de43b" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span></ix:footnote><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_49"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMzE0NQ_db7f3fab-6791-4073-a8ff-20b1c2d9bf6a" continuedat="i639fc84cb12b48bdbe5ddb7d17690368" escape="true">Tax Matters</ix:nonnumeric></span></div><ix:continuation id="i639fc84cb12b48bdbe5ddb7d17690368" continuedat="iaac0533104d14daba74601142214baeb"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was <ix:nonfraction unitref="number" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMTE1_b264ab9f-e0ec-4535-9a57-90acfe6155f4">12.9</ix:nonfraction>% for the first quarter of 2022, compared to <ix:nonfraction unitref="number" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMTU2_a580a7a2-4312-4c7e-b233-8869a317cbf8">14.2</ix:nonfraction>% for the first quarter of 2021. The lower effective tax rate for the first quarter of 2022 was primarily due to the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-9" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMTI0NQ_deb48bab-698c-4aff-a5a7-fd177d5f0f54">15</ix:nonfraction> billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fourth annual installment of this liability was paid by its April 18, 2022 due date and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of April&nbsp;3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent’s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2022 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="iaac0533104d14daba74601142214baeb"><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMzE0Ng_89331d81-b5af-496f-afa9-e9ef2d551de1" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMy02LTEtMS0yNzY3MTE_36d83234-c8c3-4408-aaea-d973af7823b9">72</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMy04LTEtMS0yNzY3MTE_5c3b7097-6c4d-46bd-b0b3-090fd368b19a">21</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNC02LTEtMS0yNzY3MTE_48dc0ff8-74f7-4f97-bc9c-dec8fec45222">32</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNC04LTEtMS0yNzY3MTE_45a564f2-e5c2-4f37-8112-444e2c53d72e">59</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNS02LTEtMS0yNzY3MTE_55e5a888-bc5e-4d54-b5cf-780741d42760">22</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNS04LTEtMS0yNzY3MTE_de3f92df-6d4e-49c2-be93-b30959cb7faa">34</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNi02LTEtMS0yNzY3MTE_bd1d7d62-1484-48cb-99e3-09690978b640">10</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNi04LTEtMS0yNzY3MTE_ba59422d-e463-4d14-a1bc-e9bed7cce7ef">93</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNy02LTEtMS0yNzY3MTE_f8bb61ad-2725-4712-844e-b7c11de8f753">17</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfNy04LTEtMS0yNzY3MTE_515b189c-3ff5-4f6c-9305-efbf3b620a03">10</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfOC02LTEtMS0yNzY3MTE_16e98990-4632-43f5-8eaf-0f0678fe5867">29</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfOC04LTEtMS0yNzY3MTE_9259e108-6bd7-4f9e-976a-6682c25bc94a">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfOS02LTEtMS0yNzY3MTE_5a196b09-74f4-4778-91df-4af829e3cbcf">12</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfOS04LTEtMS0yNzY3MTE_2eb53865-ac6b-4cb5-9342-431b192d25cc">20</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTYtNi0xLTEtMjc2NzEx_d7e88770-07ee-4797-a24f-b11db47d81dc">9</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTYtOC0xLTEtMjc2NzEx_ad9688a4-aecc-4bf8-845e-b1aa951d81a9">10</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTctNi0xLTEtMjc2NzEx_6c62ff34-fd6c-4682-92e8-f8e3616da7d5">2</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTctOC0xLTEtMjc2NzEx_2b0558d6-becf-43a7-b990-b82a37a72049">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTgtNi0xLTEtMjc2NzEx_bdc433db-ec12-481e-a060-25b7a942cea3">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTgtOC0xLTEtMjc2NzEx_ef4dcaf8-f38c-4446-b9fe-b0483466b339">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTktNi0xLTEtMjc2NzEx_977f36cd-edac-4a2a-a533-ff22f83d1728">11</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMTktOC0xLTEtMjc2NzEx_7e1c0ccc-3ae6-4482-9ac3-c1b10b6eed57">10</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMjAtNi0xLTEtMjc2NzEx_eed42126-549b-4d75-a4f9-173181f6629d">60</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RhYmxlOjg1Mzg4NjM3YWJiZDRmYzRhZDAzMGM5MjExYTQ3MzcyL3RhYmxlcmFuZ2U6ODUzODg2MzdhYmJkNGZjNGFkMDMwYzkyMTFhNDczNzJfMjAtOC0xLTEtMjc2NzEx_df8e6c88-27e0-471e-8d20-08e8c5a394dc">84</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl80OS9mcmFnOjdhMjM4NDM5YzRiMjQzYmI5NDFlMzNjZjg1MGZjM2M4L3RleHRyZWdpb246N2EyMzg0MzljNGIyNDNiYjk0MWUzM2NmODUwZmMzYzhfMzEzNQ_678dec91-ae9c-4a98-8277-e47d087a1892" footnoterole="http://www.xbrl.org/2003/role/footnote">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_52"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RleHRyZWdpb246OTQ3Mzk5YjEzNWZlNDcwNzgyYjQ1ZWYyYjQ0N2U5NDFfNDIz_82e3dbdc-df92-4d25-996b-a5b0823059fd" continuedat="if8146a2d712147c289b07ebe05f820f2" escape="true">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonnumeric></span></div><ix:continuation id="if8146a2d712147c289b07ebe05f820f2"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RleHRyZWdpb246OTQ3Mzk5YjEzNWZlNDcwNzgyYjQ1ZWYyYjQ0N2U5NDFfNDQy_4e62ce55-168c-4054-b9de-a95ef0898ca8" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.818%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6f81f90ccc9c420d8581eff30eeb192d_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfMy0yLTEtMS0yNzY3MTE_88458094-a748-4776-90b8-dfe06c19a46b">6,172</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57e21079a04843ccac94ff0193b25051_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfMy00LTEtMS0yNzY3MTE_4daa05fe-1f28-410a-afd8-aef091138fec">119</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i80810fe7b1fb4e84ac1cdcf70d0251a1_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfMy02LTEtMS0yNzY3MTE_1f01a438-1e45-4b8f-8e69-25c5aef015a9">220</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd22db8c38aa417981ad7a0e2adb8189_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfMy0xMC0xLTEtMjc2NzEx_482ea4f1-8417-4bdd-a78d-75894a9e6932">377</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8511b3061229447b8d673d4ed6657a87_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfMy0xMi0xLTEtMjc2NzEx_fe930192-9c84-4ac2-a82d-9e3811ec91ba">5,897</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad6e5a93db534b438c8606c1f7937563_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC0yLTEtMS0yNzY3MTE_f2e69915-d6b8-4db4-94dd-f75ff2ad3579">291</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6cff15f7abe44cf49e467a3297fab453_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC00LTEtMS0yNzY3MTE_6c4fb955-37e5-45da-a6e0-c9549d36034e">20</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89c9124da14d4587b7cad1bc582c4951_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC02LTEtMS0yNzY3MTE_fb76c241-7501-4ced-8b51-ce685514d8a6">87</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9b73d6c111e444508e42f974c521096d_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC0xMC0xLTEtMjc2NzEx_038ffe18-8497-4a2c-beef-ce6f274507ea">36</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40cd2a56baa6486fb861a72bd0d777df_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNC0xMi0xLTEtMjc2NzEx_f4626249-ba42-40f4-a656-5a8ea1c87df4">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, April 3, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1cf0746d1f7f4449a4bbe5dba43df7be_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNi0yLTEtMS0yNzY3MTE_1ea5275f-c4af-4f15-8791-307ed13dbf39">6,463</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i516731bc71ea48fe8d48153c642aedab_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNi00LTEtMS0yNzY3MTE_f7bd6cf6-d3fb-481d-ae48-e197bccaef43">99</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia4ea2ecde3c64d27999fbf67ea2b1427_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNi02LTEtMS0yNzY3MTE_7d3f0977-7e08-45d4-aa15-68ed0e5f1656">133</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i374a7b3695714592af18df30ab5e6735_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNi0xMC0xLTEtMjc2NzEx_3a204cb5-4701-4732-8bc6-72cbe9b9bdc8">341</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifee369d41246499390fcd23d443dc9e2_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RhYmxlOmM4ZmRmYmMwNzFlYzQyZGRiNTI5ZWFlNmUxNDAxOGE2L3RhYmxlcmFuZ2U6YzhmZGZiYzA3MWVjNDJkZGI1MjllYWU2ZTE0MDE4YTZfNi0xMi0xLTEtMjc2NzEx_5f780488-89dc-47ba-8522-896e87385213">6,157</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81Mi9mcmFnOjk0NzM5OWIxMzVmZTQ3MDc4MmI0NWVmMmI0NDdlOTQxL3RleHRyZWdpb246OTQ3Mzk5YjEzNWZlNDcwNzgyYjQ1ZWYyYjQ0N2U5NDFfNDM4_7eaa69a0-dadf-4575-a953-f6a33fbb79e2" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="text-indent:9pt"><span><br></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_55"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMTIxNQ_6f3d3942-e01f-4902-9f8d-b5a2e9a3f92d" continuedat="i5d790fb87ccf4ea286db75a48684672b" escape="true">Financial Instruments</ix:nonnumeric></span></div><ix:continuation id="i5d790fb87ccf4ea286db75a48684672b" continuedat="ia11eac669b6e4970828710c2f902fa11"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br></span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMTIwOA_595b4b3d-6f97-4067-807c-c4ba71c0e301" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i367fc1c6e7b64b73a217ff29fda9d9f0_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNS0yLTEtMS0yNzY3MTE_c64545d0-5ae0-494d-aac9-816afd9949ba">2,759</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6c07a699ef44298b841bf2c068bf51c_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNS00LTEtMS0yNzY3MTE_adcade65-068d-426c-8432-aff400b9d5fa">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd924c84adf54e518c3e1d75cd69936e_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNS02LTEtMS0yNzY3MTE_c3ce9869-ece0-4c6c-8990-d2ef0443c5be">2,759</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia94a83f310e84ba4aa701380ba2edca2_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNS0xMC0xLTEtMjc2NzEx_e431cfe6-5ae2-4d10-8cb6-e79e76197f92">5,365</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0f3def88b804499af53cf624612bf4a_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNS0xMi0xLTEtMjc2NzEx_0cb4ed62-fea2-49f3-8fec-422eeef135bf">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id44a7c8fd9984ac28a7e2d7155a0847d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNS0xNC0xLTEtMjc2NzEx_17d158ba-82c1-49fe-a1f4-b32081006382">5,365</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1023b68735d1408080ea06bff3ba9950_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOC0yLTEtMS0yNzY3MTE_7db56c2a-f62e-4f72-974d-896a45433125">14,548</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49c0d194acc94c2795747bf67459897d_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOC00LTEtMS0yNzY3MTE_0905e8b2-6a2c-4fd5-8e55-5040c24376a3">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9182925c87fd421b9a3ee71e067144da_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOC02LTEtMS0yNzY3MTE_39b1728f-6802-4a09-906a-412394b52f95">14,548</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id93e24d58c7e43b58b6132641e42881a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOC0xMC0xLTEtMjc2NzEx_be22b41b-e180-4d70-91df-60e810c85b92">17,318</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ce1c28205114c3b835fe5959d0fa198_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOC0xMi0xLTEtMjc2NzEx_a78da7e5-2a19-493f-82f6-abb3eba6dc7f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic09ad8403c2f48ffa6768d5cb0c25dff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOC0xNC0xLTEtMjc2NzEx_a01d6aff-0f49-443b-9c66-82cdfd757760">17,318</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i81b8d860fd6b4952832cb789b371b3d4_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOS0yLTEtMS0yNzY3MTE_fa28eb79-0b7f-49e3-b2d4-63b5df0b62be">1,830</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0a6af5df56b84dd6b562218fa5add6a1_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOS00LTEtMS0yNzY3MTE_1cbbcd7a-5283-451b-9d40-b35167b26238">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab864c90b18646c4ae99b4a93fd52671_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOS02LTEtMS0yNzY3MTE_e47fae06-6490-48fb-b686-706b38ae73ca">1,830</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3645413e985740eda0525681c093b00e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOS0xMC0xLTEtMjc2NzEx_ce69c9c9-2036-40ae-8605-dc4d33f08eb3">4,050</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iac9b309377d443e092ec47f072ae8917_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOS0xMi0xLTEtMjc2NzEx_84ba0da3-bc30-4a11-a340-72ea296a11a8">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i84ad69d7dfb243d19c9b990d51361869_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfOS0xNC0xLTEtMjc2NzEx_a631ad13-104a-445c-a224-714ecd0d4bb5">4,050</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if6be370f501b4c01b623fd1a62663ae2_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTAtMi0xLTEtMjc2NzEx_7224db00-6f24-440d-aebb-2b520a4b139d">958</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d4d7011fa9e426f83235daedfbc0d2b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTAtNC0xLTEtMjc2NzEx_02c97b6e-45f1-48ba-abdf-f6c2ce108e64">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e262309c1fa48079d1867ec5a658a7a_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTAtNi0xLTEtMjc2NzEx_c4c02844-fc6c-4228-9f52-271f1630e03f">958</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc9c44e6d8fb4a709b48e7648b7a23e9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTAtMTAtMS0xLTI3NjcxMQ_3472bbad-e2bd-4543-b177-ec3ff5b6a495">647</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1086a770a6af4910ab5e126d369ea8db_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTAtMTItMS0xLTI3NjcxMQ_d391b2bc-bf38-44ca-a44a-710bc4553a93">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f3f7158d6a44e7391143520201bad9f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTAtMTQtMS0xLTI3NjcxMQ_76f2d8bf-a7fe-40cb-be8a-f308d6ddb577">647</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice4155fa85584031b189ee801a6dc1d0_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTEtMi0xLTEtMjc2NzEx_a1215726-10fa-420b-9358-5c68be1ff554">17,337</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i899f8f926052420abb4e2b852a344789_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTEtNC0xLTEtMjc2NzEx_a5b5f7ca-94e4-4443-9010-9c6ddaacc2fe">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idbd5be9a103f48e58baacf8c92602ca7_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTEtNi0xLTEtMjc2NzEx_c97b8254-2f9d-4458-8160-b69b5832dae0">17,337</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i132528a30e7045eb8f6c246d64cf873a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTEtMTAtMS0xLTI3NjcxMQ_f0d32014-0c65-4c54-946d-6c223469a84f">22,014</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i70aeab5e7fb14a8b8e6ad8f076f52a1e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTEtMTItMS0xLTI3NjcxMQ_dbb36285-8bff-4d05-b3e3-93b01607745a">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e6bd2a48b6742c0a3a49791feb6ee49_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTEtMTQtMS0xLTI3NjcxMQ_4d4293f7-1999-4fa0-b541-1c1594fe13cf">22,014</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice4155fa85584031b189ee801a6dc1d0_I20220403" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTItMi0xLTEtMjc2NzEx_46ca92d6-6e1f-4a51-8f4e-101d2f5d1c17">20,096</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i899f8f926052420abb4e2b852a344789_I20220403" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTItNC0xLTEtMjc2NzEx_1cb3bdb7-8236-404e-a268-5e075a887c5e">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idbd5be9a103f48e58baacf8c92602ca7_I20220403" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTItNi0xLTEtMjc2NzEx_d36052d2-85b0-40cf-8c03-ba6a8fc26c54">20,096</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i132528a30e7045eb8f6c246d64cf873a_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTItMTAtMS0xLTI3NjcxMQ_12d9eca2-6100-4054-b531-9f97d42fda8a">27,379</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i70aeab5e7fb14a8b8e6ad8f076f52a1e_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTItMTItMS0xLTI3NjcxMQ_7406ead8-dc86-4227-9a85-b1dadb9a3b73">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e6bd2a48b6742c0a3a49791feb6ee49_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTItMTQtMS0xLTI3NjcxMQ_3ad1d26d-377b-472f-baf7-708922b55407">27,379</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i777f7d8b8dac411fa534243e37ef391b_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTUtMi0xLTEtMjc2NzEx_604205c6-cea3-461b-9883-4630c370b4b2">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i265d1ab5f2204789a03c901a23576f0f_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTUtNC0xLTEtMjc2NzEx_0a1d8b09-8e6c-4f8f-9513-6a2e95cdf6b2">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id3380e00e55b4fa8a65a2600c294edf2_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTUtNi0xLTEtMjc2NzEx_29132812-1d9f-49f8-92bd-f8b8bba9772e">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib6d637f8a7444503a4e6cf4de5380fa8_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTUtMTAtMS0xLTI3NjcxMQ_3cc97178-bdea-43c5-a054-153cd95bd0b4">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9ee17e41e72466b8fcf0845ac036899_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTUtMTItMS0xLTI3NjcxMQ_0bbc0855-3589-455d-9872-215bda2718aa">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib345d23c234e46ff98d7f91c21cb82aa_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTUtMTQtMS0xLTI3NjcxMQ_4bbd7da4-3170-4ef3-a9d4-efef718e39de">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia606af2750074b6f92e3a1d980944cf2_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTYtMi0xLTEtMjc2NzEx_38a80c9d-10f1-4782-a702-163ea6406354">832</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7aac0a61606430e805b8d65b630d1d6_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTYtNC0xLTEtMjc2NzEx_30e8e478-a9f4-4336-8440-928e17e4c35c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia86d7bc0c42142f6a114ddab32985469_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTYtNi0xLTEtMjc2NzEx_a60916ee-2d21-49af-8f14-e13baee0867f">832</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab4ec9706c88412ba8ce450b04555bfc_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTYtMTAtMS0xLTI3NjcxMQ_bc316094-a31e-4401-b6d5-23fe2139aed8">704</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaa6d26a6476a458881d852d3586cd5c0_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTYtMTItMS0xLTI3NjcxMQ_f7011e16-2e03-4dbf-8e2d-432cc11aa83a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54352f1ccf2d448ca7264d501e48b8f4_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTYtMTQtMS0xLTI3NjcxMQ_c53ae600-7ae0-4c9b-bda1-3f45140b2199">704</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb87c734f7f347ddb27c69599af93d7d_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTctMi0xLTEtMjc2NzEx_3e9cae40-75dd-4686-883e-8a88b07abac0">837</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i541da0bebf1044f586fbc5deab12fdfd_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTctNC0xLTEtMjc2NzEx_394f04f3-5eb1-4832-9476-df884ee560fe">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6a35176acb49c789c4bc2d7ca2bc1c_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTctNi0xLTEtMjc2NzEx_a3e37d68-e63f-47a7-af6c-3800d6215843">837</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4c26d1c2f7174d85aca8fe47b491fa6f_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTctMTAtMS0xLTI3NjcxMQ_3c509df8-f953-484f-b7ca-383d56e76e0e">709</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a7adbbe21ac41f0854cd160e5ee44db_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTctMTItMS0xLTI3NjcxMQ_85e0ff9d-6704-42e5-9c53-e52ddcd5e9bb">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i484b8ae596c04bcd89a368b7a2e68298_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTctMTQtMS0xLTI3NjcxMQ_e0d7a8a6-267d-464b-b001-8713a9f4a7d6">709</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b27d4306b29494189af95f228ce9e9d_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMi0xLTEtMjc2NzEx_2205dcd7-ee08-4153-b3d3-9105035fbef6">3,486</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64feb9bb789644be90e0a3fb62415770_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktNC0xLTEtMjc2NzEx_b65b4566-138a-47c4-b24d-be27ddde9841">3,470</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3aca7059c60454d9dbd7882c92be026_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktNi0xLTEtMjc2NzEx_ad1b98a9-6051-482d-bf7c-1bcc271e0d9f">15</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0dc9966961aa4a5eac7914b79fbb5de9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMTAtMS0xLTI3NjcxMQ_559d0b56-8d4e-4026-92bc-ae9cec9d7332">3,876</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i953ab40c38434820b511d8eae1e4f0f0_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMTItMS0xLTI3NjcxMQ_a21913a4-997d-4ca8-b133-e70674d929a5">3,849</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i083e2ed7f3074844ad343029b35a2f2d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMTktMTQtMS0xLTI3NjcxMQ_5b06c9d6-b5ca-4c74-95f2-ceeb3407384d">27</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic844c100d4834aed866f277008b1d119_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjItMi0xLTEtMjc2NzEx_1c2e0174-cae2-47af-b923-bc21288e5bc7">519</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fb96f65c79e4e43a9b0f2ba8778da01_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjItNC0xLTEtMjc2NzEx_6832e299-9af6-4a19-825b-ff0ff6a0c639">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if6ca6b12f388430abf8cc5a646e002a3_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjItNi0xLTEtMjc2NzEx_7405abd9-cd4a-4d8d-943e-66f7c2049618">519</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a52fcde776142edb175b1102e0c7a0b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjItMTAtMS0xLTI3NjcxMQ_9b3b2856-8f1f-4d3a-b22d-71528f838e1b">465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i79affbb0227f46e5b8193b279164f06e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjItMTItMS0xLTI3NjcxMQ_fa6646f8-c8ff-43b7-bd7e-30aade6559fc">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iefeb71ef3a024176a43e49c746f31e5d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjItMTQtMS0xLTI3NjcxMQ_f4336935-d156-421b-9461-0951e4a80a45">465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b55a96852094be28009c7eab13a9ad9_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjMtMi0xLTEtMjc2NzEx_be5669c5-7542-44a2-b4d3-ff895a449a8e">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d273b96ee4c409bb5f4f8877c52d348_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjMtNC0xLTEtMjc2NzEx_2a130ee9-d923-4a87-b6f1-09337ca1e46f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aedb68827634218b6bb0e55c03538a9_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjMtNi0xLTEtMjc2NzEx_462bcac8-d710-46f5-8a0e-b5aead95b229">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib8aaa4d14cf74e1aa03eebfa4b8718ed_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjMtMTAtMS0xLTI3NjcxMQ_b6fc6927-1814-4b06-95ad-4b79567a3032">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7490796ada7748128aa8d6bac9da74ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjMtMTItMS0xLTI3NjcxMQ_079b6a80-7b57-43b2-a951-ccfb87447800">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8277c08f9d904a77bc70208edc20943a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjMtMTQtMS0xLTI3NjcxMQ_d1d2ca78-55a3-41ba-8c5a-21806fe36724">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4dacd2bb16c44f7fafc72fedcca37073_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjQtMi0xLTEtMjc2NzEx_9aff0a59-4bf8-408f-9bac-64a9e2c84b38">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if8e64d93f9ae4ba9b6e9871fb87b756e_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjQtNC0xLTEtMjc2NzEx_061b115a-900b-4444-b181-5de45645cf7a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i24e9c9c43dbc4ed6bed956603fbd59a6_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjQtNi0xLTEtMjc2NzEx_82cc057d-9fac-4261-9f8e-63b9cd5f4624">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc4a0e30a6c343fbb4bc057f57758a01_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjQtMTAtMS0xLTI3NjcxMQ_29a3ffd2-eaea-4991-8504-cc3d83508425">50</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id866d739037a40f399ffb04baa18b70a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjQtMTItMS0xLTI3NjcxMQ_fc13136e-73fb-45e1-a647-5a83d17fe1d7">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf1adbec93ff4152896ef3dbc266fe13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjQtMTQtMS0xLTI3NjcxMQ_df309c2e-a0f7-43da-ae60-1d5bab303321">50</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b27d4306b29494189af95f228ce9e9d_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjUtMi0xLTEtMjc2NzEx_bc470049-ebb5-42d1-b6c0-c9ee030ebe35">569</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64feb9bb789644be90e0a3fb62415770_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjUtNC0xLTEtMjc2NzEx_be748d2d-0fe7-4bc2-9ad0-ac3bcd9c3333">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3aca7059c60454d9dbd7882c92be026_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjUtNi0xLTEtMjc2NzEx_f65572a9-752b-4a11-9a80-ab43e07d59c0">569</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0dc9966961aa4a5eac7914b79fbb5de9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjUtMTAtMS0xLTI3NjcxMQ_70efc110-04fb-4764-aefc-9ed634b7e785">521</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i953ab40c38434820b511d8eae1e4f0f0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjUtMTItMS0xLTI3NjcxMQ_7dfb27bb-e303-473f-b67c-dbca87d0de66">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i083e2ed7f3074844ad343029b35a2f2d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjUtMTQtMS0xLTI3NjcxMQ_506bc8cc-a9f3-4982-bd42-b6391070f8ea">521</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b27d4306b29494189af95f228ce9e9d_I20220403" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjYtMi0xLTEtMjc2NzEx_12b8d270-53d4-497c-9f43-2a56ec876d6a">4,055</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64feb9bb789644be90e0a3fb62415770_I20220403" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjYtNC0xLTEtMjc2NzEx_273d8950-4460-4017-a3b0-42050eb27f41">3,470</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3aca7059c60454d9dbd7882c92be026_I20220403" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjYtNi0xLTEtMjc2NzEx_c610415e-b9d1-4aa3-8cc8-ddd483b94ef1">584</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0dc9966961aa4a5eac7914b79fbb5de9_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjYtMTAtMS0xLTI3NjcxMQ_c7729404-3772-4132-9b5e-03cb55434325">4,397</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i953ab40c38434820b511d8eae1e4f0f0_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjYtMTItMS0xLTI3NjcxMQ_f455d323-9d3d-40bc-9a5e-a8f12d8fee41">3,849</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i083e2ed7f3074844ad343029b35a2f2d_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjYtMTQtMS0xLTI3NjcxMQ_f58f8fff-2950-4797-9683-e845db54e354">548</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i396fd3b33a1143059031b513c082f2aa_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjktMi0xLTEtMjc2NzEx_7cfba281-7c7d-4e0b-bb6d-4cce5d3939a2">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie88a87477d86467e898ff362ffa2aa1e_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjktNC0xLTEtMjc2NzEx_a492b02a-86ab-4793-b0b6-08c143fe4aa4">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ec7cf6ce80c4d4799458ac9c7beab5a_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjktNi0xLTEtMjc2NzEx_87ae9a1d-4867-4ab7-a6c3-f9e01133e5e6">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0faa6c4d3af472faa12b8e11c63078e_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjktMTAtMS0xLTI3NjcxMQ_24a62f06-5a2c-4dbe-b37a-3432533760eb">16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i27e6c6dba43a465bbd6ed102073943ec_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjktMTItMS0xLTI3NjcxMQ_ae4bbc1d-f732-4338-b744-892c3381d917">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibde02c3ebcfe4f30b0ba0864e0956b5e_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMjktMTQtMS0xLTI3NjcxMQ_49bb8266-e093-4ba4-8bd7-51275a8ee764">16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1841bc47ec5849cb990c8e2fd67e0ceb_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzAtMi0xLTEtMjc2NzEx_ba70c7b5-80e7-48b5-9cfe-dde450d13502">267</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c0a252ab28d43a597fb4f9087606fbf_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzAtNC0xLTEtMjc2NzEx_0f376356-7508-45f2-9d7c-ebca8399bcfc">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iddd9e722697f43979694326c4506fc1d_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzAtNi0xLTEtMjc2NzEx_3777631f-dc70-4500-9b56-26aff5f5fc78">267</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c72b82f17544997a5bf97be6bd4e5dc_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzAtMTAtMS0xLTI3NjcxMQ_fe3c2647-c9f6-4e2e-9cdb-113e3662f642">242</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb38c1d78e61439e9eeb9d60f7892ec4_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzAtMTItMS0xLTI3NjcxMQ_44969e88-0f25-4ecb-9361-57d67df0d01d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1cd5c70a571b46aea9e14950eaa3a577_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzAtMTQtMS0xLTI3NjcxMQ_1f0f10df-6595-45c2-9337-7032b165cb2b">242</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic46d9886d139416099e1fe4e1c436cfc_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzEtMi0xLTEtMjc2NzEx_ae0d49f8-cb0b-4261-8ce1-f4a10ef4fbc5">267</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3fa62e7bd4584cacb0af7fb9e9a04dd9_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzEtNC0xLTEtMjc2NzEx_b6e21306-78e7-460a-8350-56b97fa8fa56">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib298875f836445ae8a6621e8d2dca823_I20220403" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzEtNi0xLTEtMjc2NzEx_e90fc5f9-5c23-4c2b-af5a-d848b43584f4">267</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6f5d26b1f0340bd9221e5289ffbcc08_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzEtMTAtMS0xLTI3NjcxMQ_c556bdbd-3183-4f72-8e39-960a155e0262">259</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i937d9ad38d844977a86c316086936710_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzEtMTItMS0xLTI3NjcxMQ_e7155865-72d5-4a4a-9606-b7a77c58b361">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iecdc18a6c65448a7bf2bb84676aedf73_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzEtMTQtMS0xLTI3NjcxMQ_376b30f9-83bb-4408-b4fe-c049b1776509">259</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic46d9886d139416099e1fe4e1c436cfc_I20220403" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMi0xLTEtMjc2NzEx_038534ce-0fdf-4af2-869c-ffc3554969e6">765</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3fa62e7bd4584cacb0af7fb9e9a04dd9_I20220403" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItNC0xLTEtMjc2NzEx_85928fcd-63d7-47f7-9a31-8a50ff87b0ea">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib298875f836445ae8a6621e8d2dca823_I20220403" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItNi0xLTEtMjc2NzEx_5a660e0c-8cc4-4031-9236-f18e7e39fcd7">765</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6f5d26b1f0340bd9221e5289ffbcc08_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMTAtMS0xLTI3NjcxMQ_626aa49f-8659-4432-bdc5-b2b85f5e2012">808</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i937d9ad38d844977a86c316086936710_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMTItMS0xLTI3NjcxMQ_2c1eb10e-ac65-43b2-8aa2-442a2ab4e165">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iecdc18a6c65448a7bf2bb84676aedf73_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzItMTQtMS0xLTI3NjcxMQ_a6207a6d-7400-4f2d-a597-c9c1a160927c">808</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic46d9886d139416099e1fe4e1c436cfc_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzMtMi0xLTEtMjc2NzEx_4bc73618-2ffd-44c7-a928-42fd1509e4ba">1,032</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3fa62e7bd4584cacb0af7fb9e9a04dd9_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzMtNC0xLTEtMjc2NzEx_1f852447-2610-4240-be19-a388ad27ee6f">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib298875f836445ae8a6621e8d2dca823_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzMtNi0xLTEtMjc2NzEx_122cb183-787e-4b3d-b313-1b5e1d93e45a">1,032</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6f5d26b1f0340bd9221e5289ffbcc08_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzMtMTAtMS0xLTI3NjcxMQ_3a57ae3c-d40b-4f7f-87d8-369ba39a8525">1,067</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i937d9ad38d844977a86c316086936710_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzMtMTItMS0xLTI3NjcxMQ_c64aeb52-8601-407f-ae75-ffbeccde0c2b">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iecdc18a6c65448a7bf2bb84676aedf73_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzMtMTQtMS0xLTI3NjcxMQ_c4173ff3-3aa9-4dcb-aa9a-b0de89c454a9">1,067</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7e7a3e26b1f4205a25688a89353b225_I20220403" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzQtMi0xLTEtMjc2NzEx_0d91fafd-332f-4518-983a-3212aa3e4ba9">26,020</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id45f911275bc4aaab14275dd8cfe6095_I20220403" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzQtNC0xLTEtMjc2NzEx_26dc1118-77eb-46f6-9e1f-16f84d5df173">3,470</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3237feda4c4489dbdc11b98eda3a5c0_I20220403" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzQtNi0xLTEtMjc2NzEx_e3a86843-79fc-4a1d-a900-b5ccab755f17">22,550</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia424a17af85d43a19699a8467ec27637_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzQtMTAtMS0xLTI3NjcxMQ_a80c93e8-8c4f-4ca7-a9cf-a33cf45a7bc3">33,552</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ac2185b14e45618404196604b5111a_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzQtMTItMS0xLTI3NjcxMQ_1c81423c-8a79-442d-91e4-10f81d6467d4">3,849</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67bc35520f2a483cb6b9cdfa53bc64e5_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfMzQtMTQtMS0xLTI3NjcxMQ_34f72396-f9ab-4dd2-b94f-75babedf20b1">29,703</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i718ef01248f844da9cec0c790c09bb43_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDAtMi0xLTEtMjc2NzEx_4bca2d00-cb59-4c99-9ede-75ff264274b8">330</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0f4fce547f7c4e05b2fd2b54f36b2f99_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDAtNC0xLTEtMjc2NzEx_612d3fc6-30f6-406d-95ea-949830c86320">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i980ed2156e2d46ebbaaac1fe61b299fd_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDAtNi0xLTEtMjc2NzEx_14ebf324-e72d-4207-b82c-fd86033a3238">330</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic970cf381542457eb1d31d8d05a944f2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDAtMTAtMS0xLTI3NjcxMQ_27856aca-acf9-4dc8-ac7e-721e0897da9c">476</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a92f46d466f4f0ea19618a069bc086f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDAtMTItMS0xLTI3NjcxMQ_f0ed31f4-aa92-405d-9ba6-601eba4c1779">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88325aa4e3194b258b34676870fc5884_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDAtMTQtMS0xLTI3NjcxMQ_691702c5-523c-4520-95ba-238ac95df588">476</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i91e80bc24e5e4c6aae93be0b471eb98f_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDEtMi0xLTEtMjc2NzEx_e8dd5117-1b23-49fa-8554-1f3244a195f4">330</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a7477d180a840afa9c28f05c45db07d_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDEtNC0xLTEtMjc2NzEx_aefa45eb-3714-4373-b7eb-40c727ac7cce">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia1ecdb311a254f6d98d019c9fe38bdf0_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDEtNi0xLTEtMjc2NzEx_f9679b27-2f20-4bdd-a525-2de711722196">330</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i24cf3e20cfab496184ca0a790855cfc0_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDEtMTAtMS0xLTI3NjcxMQ_e0801606-c9ed-4f1d-adc5-a04594907164">476</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie2092f8d599e4e11b19ac32005dfe23b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDEtMTItMS0xLTI3NjcxMQ_3a2c6356-a386-4d5d-a509-3b44cfb4d407">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3805af9bb2814a7eb9b1cb8dc96bf885_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDEtMTQtMS0xLTI3NjcxMQ_c156f282-dda1-41a3-b216-4a2aacfe4b69">476</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic19cbdb5b38142acb2dcf9c0cb123ed0_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDQtMi0xLTEtMjc2NzEx_0193bf41-3730-408e-96d3-f624edde4722">140</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id093ab2cce2548c29bd2e23e4b65c955_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDQtNC0xLTEtMjc2NzEx_47bef53e-b2ab-4a71-9900-c774876dcdfd">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b7df2e8d36a4cff8704219305fa0bc2_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDQtNi0xLTEtMjc2NzEx_c1a2e830-37c7-46c1-b0da-10a6a33eab8f">140</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaad3f7d2bb3e4ecfa616ae5f1be4d97c_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDQtMTAtMS0xLTI3NjcxMQ_2b151a8c-59b6-4061-b9d2-3ec7400b3b20">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ba54d9d67334d059112da451da77d20_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDQtMTItMS0xLTI3NjcxMQ_7774b415-8765-437a-b12d-e6e5b2f70e75">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida9b249cb7b14accb08b47084b6eb3a7_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDQtMTQtMS0xLTI3NjcxMQ_f0e843db-b275-4c97-a610-7b693858361f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34ba721cefcf41108731e9f656f2ac9c_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDUtMi0xLTEtMjc2NzEx_388f5a48-9ea8-4902-8377-d8145f91d9bc">460</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5f91e20641a5487e8960ffd765345898_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDUtNC0xLTEtMjc2NzEx_e4fd0952-076f-437d-b81c-89cc0ed5f2e7">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i80a9295e6baa49ac8c1971c3e2f49589_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDUtNi0xLTEtMjc2NzEx_7eaaf942-9ba0-4f97-accf-21eeb63dd881">460</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72d5c87710cb4cf6b2dcc21a22eee38e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDUtMTAtMS0xLTI3NjcxMQ_c07edbaf-8842-4cf6-b774-d150297ce55b">405</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b423cd5f8044aeebfa454f818203159_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDUtMTItMS0xLTI3NjcxMQ_d2ea0f36-e4fa-4383-a9d0-1d43c57339fd">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i559df6d8ac8b40abaccd506982c32750_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDUtMTQtMS0xLTI3NjcxMQ_ce9d4d2f-02f8-4157-ac64-036c7d50099c">405</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab549c119acd4314bd304269f3780fda_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDYtMi0xLTEtMjc2NzEx_abe5fcfb-e554-47b7-92b9-6f0ede617b2d">600</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i029741954cac43309481482a59fa20ee_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDYtNC0xLTEtMjc2NzEx_9fb835a4-810a-4399-8f92-fb1d54f6b0c9">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i215d247adb684998aa5d55f4dba4e4f5_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDYtNi0xLTEtMjc2NzEx_0adaf826-dead-4eb9-9ef5-04bea93139b7">600</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd3e0c38481b4b1e90caea4458c81e71_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDYtMTAtMS0xLTI3NjcxMQ_b492369d-710b-4d28-a5d0-c3ff54d243b1">405</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd33865dd9e149fc93d64b40cfde2f91_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDYtMTItMS0xLTI3NjcxMQ_8a41d3c9-7345-4ae9-90a4-935614dc0fa3">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id7fb214d9798460ea2ae1fd55eeb565c_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDYtMTQtMS0xLTI3NjcxMQ_f6d71b74-2afb-4d5a-8471-b8f3e66f3349">405</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7e7a3e26b1f4205a25688a89353b225_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDctMi0xLTEtMjc2NzEx_6e9e8681-062b-4f9d-8e64-cf5df315841c">930</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id45f911275bc4aaab14275dd8cfe6095_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDctNC0xLTEtMjc2NzEx_b92e0e0f-708e-401c-a325-0f490e7c2756">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3237feda4c4489dbdc11b98eda3a5c0_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDctNi0xLTEtMjc2NzEx_2b068f0b-672e-4941-8d83-bb07503654f6">930</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia424a17af85d43a19699a8467ec27637_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDctMTAtMS0xLTI3NjcxMQ_648d9fbe-d803-4464-850e-d45afdcd5e03">881</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ac2185b14e45618404196604b5111a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDctMTItMS0xLTI3NjcxMQ_f03adf08-a858-4574-9f37-5297fbaab8a4">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67bc35520f2a483cb6b9cdfa53bc64e5_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RhYmxlOmFlMTczNjM2NGU4NzRiMmQ4N2I3ZDFiMTNlMzZiMjgxL3RhYmxlcmFuZ2U6YWUxNzM2MzY0ZTg3NGIyZDg3YjdkMWIxM2UzNmIyODFfNDctMTQtMS0xLTI3NjcxMQ_7be93ebb-f852-4c5f-a5fa-b3df573ea351">881</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMTIxMQ_a8d1e4eb-8630-4877-b3c9-875daa4462a2" footnoterole="http://www.xbrl.org/2003/role/footnote">Long-term equity securities of $<ix:nonfraction unitref="usd" contextref="ia7e7a3e26b1f4205a25688a89353b225_I20220403" decimals="-6" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMjA3_3772bc4d-82cf-4ac8-a95a-2ba3fc1ac6f1">155</ix:nonfraction> million as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="ia424a17af85d43a19699a8467ec27637_I20211231" decimals="-6" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMjIz_452a7496-96cd-431d-8d62-250892dd2caa">194</ix:nonfraction> million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfMTIyMg_046435b5-0147-49d5-964f-7cfac17b9050" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ia11eac669b6e4970828710c2f902fa11" continuedat="idb0bb705e242431f9cb75a8c947aeb98"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $<ix:nonfraction unitref="usd" contextref="i19692c6f377647e7986f9362562da4e3_I20220403" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfNzY5NjU4MTM5NTk2Mw_ae0d444b-72f4-4ef4-9162-5453b5cfe145">36</ix:nonfraction>&nbsp;billion as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="i5453ac09abb94063b45ec113cebe09ec_I20211231" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfNzY5NjU4MTM5NTk0MQ_146cde4c-d301-4d3d-8b1d-3438604d3ac7">36</ix:nonfraction>&nbsp;billion as of December 31, 2021. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $<ix:nonfraction unitref="usd" contextref="icb3c2f2f374840e8a8a86086a4243ca6_I20220403" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfNzY5NjU4MTM5NTk5MQ_1e6e3bf3-2714-4220-9ea9-3d7454278e66">38</ix:nonfraction>&nbsp;billion as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="ib0cf964e76614510b8932379c70dd5aa_I20211231" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81NS9mcmFnOmVlZGQ4MzA3OGQyYTRiMDA5YzViYmMxMjc1MDYwZGQ2L3RleHRyZWdpb246ZWVkZDgzMDc4ZDJhNGIwMDljNWJiYzEyNzUwNjBkZDZfNzY5NjU4MTM5NjAwMA_370f8946-234d-465d-b1b8-ccac0c8a21da">42</ix:nonfraction>&nbsp;billion as of December 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April&nbsp;3, 2022 and December 31, 2021. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</span></div></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_58"></div><ix:continuation id="idb0bb705e242431f9cb75a8c947aeb98" continuedat="ie767dcd35e2243338df19868ba8d76d0"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Short-Term, Long-Term and Equity-Method Investments</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzU1_6957a733-4e9c-4166-bca2-dddf629f6bcb" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMy0yLTEtMS0yNzY3MTE_85ae3aae-07b3-4a24-8f16-3277bfbc5e39">2,759</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMy00LTEtMS0yNzY3MTE_95f4daf6-14f1-476d-94fc-e7cd3aed2aa2">5,365</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfNC0yLTEtMS0yNzY3MTE_72894923-d3c6-4401-af44-cd1e1206ebb5">17,337</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfNC00LTEtMS0yNzY3MTE_11fc9ed2-5fe1-4804-8f85-48f3fc214882">22,014</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfNS0yLTEtMS0yNzY3MTE_ad1fb33f-7685-4741-be08-0ce47be8f301">1,331</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfNS00LTEtMS0yNzY3MTE_94786378-1409-4d04-aca5-4e27ffe7a5bb">1,746</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfNi0yLTEtMS0yNzY3MTE_04243e36-2b41-424b-8b1e-254be905913e">21,427</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfNi00LTEtMS0yNzY3MTE_e2bf1bc2-2518-4136-8309-db0ac70424d5">29,125</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfOS0yLTEtMS0yNzY3MTE_d95e2402-575a-450e-a939-64abbc1b728c">3,486</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfOS00LTEtMS0yNzY3MTE_997d60dd-8846-4fa0-a272-c244c6003417">3,876</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTEtMi0xLTEtMjc2NzEx_48b768b2-fec6-470b-bbc4-4f9f2ccfa746">569</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTEtNC0xLTEtMjc2NzEx_2a80ffcd-b2a8-4722-9a19-0478df372804">521</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTItMi0xLTEtMjc2NzEx_779a59be-9a95-4cb7-b3c2-8a92dcea5f88">41</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTItNC0xLTEtMjc2NzEx_1529b9fa-e1ca-4051-958f-428a2a2d2c76">34</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTMtMi0xLTEtMjc2NzEx_2bd8ed9a-1a0e-4a96-a303-b988e3951abf">647</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTMtNC0xLTEtMjc2NzEx_caacd079-b7fb-4dad-bb39-2db7c0de1be7">623</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTQtMi0xLTEtMjc2NzEx_59af1eee-412d-4499-8e7e-75870ead56bf">4,742</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTQtNC0xLTEtMjc2NzEx_2aec19ce-572b-42ba-8ba9-6d50af8b0376">5,054</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTUtMi0xLTEtMjc2NzEx_0f17970b-36f6-4dc1-815f-25c55b3fb5fb">15,995</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTUtNC0xLTEtMjc2NzEx_7edb83f1-3633-4236-b533-ec066ab7f446">16,472</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTYtMi0xLTEtMjc2NzEx_a57b01ed-4444-4b5c-9ce7-463565da067a">20,737</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTYtNC0xLTEtMjc2NzEx_d225ed9b-4fad-4be3-98bf-d0b554b2209a">21,526</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTctMi0xLTEtMjc2NzEx_d8fca7a3-8531-43db-986b-f9d2680c5705">458</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjQzZTJjMzUwN2FiNDQ1OGE5YzM5Yzk3YWIwNmQyNjIxL3RhYmxlcmFuZ2U6NDNlMmMzNTA3YWI0NDU4YTljMzljOTdhYjA2ZDI2MjFfMTctNC0xLTEtMjc2NzEx_bd3b763c-8b85-4c11-8d59-edf8b70c131b">268</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzc3_7e5667d7-4f1d-4a81-8095-ef63a3345b55" footnoterole="http://www.xbrl.org/2003/role/footnote">As of April&nbsp;3, 2022 and December 31, 2021, includes money market funds primarily invested in U.S. Treasury and government debt.</ix:footnote> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzY3_c76ff992-e94e-4d84-bf6e-7b85e7360234" footnoterole="http://www.xbrl.org/2003/role/footnote">Represent investments in the life sciences sector</ix:footnote>.</span></div></ix:nonnumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:3pt"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzU2_f93529d6-d892-467e-b518-a46fb02569b1" escape="true"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzY4_59a76e86-672d-4440-8e91-64d572c2c3fa" escape="true"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzc5_81decf15-0532-4979-b3f6-838f992a1ff8" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April&nbsp;3, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0yLTEtMS0yNzY3MTE_2e0760f9-9732-445f-86d7-25704850e06d">15,217</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS00LTEtMS0yNzY3MTE_0e971543-512d-4856-82aa-83fc9e2a327c">8</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS02LTEtMS0yNzY3MTE_5c3d1a1c-a910-4e9e-897d-59fc959cecf9">158</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS04LTEtMS0yNzY3MTE_ad829972-e589-44e0-8ca3-04f86a8090e0">15,067</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0xMC0xLTEtMjc2NzEx_3d7f9284-80b9-44c0-b044-567daf3dc1d8">14,548</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0xMi0xLTEtMjc2NzEx_bd58e763-9c6b-4ede-be34-164ce8ae9dc4">519</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0xNC0xLTEtMjc2NzEx_0ad94bd6-d568-40ef-a906-7be440a32287">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0xNy0xLTEtMjc2NzEx_71e5260f-2374-417f-b406-7f0345c6d5c0">18,032</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0xOS0xLTEtMjc2NzEx_8f180639-edf2-403e-84e4-3842efb14026">13</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0yMS0xLTEtMjc2NzEx_60064408-cfe9-49fc-aab7-3ca2947f22f1">263</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNS0yMy0xLTEtMjc2NzEx_0f9b6b6c-fe3a-41c7-85ad-23dd48dbcffc">17,783</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency––U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0yLTEtMS0yNzY3MTE_d83c9643-bc99-4e01-acc3-2308ff94df48">1,832</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi00LTEtMS0yNzY3MTE_5cc927f6-025a-4bd2-a31d-15cd3835e90c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi02LTEtMS0yNzY3MTE_ef9467c5-4a1e-4058-ae32-db7e4616d0df">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi04LTEtMS0yNzY3MTE_da3ef96e-4e07-4843-9928-4ebab0911e92">1,831</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0xMC0xLTEtMjc2NzEx_52b90802-d1ae-4d56-9315-f8335c0e40c8">1,830</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0xMi0xLTEtMjc2NzEx_1d9e227a-07eb-4e33-a86f-05ea28e8fa27">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51b1efc832b64c588a72817464d816f5_I20220403" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0xNC0xLTEtMjc2NzEx_fe5167f8-5252-49d2-a85e-8e74e64e590c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35cf5f9de62244cc8be4fcba4f7cd173_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0xNy0xLTEtMjc2NzEx_37a78b54-04c4-4e41-abaa-194e4264e5fe">4,056</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35cf5f9de62244cc8be4fcba4f7cd173_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0xOS0xLTEtMjc2NzEx_f4455849-3094-4ac9-a4ff-344552cdfd30">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i35cf5f9de62244cc8be4fcba4f7cd173_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0yMS0xLTEtMjc2NzEx_42f64d57-8a69-4b0c-85e5-e379ab278d7b">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35cf5f9de62244cc8be4fcba4f7cd173_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNi0yMy0xLTEtMjc2NzEx_281b16ea-457a-471e-b340-9581aee8e5aa">4,055</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0yLTEtMS0yNzY3MTE_6b92353f-3de4-48d2-aa08-455ced2f8470">1,009</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy00LTEtMS0yNzY3MTE_3561439f-13be-4b97-9b21-63e539bc02b1">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy02LTEtMS0yNzY3MTE_6ce701a9-cedf-43f9-b8e5-d4b370c691f7">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy04LTEtMS0yNzY3MTE_7d13c0db-12c1-4349-849c-1cabdc19af54">1,008</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0xMC0xLTEtMjc2NzEx_0f332b03-15fe-47fd-b9f2-dd33fbdecd6b">958</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0xMi0xLTEtMjc2NzEx_ea5f5093-2d3b-4ec5-8043-e355499eec74">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7721b15b084a443f9c80866a92bffc81_I20220403" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0xNC0xLTEtMjc2NzEx_24dca849-d98c-4b54-aa01-7e1be25c0e5f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5daa53fe61464bb199949d6f116b3430_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0xNy0xLTEtMjc2NzEx_a115704e-40ce-45d7-81ba-fe47fac87eb8">698</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5daa53fe61464bb199949d6f116b3430_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0xOS0xLTEtMjc2NzEx_3d68fa2e-532c-4a5c-a7ca-987dbec3e269">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5daa53fe61464bb199949d6f116b3430_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0yMS0xLTEtMjc2NzEx_b8d6af89-6f4e-4185-ae94-24f02d85d1ff">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5daa53fe61464bb199949d6f116b3430_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfNy0yMy0xLTEtMjc2NzEx_5a08e5ad-8070-4ba1-8b08-d96925e75f83">697</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0yLTEtMS0yNzY3MTE_e7fe811b-845c-4ab0-a3ac-906fcdd2b5d7">1,015</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS00LTEtMS0yNzY3MTE_fbeaa1ea-0393-4de1-aa91-182d77a6578c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS02LTEtMS0yNzY3MTE_dd582e62-0629-4dd1-8ed4-268730a8de10">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS04LTEtMS0yNzY3MTE_8b6d72f3-5d9c-437a-ae0b-4395237907ef">1,015</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0xMC0xLTEtMjc2NzEx_e3cabbd3-5832-456c-9ae5-ce6fbd82791b">979</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0xMi0xLTEtMjc2NzEx_5bcfd110-70fe-483e-aa17-0eb11ce7d2bf">25</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6561ad527067439dac5114f8dd1472de_I20220403" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0xNC0xLTEtMjc2NzEx_847d6af7-3f4d-4a63-b2fe-6194bbd3c6cf">11</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i895ebe8dcdad4932a99763adef37fa6b_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0xNy0xLTEtMjc2NzEx_c894b1b3-6531-41b8-89e2-7a8fd0318290">947</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i895ebe8dcdad4932a99763adef37fa6b_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0xOS0xLTEtMjc2NzEx_3a2125eb-f1f6-4f2d-95ab-ef958af08871">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i895ebe8dcdad4932a99763adef37fa6b_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0yMS0xLTEtMjc2NzEx_3a831870-d460-4e84-ae61-84857d043b74">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i895ebe8dcdad4932a99763adef37fa6b_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfOS0yMy0xLTEtMjc2NzEx_0805f389-9614-4c93-b61d-9e6b9ffc85c0">947</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMi0xLTEtMjc2NzEx_573afc2f-e938-448f-94d3-d14e6ec6c63a">814</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtNC0xLTEtMjc2NzEx_5fb51237-8e35-4822-a8a9-ca18886aa714">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtNi0xLTEtMjc2NzEx_304640e4-d890-44bf-9542-d67a4b71f8b3">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtOC0xLTEtMjc2NzEx_77dbd3c1-22de-4660-ac17-d6408ddae11e">814</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMTAtMS0xLTI3NjcxMQ_4b52b40a-4c71-4caf-8a74-7bbbad00afe7">809</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMTItMS0xLTI3NjcxMQ_78854729-2caf-4b52-9c8d-d929502e980f">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c47c001218d487792a980332f456adc_I20220403" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMTQtMS0xLTI3NjcxMQ_df24470c-111c-4f88-9ac3-8dbbffcdbbf8">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMTctMS0xLTI3NjcxMQ_76b4a990-083b-4eb4-8943-cb5493460767">1,102</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMTktMS0xLTI3NjcxMQ_d8695073-efcb-4f1c-b15d-252fe3df5d24">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMjEtMS0xLTI3NjcxMQ_868cc6bf-c982-4cd5-b9da-45104a0332d0">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c7a9e7252e6467a9d875689967e6b61_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTAtMjMtMS0xLTI3NjcxMQ_ab39c759-e449-42a6-ae24-197aaa11b9de">1,102</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMi0xLTEtMjc2NzEx_9cac47b0-d233-431b-98aa-f5ce4dbb2617">19,887</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtNC0xLTEtMjc2NzEx_28ba4296-e6c7-4f6e-91f6-4c7f233f5974">8</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtNi0xLTEtMjc2NzEx_651c3a0a-8316-4f46-9ba0-5289be9cfab7">160</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtOC0xLTEtMjc2NzEx_4ae9ad0c-d3cf-4bf1-8c28-8debd1a4a9d8">19,735</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMTAtMS0xLTI3NjcxMQ_5df819e8-0432-4109-a453-e22a0cef18b4">19,125</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMTItMS0xLTI3NjcxMQ_cbe5939c-bf3b-44ba-8baa-6209d7809104">598</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMTQtMS0xLTI3NjcxMQ_c83359a9-b33c-4a16-86cd-f694a8dd4399">12</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:DebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMTctMS0xLTI3NjcxMQ_253a03e1-b455-4176-8ea8-30b615051615">24,835</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMTktMS0xLTI3NjcxMQ_f4298da6-0f0d-4d07-95df-38a5650bb88b">14</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMjEtMS0xLTI3NjcxMQ_9742b748-3de8-48a6-a83e-c8253249ef09">265</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOmU4ZmU2NzdmNTRjYjRkMjY5MzlkNDJkMWVhMzQyZTQzL3RhYmxlcmFuZ2U6ZThmZTY3N2Y1NGNiNGQyNjkzOWQ0MmQxZWEzNDJlNDNfMTEtMjMtMS0xLTI3NjcxMQ_d71f36df-3cc8-459f-b406-190cf7a9fe8b">24,584</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></ix:nonnumeric></ix:nonnumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ie767dcd35e2243338df19868ba8d76d0" continuedat="i8fd46c03ec1740d1bafad93550287295"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzc2_1a3bb740-8deb-4b4d-baa1-806342e24248" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfMy02LTEtMS0yNzY3MTE_85bf167d-2617-49a4-9930-f7d14f5d58b3">699</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfMy04LTEtMS0yNzY3MTE_134a22de-b232-4005-a750-d2cf6cca8ef0">401</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfNC02LTEtMS0yNzY3MTE_f7b3edd9-3ba0-4981-ad35-c1408ce3d9be">11</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfNC04LTEtMS0yNzY3MTE_7dae5e6d-4af5-4128-8407-544ef6e3518b">28</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfNS02LTEtMS0yNzY3MTE_19054934-6604-406a-985a-c159e856f10e">710</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RhYmxlOjI5YWFiNzIxYTMwMTRlMDQ4NWFjMDk5YWZlODY0YzE2L3RhYmxlcmFuZ2U6MjlhYWI3MjFhMzAxNGUwNDg1YWMwOTlhZmU4NjRjMTZfNS04LTEtMS0yNzY3MTE_8b3c45b7-cedf-4f13-ae73-475321ece20e">372</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzYz_154b00ab-1e97-4774-add4-c86b8358f3e0" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNzUz_03a8e262-3f2e-437e-96c4-a4f5d4fcf932" footnoterole="http://www.xbrl.org/2003/role/footnote">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April&nbsp;3, 2022, there were cumulative impairments and downward adjustments of $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNjI0_c1c21c63-64d3-4260-9b23-9e3d303b7a7b">110</ix:nonfraction> million and upward adjustments of $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl81OC9mcmFnOjEzZGQzYWM3OTRkNTQ0YzE5YWNiMmY3MDM5N2E0NTVkL3RleHRyZWdpb246MTNkZDNhYzc5NGQ1NDRjMTlhY2IyZjcwMzk3YTQ1NWRfNjUz_cb0d4046-be84-45be-bb5a-f22e9525602d">167</ix:nonfraction> million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_61"></div><ix:continuation id="i8fd46c03ec1740d1bafad93550287295" continuedat="i4af2cc138bd04fa98eef8119829282c5"><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RleHRyZWdpb246NGE0ZGQ1ODkzOTIwNDA0NGE0MWQ2ZDQxNWJkNGVkYzhfNzA_39ba856d-c5aa-4a3d-a1b6-81d696e7a774" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfMy0yLTEtMS0yNzY3MTE_7d272ea1-1bc3-4d69-a2f7-6f6c98ef24be">251</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfMy00LTEtMS0yNzY3MTE_ee806965-95d5-4a83-adaa-e24c3673f965">1,636</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNC0yLTEtMS0yNzY3MTE_4b5017aa-9144-4c9b-bee6-e1c6563fee7c">385</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNC00LTEtMS0yNzY3MTE_a7e81a59-90a1-4278-a818-49211405c72e">605</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:ShorttermDebtGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNS0yLTEtMS0yNzY3MTE_d2703a9d-3320-4eac-a2dd-69d27b9a4d53">636</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:ShorttermDebtGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNS00LTEtMS0yNzY3MTE_85a68355-e332-4913-b926-8d8b16e3a8a1">2,241</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNi0yLTEtMS0yNzY3MTE_954c0e57-c0b0-4645-ab8a-e1ead5c42ce1">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfNi00LTEtMS0yNzY3MTE_c618cb29-ba93-4027-b7bf-d6739ba80024">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfOC0yLTEtMS0yNzY3MTE_4c821b94-8d04-439a-a0ce-efcb275bfd67">645</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RhYmxlOmQwOGY2OGM1NTFiMjQ3MDlhZjU4NDI2NWJkOGY3ZmYzL3RhYmxlcmFuZ2U6ZDA4ZjY4YzU1MWIyNDcwOWFmNTg0MjY1YmQ4ZjdmZjNfOC00LTEtMS0yNzY3MTE_db61408b-4624-4d55-bbee-16e3d06e3206">2,241</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82MS9mcmFnOjRhNGRkNTg5MzkyMDQwNDRhNDFkNmQ0MTViZDRlZGM4L3RleHRyZWdpb246NGE0ZGQ1ODkzOTIwNDA0NGE0MWQ2ZDQxNWJkNGVkYzhfNzY_e0081be1-6aaa-449b-9c2c-2220fefb210c" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_64"></div><ix:continuation id="i4af2cc138bd04fa98eef8119829282c5" continuedat="ia7826d4fc24b4c489828a0869bf04ae8"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-bottom:8pt"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RleHRyZWdpb246ZDk1NmIwYzY0MWQzNDM5MzgxNjA3OTc3ZTU2NGVkNjVfMTcz_37ccf25e-2095-4132-bfc6-cc5a4080c428" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba33fa09a0bb479986526c41985e2248_I20220403" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfMi0yLTEtMS0yNzY3MTE_1f2f6b44-1294-4e31-a10a-6612e7a7a31c">34,603</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ec0143ec854c2897cc4517221c9fd2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfMi00LTEtMS0yNzY3MTE_4de7a916-3fdc-4396-b93b-3ffb3b707614">34,948</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba33fa09a0bb479986526c41985e2248_I20220403" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfMy0yLTEtMS0yNzY3MTE_57dd831f-09f6-4306-9d3c-9c1b64416d9c">1,240</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ec0143ec854c2897cc4517221c9fd2_I20211231" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfMy00LTEtMS0yNzY3MTE_66cc5722-5e83-4716-83aa-9b70ab3147a2">1,438</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iba33fa09a0bb479986526c41985e2248_I20220403" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNC0yLTEtMS0yNzY3MTE_6b15b594-f6e8-412c-87ac-9a9488b6cfd7">190</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i10ec0143ec854c2897cc4517221c9fd2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNC00LTEtMS0yNzY3MTE_f61999a8-f984-41c4-aa07-6204f7fa8052">195</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba33fa09a0bb479986526c41985e2248_I20220403" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNS0yLTEtMS0yNzY3MTE_f65b5d1d-054d-485c-92ed-0954e2cdf961">3</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ec0143ec854c2897cc4517221c9fd2_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNS00LTEtMS0yNzY3MTE_706f26cd-c269-418f-beef-aca898a234f9">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba33fa09a0bb479986526c41985e2248_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNi0yLTEtMS0yNzY3MTE_fd9fb046-2d68-43f2-85d6-2ed945c1d88e">35,656</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ec0143ec854c2897cc4517221c9fd2_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNi00LTEtMS0yNzY3MTE_559a8219-2845-473d-bd19-a0f7c7a4c7e4">36,195</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba33fa09a0bb479986526c41985e2248_I20220403" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNy0yLTEtMS0yNzY3MTE_29e648ea-425f-4069-8715-e6df69e72f33">260</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10ec0143ec854c2897cc4517221c9fd2_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82NC9mcmFnOmQ5NTZiMGM2NDFkMzQzOTM4MTYwNzk3N2U1NjRlZDY1L3RhYmxlOmVmMDNhNGQwODZlMjRlNWU4Njg1YjIyN2JmOWYzNzY3L3RhYmxlcmFuZ2U6ZWYwM2E0ZDA4NmUyNGU1ZTg2ODViMjI3YmY5ZjM3NjdfNy00LTEtMS0yNzY3MTE_7d3402c4-20d3-4b18-9416-6eb3d32a7c47">1,636</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></div></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_67"></div><ix:continuation id="ia7826d4fc24b4c489828a0869bf04ae8" continuedat="ia062179ae999443a87b788f76081ed05"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Risk––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen and Canadian dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to <ix:nonnumeric contextref="i9e97e6292f19433898e6a4bb89ec456a_D20220101-20220403" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzYy_bc056a10-5a5b-4147-a631-a37dd95c072b">two years</ix:nonnumeric>. We may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div></ix:continuation><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgyMQ_41137f2d-8541-4d44-92b7-5d1531465748" continuedat="i6152463be82d422bb1f527215f0c8dae" escape="true"></ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg0OA_b3463ce6-854e-43e6-83b3-e802e65a9bc7" continuedat="i9f40d66e0eb8415ead1e3ea69c9edf49" escape="true"></ix:nonnumeric><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1OA_4b8b4672-25ea-46b2-bb9e-468a963e87f7" continuedat="i1e603bc90b9d4c9380584aa332493786" escape="true"></ix:nonnumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ia062179ae999443a87b788f76081ed05" continuedat="i830e313110df462ea1019cc8a662bc1c"><ix:continuation id="i6152463be82d422bb1f527215f0c8dae"><ix:continuation id="i9f40d66e0eb8415ead1e3ea69c9edf49"><ix:continuation id="i1e603bc90b9d4c9380584aa332493786"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i287186eb6a974298a7425f7b06e010dd_I20220403" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS0yLTEtMS0yNzY3MTE_e8e0ef2a-2561-4721-875a-9ad1ead4317c">29,833</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i287186eb6a974298a7425f7b06e010dd_I20220403" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS00LTEtMS0yNzY3MTE_fcb0d532-e28c-4f1f-8592-5360ccedfbb5">899</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i287186eb6a974298a7425f7b06e010dd_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS02LTEtMS0yNzY3MTE_daf78c02-2ecf-4cfd-ad5e-f48f0e03531a">647</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia091df0e14ae41eb852a4ff3e0d05bf7_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS04LTEtMS0yNzY3MTE_6ed6b336-4e2d-40f6-9122-d28d69facdc6">29,576</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia091df0e14ae41eb852a4ff3e0d05bf7_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS0xMC0xLTEtMjc2NzEx_7f83554d-ab47-412a-88c4-614b6892d3e2">787</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia091df0e14ae41eb852a4ff3e0d05bf7_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNS0xMi0xLTEtMjc2NzEx_c67ac17e-5db8-40b5-9ad7-f1c3d95e81c0">717</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i099e4c93c24442cea664ea3a40981096_I20220403" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNi0yLTEtMS0yNzY3MTE_cbc88dd9-64ff-4816-81ed-7338b89d14c3">2,250</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i099e4c93c24442cea664ea3a40981096_I20220403" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNi00LTEtMS0yNzY3MTE_e536156d-cfcf-4c41-8d26-5102cf39b45e">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i099e4c93c24442cea664ea3a40981096_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNi02LTEtMS0yNzY3MTE_d2705b3b-2be4-4fa1-aa7e-b060c30bbe87">140</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78f5cb7438c644edbbef490f2b60c786_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNi04LTEtMS0yNzY3MTE_1122013b-e8de-4a30-bc95-3685ed810878">2,250</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78f5cb7438c644edbbef490f2b60c786_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNi0xMC0xLTEtMjc2NzEx_4773e085-8bfe-402e-8372-2a40c460e412">21</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78f5cb7438c644edbbef490f2b60c786_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNi0xMi0xLTEtMjc2NzEx_fa5366e9-c053-4cc3-82d8-ad4d37abec81">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id48b94a8161f40a5a32b669f86d18f22_I20220403" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNy00LTEtMS0yNzY3MTE_7659f577-268e-4927-a8ca-6b457733ea14">904</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id48b94a8161f40a5a32b669f86d18f22_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNy02LTEtMS0yNzY3MTE_ff1bf7c6-27d6-40a3-b2cb-cde295c4bbd5">787</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i79317728ed6542abaa35eedc73d7ee8f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNy0xMC0xLTEtMjc2NzEx_07830665-40e8-459a-b9dd-7b70e4c8d965">808</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i79317728ed6542abaa35eedc73d7ee8f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfNy0xMi0xLTEtMjc2NzEx_b70a08bf-e84d-4641-96a7-5b6ec332b009">717</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7bcb394e9d4f4ec58625eac2ea7e53bb_I20220403" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfOS0yLTEtMS0yNzY3MTE_7c5c737c-fd9a-4b1e-bda7-35576e7ce7eb">22,009</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7bcb394e9d4f4ec58625eac2ea7e53bb_I20220403" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfOS00LTEtMS0yNzY3MTE_29a60747-69ab-4446-af63-6bee3f36b7b3">200</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7bcb394e9d4f4ec58625eac2ea7e53bb_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfOS02LTEtMS0yNzY3MTE_37a4a92b-6bdf-4218-9165-a66d751e2e3e">143</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i468b1b161ad14b9d97c0f127846b153f_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfOS04LTEtMS0yNzY3MTE_840b81dd-a43f-4564-b2e0-7d8cc9122136">21,419</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i468b1b161ad14b9d97c0f127846b153f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfOS0xMC0xLTEtMjc2NzEx_ba408b8b-7ef4-43f2-9cdc-ef447ff1c861">160</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i468b1b161ad14b9d97c0f127846b153f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfOS0xMi0xLTEtMjc2NzEx_2021750b-e85d-455c-84cc-0519affa226a">164</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfMTAtNC0xLTEtMjc2NzEx_2662f2d0-e988-4b38-86b6-783d253ed725">1,104</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfMTAtNi0xLTEtMjc2NzEx_3f75b3e2-d72b-4f09-a703-fa72d56ab930">930</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfMTAtMTAtMS0xLTI3NjcxMQ_a7ec7f5c-45b2-42e7-9d88-a11ce84ec73b">968</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjQwZGRmZmQyMWI4ZDQ5ZWE4YTE1MzNkZThhOTg0OWUxL3RhYmxlcmFuZ2U6NDBkZGZmZDIxYjhkNDllYThhMTUzM2RlOGE5ODQ5ZTFfMTAtMTItMS0xLTI3NjcxMQ_b2faa9ea-3212-483c-be31-53669e1fa9d0">881</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMg_9f5db33d-320f-436a-9103-2cb6eff909db" footnoterole="http://www.xbrl.org/2003/role/footnote">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $<ix:nonfraction unitref="usd" contextref="iabfea622864b480896a73c7f050d548e_I20220403" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5NzQ1OA_1f669da2-6027-4185-8855-dce9a5c48ba0">4.7</ix:nonfraction>&nbsp;billion as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="i45a18079dbef41d98ea4a6ab1cd9a190_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5NzQ1NA_117a8570-fa54-4982-88d3-d6756d781e6a">4.8</ix:nonfraction>&nbsp;billion as of December 31, 2021.</ix:footnote></span></div></ix:continuation></ix:continuation></ix:continuation><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxNw_4e1275b8-9cd6-47c6-ae4d-c1b18e40b6ef" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:36.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib568e9ca553c4320b3d05348eadd779c_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS02LTEtMS0yNzY3MTE_d746bb0f-57d5-496a-9af0-7105665fca23">187</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i211fdae85534430ba6e76395bbfbbff3_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS04LTEtMS0yNzY3MTE_ae4f5815-c0a6-4920-8785-273dba4fe0bd">202</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1520d5b9360b4dccbc16aca3de72c6fa_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS0xMC0xLTEtMjc2NzEx_3cd8b7e1-4ad1-4175-b44c-e32d35500eb6">195</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2060793d8a2b4589b4afe60d1c4124c8_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNS0xMi0xLTEtMjc2NzEx_c623093e-c8b4-4007-8d99-1f123c5c0f7b">268</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2cc927240ee49718a9da4c83c67c3f0_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi02LTEtMS0yNzY3MTE_7f904f59-2b94-4cfa-8098-6974d7eff8d9">16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i27d9dc24c3374f95a7196e54aed4d445_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi04LTEtMS0yNzY3MTE_5525066e-7044-4bf4-980a-6d148b9fd246">12</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if8bb7913d8c14e439bfef9e1f67ed399_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi0xMC0xLTEtMjc2NzEx_447a5f64-809c-4911-b062-6052094465ca">18</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f29585765b5403ebfa7ac36c55ed8e3_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfNi0xMi0xLTEtMjc2NzEx_45ca419e-09c7-41a0-bde5-030aa098e917">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9e0b582be5744723a93574247953ec62_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOC0yLTEtMS0yNzY3MTE_f4b961e6-8642-4342-be72-9e24e9a7aab9">156</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2c18f829975a45c8b2772303aa6245c9_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOC00LTEtMS0yNzY3MTE_80d7ee16-c896-4ba5-81a4-c487b104ae86">26</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9e0b582be5744723a93574247953ec62_D20220101-20220403" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOS0yLTEtMS0yNzY3MTE_018309f0-7a11-4ed6-a151-a51cfee5df72">156</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c18f829975a45c8b2772303aa6245c9_D20210101-20210404" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfOS00LTEtMS0yNzY3MTE_fad73cc1-1fea-42aa-891d-111d3d0b3ab3">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib568e9ca553c4320b3d05348eadd779c_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtNi0xLTEtMjc2NzEx_e1c1c997-b2bb-4ae9-9267-044f4d906683">259</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i211fdae85534430ba6e76395bbfbbff3_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtOC0xLTEtMjc2NzEx_b78f4ec6-698f-46ca-aba7-6e5954e408e5">154</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1520d5b9360b4dccbc16aca3de72c6fa_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtMTAtMS0xLTI3NjcxMQ_33ba152c-7823-4329-b3f2-3d404d6d9548">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2060793d8a2b4589b4afe60d1c4124c8_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTMtMTItMS0xLTI3NjcxMQ_8a9aa773-db98-4c1e-8086-12db606fc14c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i69912f6e91cb4f54808b3e8f6d53582c_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtNi0xLTEtMjc2NzEx_06cd7ec5-8532-404c-bc84-8690df805a28">74</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia005f37871144c8081897f52aee78eaf_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtOC0xLTEtMjc2NzEx_9f6fdf61-98b0-4030-879c-b2ad74a5fa35">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic79702f570114ca8aa26a3518fee3a60_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtMTAtMS0xLTI3NjcxMQ_b4be2a4c-5a7c-4b6b-8119-dcd4822b159a">30</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4d035143a774fce8c1990d62a741fbb_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTQtMTItMS0xLTI3NjcxMQ_4b4fbe88-3cb2-4640-9f1a-8ac1706c2b90">29</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98c5c9cd3d2644b3ae64e25bde3073fc_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtNi0xLTEtMjc2NzEx_d0a75abd-9211-4a4e-903a-073095a2fc3f">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id00e506e152345dfaca17bd236a853bd_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtOC0xLTEtMjc2NzEx_9f08e456-f873-4076-a796-696009468804">38</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib574dd5d5f9a430289499455874d1ef1_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtMTAtMS0xLTI3NjcxMQ_013d88bf-e477-40bf-838e-46267f8d960a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie91268be5c3445fa978fbc2aa1e6509e_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTYtMTItMS0xLTI3NjcxMQ_5a3233be-5d0b-45ab-8135-98caad13d316">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia1b53d02b8c24768a1155d5c1b4dfff7_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctNi0xLTEtMjc2NzEx_e3b05536-3587-44ae-9465-b97957d12fe5">23</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f0f8441cb664a659b14b7508702ef4b_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctOC0xLTEtMjc2NzEx_61d8ddcb-3a39-4324-a806-487f6e354835">56</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9323a1ccabfd4bd69e0ed1df96bcf347_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctMTAtMS0xLTI3NjcxMQ_e7ddecf5-5458-4f1d-aaa7-7270d87bad80">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if40a973f4e744f1ea7561e3e8fb00fd8_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTctMTItMS0xLTI3NjcxMQ_1138f874-8e41-4f4d-9d7d-a28c1b10695a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia12d191e668e411b9dfdb627695e3179_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTktMi0xLTEtMjc2NzEx_beeba019-39f0-465c-b959-944171c879ed">19</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d5076ab6d3647d3af23f0d5e94e2d8a_D20210101-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMTktNC0xLTEtMjc2NzEx_19d46b75-cd4d-43cf-8262-f512c092a96c">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6764ff911980490d90a88335c9c244cf_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtMi0xLTEtMjc2NzEx_b07022ad-18f2-4c55-868f-cdf4c887aeaf">19</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7997f3c210e42e59fbf52fbd7f8225f_D20210101-20210404" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtNC0xLTEtMjc2NzEx_8c3a1a3f-f874-458c-b251-00c79bfd6628">42</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtNi0xLTEtMjc2NzEx_179d4b0a-534e-4fea-a0be-5f228e91e836">436</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtOC0xLTEtMjc2NzEx_4a29e1b9-3a58-4c48-b534-aedc1c22623c">460</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i36f2b81121c4492694330f1d72200491_D20220101-20220403" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtMTAtMS0xLTI3NjcxMQ_087dfb94-7c6f-4e9b-900f-67ff5c378c54">243</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i80fac32edc9d4fe9b9fb1a6683a9e17f_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOjI0MWU2ZDg4ZTE3MTQ4MDU5MDQwZjQ4MGMwYWY3YTQ1L3RhYmxlcmFuZ2U6MjQxZTZkODhlMTcxNDgwNTkwNDBmNDgwYzBhZjdhNDVfMjEtMTItMS0xLTI3NjcxMQ_9b6f4495-e341-4efb-9903-69c328112172">230</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg1Ng_b031e79d-0449-4636-a3de-17a70dfdb683" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions—net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></ix:footnote><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzMA_06d8a0b1-c451-4c72-b22b-9033aeb116a0" continuedat="iffc7d15eb3da441abe40629479056249" footnoterole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI into COS were:</ix:footnote></span></div><ix:continuation id="iffc7d15eb3da441abe40629479056249"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $<ix:nonfraction unitref="usd" contextref="i675cd1e86ee94c82a4af543340567532_D20220101-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMTg3NA_4ec9d450-ef98-4436-9023-294c9a67649d">34</ix:nonfraction> million in the first quarter of 2022; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $<ix:nonfraction unitref="usd" contextref="i7ac4f5688687404498e8cb1412553fbf_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMTk0NQ_362aaf62-75d6-4122-8b1a-78d4f4b9ad77">45</ix:nonfraction> million in the first quarter of 2021.</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjE3OQ_cfef6f09-cd15-4973-a881-2a41defee3b7">332</ix:nonfraction> million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately <ix:nonnumeric contextref="ib568e9ca553c4320b3d05348eadd779c_D20220101-20220403" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjM2MQ_6721176b-9876-44dd-a17a-31dd70d5b81b">21</ix:nonnumeric> years and relates to foreign currency debt. </span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgxMg_fb999420-6124-4ff4-8bbd-2f7a550d3655" footnoterole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI were reclassified into OID.</ix:footnote></span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjgzOA_af47e212-e2bb-46d4-b269-49eaa9d3ebae" footnoterole="http://www.xbrl.org/2003/role/footnote">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings’ carrying value as of December 31, 2021 was $<ix:nonfraction unitref="usd" contextref="if1b5682c5e4b467da08e6ed5d8a73d83_I20211231" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5ODY0Mg_72c26eaa-8644-4d34-bd83-3ec6865e83e6">1.1</ix:nonfraction> billion. The long-term debt carrying values as of April&nbsp;3, 2022 and December 31, 2021 were $<ix:nonfraction unitref="usd" contextref="if4a79241f6454ff98bb9da3f918b54c1_I20220403" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5NzY1OQ_86eff1c5-322a-48ea-b4ca-354f30c98327">821</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="if1b5682c5e4b467da08e6ed5d8a73d83_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfNzY5NjU4MTM5NzY1MA_4e45cd88-9ce9-4619-83d0-136d623409ce">844</ix:nonfraction> million, respectively.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i830e313110df462ea1019cc8a662bc1c" continuedat="ia68fb27862af491f827bd5169a6dbb6a"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg0Ng_d5d64355-bf3f-4a13-b0e6-659f01051f43" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our debt in fair value hedges:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 3, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22a48418dee947e18abd4864cc1d8ab4_I20220403" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi0yLTEtMS0yNzY3MTE_3818c13b-e690-40b9-8d2f-3eac330e4eb6">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22a48418dee947e18abd4864cc1d8ab4_I20220403" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi00LTEtMS0yNzY3MTE_0a752a3e-492d-48d9-8410-04409ac96dda">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22a48418dee947e18abd4864cc1d8ab4_I20220403" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi02LTEtMS0yNzY3MTE_db04c1e5-7acc-4058-91d8-ef72c988fc8b">4</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib790556a844a4fb189d2de69ab2b2dac_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi04LTEtMS0yNzY3MTE_20ba2f94-737b-4555-b063-ccd2d40a7306">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib790556a844a4fb189d2de69ab2b2dac_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi0xMC0xLTEtMjc2NzEx_43e64607-2037-4444-bd00-9b5f44156f38">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib790556a844a4fb189d2de69ab2b2dac_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfNi0xMi0xLTEtMjc2NzEx_78d973be-21f6-4b65-9507-7c58d8f8f8fc">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64ccf7d575174b87877bde949d32ff1f_I20220403" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC0yLTEtMS0yNzY3MTE_99bd3141-c260-4d8e-811d-7fbc73e08628">2,234</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i64ccf7d575174b87877bde949d32ff1f_I20220403" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC00LTEtMS0yNzY3MTE_d51f830a-9e53-4f13-92b1-2053406cb062">140</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64ccf7d575174b87877bde949d32ff1f_I20220403" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC02LTEtMS0yNzY3MTE_b8e8cf86-76da-471d-9736-581cfaa71aa6">1,124</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i718b08327f864680b807c8f2f52d0d3d_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC04LTEtMS0yNzY3MTE_1c3bf326-9b92-422c-ad6c-58f7a9707883">2,233</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i718b08327f864680b807c8f2f52d0d3d_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC0xMC0xLTEtMjc2NzEx_2438691e-2746-4620-a3cd-3e7c5cf7a582">16</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i718b08327f864680b807c8f2f52d0d3d_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RhYmxlOmU0NDg4NzY5ZTZmOTQ4OTU4MDRjN2Y1OWQ4MmQ3OWE2L3RhYmxlcmFuZ2U6ZTQ0ODg3NjllNmY5NDg5NTgwNGM3ZjU5ZDgyZDc5YTZfOC0xMi0xLTEtMjc2NzEx_35c6240e-8d8d-4321-b037-2312b3ec24a9">1,154</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl82Ny9mcmFnOjU4NzFmNWE0M2I3NDQxODQ4YTJmZjlhMTBmNmI1MTA4L3RleHRyZWdpb246NTg3MWY1YTQzYjc0NDE4NDhhMmZmOWExMGY2YjUxMDhfMjg2Nw_3d62db41-e8eb-42cc-a2d5-9efbe697b2b6" footnoterole="http://www.xbrl.org/2003/role/footnote">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_70"></div><ix:continuation id="ia68fb27862af491f827bd5169a6dbb6a" continuedat="i32a072eada7f4f63894a34d7c3f6ac7d"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K. </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&nbsp;3, 2022, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by Canada, Japan, U.S., France, Germany, U.K., Switzerland, Austria and the Netherlands.</span></div></ix:continuation><div><span><br></span></div><div><ix:continuation id="i32a072eada7f4f63894a34d7c3f6ac7d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April&nbsp;3, 2022, the aggregate fair value of these derivative financial instruments that are in a net payable position was $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83MC9mcmFnOmZkOGUwNmRhMWY3MjQ5MjQ4YzRlOTU1YTlhNTU3OTQ2L3RleHRyZWdpb246ZmQ4ZTA2ZGExZjcyNDkyNDhjNGU5NTVhOWE1NTc5NDZfNzY5NjU4MTM5NjY0MQ_92aafe23-3056-45be-a84d-697e40544eef">568</ix:nonfraction>&nbsp;million, for which we have posted collateral of $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83MC9mcmFnOmZkOGUwNmRhMWY3MjQ5MjQ4YzRlOTU1YTlhNTU3OTQ2L3RleHRyZWdpb246ZmQ4ZTA2ZGExZjcyNDkyNDhjNGU5NTVhOWE1NTc5NDZfMTE5OQ_101238f7-3ba1-4e71-bd96-f840d2d45808">526</ix:nonfraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of April&nbsp;3, 2022, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:DerivativeNetReceivablePositionAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83MC9mcmFnOmZkOGUwNmRhMWY3MjQ5MjQ4YzRlOTU1YTlhNTU3OTQ2L3RleHRyZWdpb246ZmQ4ZTA2ZGExZjcyNDkyNDhjNGU5NTVhOWE1NTc5NDZfNzY5NjU4MTM5NjY1Mw_8c2bf4d2-2a1c-4de4-8b49-d76ff7b9e0c6">532</ix:nonfraction>&nbsp;million, for which we have received collateral of $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:SecuritiesReceivedAsCollateral" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83MC9mcmFnOmZkOGUwNmRhMWY3MjQ5MjQ4YzRlOTU1YTlhNTU3OTQ2L3RleHRyZWdpb246ZmQ4ZTA2ZGExZjcyNDkyNDhjNGU5NTVhOWE1NTc5NDZfMTQyOA_825c887d-6200-49dd-88dd-6a8826fcd965">341</ix:nonfraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_73"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjE3_d0c723a2-408a-462c-953e-4d1aefcddf19" continuedat="ibeec15894af443158dcd530f7cd3cee3" escape="true">Other Financial Information</ix:nonnumeric></span></div><ix:continuation id="ibeec15894af443158dcd530f7cd3cee3" continuedat="i60f5a4238d2542af97495617e962bd73"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjIy_678b3a0d-a184-43ff-b9de-516f647d8ecc" escape="true"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjMw_96865041-32df-4ba5-a7ed-bb592c86e335" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfMi0yLTEtMS0yNzY3MTE_7466583e-072d-4440-8488-bfaef2a48618">3,633</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfMi00LTEtMS0yNzY3MTE_97b88d3e-f4f4-467e-b581-62fee28c15f4">3,641</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfMy0yLTEtMS0yNzY3MTE_4acb981f-92d3-412b-addf-505fc9ea4e3a">4,843</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfMy00LTEtMS0yNzY3MTE_66b99afb-21ad-4f42-be55-ab28ab9d6392">4,424</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNC0yLTEtMS0yNzY3MTE_b125459a-ff1b-41d0-87ed-dc0d9ac19ae5">1,502</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNC00LTEtMS0yNzY3MTE_8762f435-1f33-4fc4-9cc3-d5d49b220303">994</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNS0yLTEtMS0yNzY3MTE_c5b139c5-b094-4883-afe0-c5694e09282a">9,979</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNS00LTEtMS0yNzY3MTE_35f91b9a-90bb-48b6-bcc2-6cd42a933320">9,059</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNi0yLTEtMS0yNzY3MTE_ab37ad5c-8b7c-4f00-8098-b65bad65f863">894</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RhYmxlOjY0NTdhMDMzNGRiNTQwNTg5MDM2M2M0MmI5Yzg5ZGE4L3RhYmxlcmFuZ2U6NjQ1N2EwMzM0ZGI1NDA1ODkwMzYzYzQyYjljODlkYThfNi00LTEtMS0yNzY3MTE_25e1ff8b-0c44-4915-8906-a36216b441bc">939</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjA1_fa57e0b8-bc58-4643-be68-d1b5479baf10" footnoterole="http://www.xbrl.org/2003/role/footnote">The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNjE2_a813c330-4403-4a34-a080-62b4556c97b8" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></ix:footnote></div></ix:nonnumeric></ix:nonnumeric><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i60f5a4238d2542af97495617e962bd73" continuedat="i695a705618f94b99858efeac77a0f5f3">Other current liabilities</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i695a705618f94b99858efeac77a0f5f3"> includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $<ix:nonfraction unitref="usd" contextref="ia837ea1226e943a79cc4e0d0d89dbf4a_I20220403" decimals="-8" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfNTUx_af9fd2b2-bec3-41d3-9aef-900a520bc5e4">10.0</ix:nonfraction>&nbsp;billion as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="i6340c1c4b1144cae8226384c7015287d_I20211231" decimals="-8" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83My9mcmFnOmY3MjNmNWM4NDNiMzQwZDQ5NDczYjE0NjBkODU1NTA0L3RleHRyZWdpb246ZjcyM2Y1Yzg0M2IzNDBkNDk0NzNiMTQ2MGQ4NTU1MDRfOTM0NTg0ODgzNjk2Mg_ce7bc242-5baa-48e5-b298-bf24a6af42bf">9.7</ix:nonfraction>&nbsp;billion as of December 31, 2021.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_76"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDg1_26cfbdae-1a59-40e7-92a4-540a32698727" continuedat="ifa49cf305c324a6fbd832536774a4b6a" escape="true">Identifiable Intangible Assets</ix:nonnumeric></span></div><ix:continuation id="ifa49cf305c324a6fbd832536774a4b6a"><div style="margin-top:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDg4_5cfb316e-0198-4c63-b065-4b361db8c18c" escape="true"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNTIy_bd7ac660-9de8-4e22-afbb-ff677e10f968" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br>Carrying<br>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br>Intangible<br>Assets, less<br>Accumulated<br>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br>Carrying<br>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br>Intangible<br>Assets, less<br>Accumulated<br>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e899807dd6a48b7a219649935f38539_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNC0yLTEtMS0yNzY3MTE_42ea3ee2-4798-403b-88ce-cac27a48d1d8">73,212</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e899807dd6a48b7a219649935f38539_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNC00LTEtMS0yNzY3MTE_25d42377-20eb-4782-b3c4-aeaaa8437aab">54,397</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e899807dd6a48b7a219649935f38539_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNC02LTEtMS0yNzY3MTE_a2a44167-ed56-4349-aef0-2adb85521eec">18,815</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7380a325d8e64496b74a1606b3b2807c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNC04LTEtMS0yNzY3MTE_f264cff6-3817-4f12-a93e-d6034af4e4db">73,346</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7380a325d8e64496b74a1606b3b2807c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNC0xMC0xLTEtMjc2NzEx_6e599cea-aec6-4b29-82f6-d3b97b6bf295">53,732</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7380a325d8e64496b74a1606b3b2807c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNC0xMi0xLTEtMjc2NzEx_c2b4d8ef-c4a7-4d92-9fd8-9c649060ec86">19,614</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2827e89952bb45e6a54899f79588fb37_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNS0yLTEtMS0yNzY3MTE_c3a4d6bd-5ac1-482b-91c2-32daa1a9836d">922</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2827e89952bb45e6a54899f79588fb37_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNS00LTEtMS0yNzY3MTE_307573a7-255f-41a4-b4ee-0c262f72ef48">816</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2827e89952bb45e6a54899f79588fb37_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNS02LTEtMS0yNzY3MTE_6e90fc93-9e39-4b6e-93b5-85f0a5a0e94f">106</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7f5fec3ee294b9eb970e707b988f13e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNS04LTEtMS0yNzY3MTE_1743fd68-ad63-4414-98ed-044bb888b1e4">922</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic7f5fec3ee294b9eb970e707b988f13e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNS0xMC0xLTEtMjc2NzEx_cfffc5af-1755-439e-85af-ad22b73f8297">807</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7f5fec3ee294b9eb970e707b988f13e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNS0xMi0xLTEtMjc2NzEx_3ea44194-eeaa-4c43-8b9f-80a2f48248c2">115</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idea9c9bc1c7f45ceaff3818ebd6058de_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNi0yLTEtMS0yNzY3MTE_0f24e86e-9fd5-4eb1-a8d9-dd641944f275">2,302</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idea9c9bc1c7f45ceaff3818ebd6058de_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNi00LTEtMS0yNzY3MTE_d1e8e3cb-a8de-4a4e-ac04-d74811df0a25">1,329</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idea9c9bc1c7f45ceaff3818ebd6058de_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNi02LTEtMS0yNzY3MTE_914c7e63-8ffa-4f97-b3af-8179fba6154f">973</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a35527a5038472e98fdfbbaad2dafd0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNi04LTEtMS0yNzY3MTE_3807e5e8-819f-450e-8a86-c09ba5cec4da">2,284</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1a35527a5038472e98fdfbbaad2dafd0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNi0xMC0xLTEtMjc2NzEx_6045435a-3240-4eb3-9c28-89a75d6ab2c4">1,299</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a35527a5038472e98fdfbbaad2dafd0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfNi0xMi0xLTEtMjc2NzEx_cb7bb590-1c8e-4b57-b18c-75bebf145910">985</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfOC0yLTEtMS0yNzY3MTE_46fadd75-a675-4362-89dc-1b76fa901049">76,436</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfOC00LTEtMS0yNzY3MTE_b7640293-3a65-4ee6-8ffc-750b79d3abc4">56,542</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfOC02LTEtMS0yNzY3MTE_c6334750-0e4f-4b00-8bd6-272fb5ffd437">19,894</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfOC04LTEtMS0yNzY3MTE_4ec221a0-7753-4eba-8f14-5dd6d283d708">76,552</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfOC0xMC0xLTEtMjc2NzEx_2b12fc98-ae44-4181-b673-e743119917e6">55,838</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfOC0xMi0xLTEtMjc2NzEx_831baca4-06e5-4ba7-86c5-a41c997f971a">20,714</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4450eb2cfd8b48bda1906bc9fd2d49ce_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTAtMi0xLTEtMjc2NzEx_50ad1076-8bd9-40d4-a791-22fe10003f55">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4450eb2cfd8b48bda1906bc9fd2d49ce_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTAtNi0xLTEtMjc2NzEx_7a97fbe7-4dbf-4eb8-891b-2a95c9ccbe87">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice4a2976439c41d5ad62263cf59d8f1b_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTAtOC0xLTEtMjc2NzEx_49617814-a164-4ecd-b5af-d5f777ee4adb">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice4a2976439c41d5ad62263cf59d8f1b_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTAtMTItMS0xLTI3NjcxMQ_340a739e-5990-427a-a3b5-07b6f03b4848">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c2d5298a36045ac8ee86c89abe1c074_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtMi0xLTEtMjc2NzEx_8b9ae502-9216-4a1a-85ef-2136794acefb">8,122</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c2d5298a36045ac8ee86c89abe1c074_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtNi0xLTEtMjc2NzEx_cbcc2ad1-94b8-4653-9771-a9f022a67f71">8,122</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i610663b8b97f44e9948c1891c2e2900f_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtOC0xLTEtMjc2NzEx_fa3d4dc0-9267-421b-9644-385db98051ff">3,092</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i610663b8b97f44e9948c1891c2e2900f_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTEtMTItMS0xLTI3NjcxMQ_400c5f95-e44f-48f3-a893-19e26c9b7992">3,092</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6df1f5f5701e4199915b8bca1ad078fe_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItMi0xLTEtMjc2NzEx_a48688c4-b6c2-4fdf-a2fa-de3f2d607e61">973</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6df1f5f5701e4199915b8bca1ad078fe_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItNi0xLTEtMjc2NzEx_65964656-ccae-4029-8e77-65a9e8a2cd41">973</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5266d51fc0514f5394a4cbb10ea6f081_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItOC0xLTEtMjc2NzEx_c4db10eb-dea2-42bd-a100-c51b0ebccec3">513</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5266d51fc0514f5394a4cbb10ea6f081_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTItMTItMS0xLTI3NjcxMQ_b8133fd6-78e0-4498-bdd9-a8e64b0045ee">513</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTMtMi0xLTEtMjc2NzEx_74b8a60e-62b4-48f5-bffb-79d9c51f8036">9,922</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTMtNi0xLTEtMjc2NzEx_847323b1-20d6-49ff-8b3d-3a4e75065343">9,922</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTMtOC0xLTEtMjc2NzEx_137cf51b-80b4-4747-86a6-b806a936feaa">4,432</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTMtMTItMS0xLTI3NjcxMQ_91cfd450-d57b-4b0f-aca2-6d212055dca6">4,432</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMi0xLTEtMjc2NzEx_28ad7b25-cb80-4844-a6f1-748ce587ea0e">86,358</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtNC0xLTEtMjc2NzEx_59f8d36d-0eb5-4f57-a7ee-c63f86380885">56,542</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtNi0xLTEtMjc2NzEx_23129a37-ce81-4831-af96-dea7200334d7">29,816</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtOC0xLTEtMjc2NzEx_b4727dc9-c3b1-4b38-83d3-b80d702f38fa">80,984</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMTAtMS0xLTI3NjcxMQ_ea4dc684-c14f-4225-9b3b-fa5fd712bb40">55,838</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjY2Y2YwYWRiMjIwYTRiZjU4ZDI2Y2Y4NDgxMzAwNWU4L3RhYmxlcmFuZ2U6NjZjZjBhZGIyMjBhNGJmNThkMjZjZjg0ODEzMDA1ZThfMTQtMTItMS0xLTI3NjcxMQ_19171ce3-7eac-44de-88e1-442fb4c70bab">25,146</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjgwOTM_3f9bc9ad-08ad-4d85-9374-49aa8d5819f4" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfNDgx_00df0c30-7da3-4b70-981c-0bc8e37632f1" footnoterole="http://www.xbrl.org/2003/role/footnote">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</ix:footnote></span></div></ix:nonnumeric></ix:nonnumeric><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Goodwill</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2MjQ_a5a00024-d222-4f11-80b8-579051bea00a" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:84.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfMi0xMC0xLTEtMjk2ODE0_eecc232e-7edc-461a-a089-519f5a37633b">49,208</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfMy0xMC0xLTEtMjk2ODE0_c5cb44ab-24e5-4fc4-92dc-4eb4fc8cae09">1,023</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfNC0xMC0xLTEtMjk2ODE0_c155a9e6-d1bf-498e-b414-dababf4ce19d">21</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, April 3, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RhYmxlOjYyMzhiMDIwMDIyYTRkMjlhMTA5ZTE1OGUyNGIzODExL3RhYmxlcmFuZ2U6NjIzOGIwMjAwMjJhNGQyOWExMDllMTU4ZTI0YjM4MTFfNS0xMC0xLTEtMjk2ODE0_66860d4f-bf90-4777-b536-82fc8a9398c0">50,211</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjc_ac3cedf0-3f46-414c-88bb-b1fd7293873b" footnoterole="http://www.xbrl.org/2003/role/footnote">All goodwill is assigned within the Biopharma reportable segment.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjg_70bfd400-a281-47c2-9d4b-cc1ed4bbd4c0" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Additions relate to our acquisition of Arena. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83Ni9mcmFnOjIzNjBmYWUyMTUwNDRhMmQ4YzU4MWRkMDRhMmEzZGU2L3RleHRyZWdpb246MjM2MGZhZTIxNTA0NGEyZDhjNTgxZGQwNGEyYTNkZTZfMTY0OTI2NzQ0MjU2Mjk_b5d9c432-b3cf-4071-a16c-c114a3f72b6e" footnoterole="http://www.xbrl.org/2003/role/footnote">Other represents the impact of foreign exchange.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_79"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfOTk3_2ef005ee-b59a-4aed-a4b8-ec2d687ea28e" continuedat="id0f882fe98ca43f4aaaaaf88afb1f972" escape="true">Pension and Postretirement Benefit Plans</ix:nonnumeric></span></div><ix:continuation id="id0f882fe98ca43f4aaaaaf88afb1f972" continuedat="i636e4555d4f44f8fb8615c83122ae685"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfMTAwNA_f54cb1c4-e248-49f2-b070-a8d03f72bc92" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br>Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjAtMi0xLTEtMjc2NzEx_051e854e-2455-4ccb-96c2-1a5b8b125253">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjAtNC0xLTEtMjc2NzEx_872aeb21-7edc-4eac-b8b2-32d125a1cdd1">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjAtNi0xLTEtMjc2NzEx_e5c828da-6d59-415d-b824-b1a6989ac3f7">30</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjAtOC0xLTEtMjc2NzEx_a9c0d1a1-d4ca-4d07-8e76-631602c3b213">33</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjAtMTAtMS0xLTI3NjcxMQ_da888429-39f3-401e-9e1b-8b10b100b887">7</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjAtMTItMS0xLTI3NjcxMQ_cd0f2730-d841-4941-a987-2b82ffa76f6c">9</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjEtMi0xLTEtMjc2NzEx_49621dce-1413-4e8f-95f3-72d5d0305243">118</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjEtNC0xLTEtMjc2NzEx_decbd5a5-e522-4319-9f3d-a3f3211df8d7">113</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjEtNi0xLTEtMjc2NzEx_717462f9-cae8-4e95-830f-3f022f2e9b69">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjEtOC0xLTEtMjc2NzEx_fae15353-20d9-4e68-a37f-5bf07a5a254d">36</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjEtMTAtMS0xLTI3NjcxMQ_2ffea01c-561a-4320-b3fa-5d111411e431">7</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjEtMTItMS0xLTI3NjcxMQ_fbb3acc4-0520-402d-bdbb-0f895215d704">7</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMi0xLTEtMjc2NzEx_505ffe1f-9584-41dd-8c6a-37e24e327b45">245</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItNC0xLTEtMjc2NzEx_2e267ec0-f6b5-4c48-b3be-aa04dbaf3ed2">261</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItNi0xLTEtMjc2NzEx_702fc6f6-9a1e-4b0c-a9e7-5728a08ea495">79</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItOC0xLTEtMjc2NzEx_6aa24974-8e6b-4b3c-96d2-837754f05979">82</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMTAtMS0xLTI3NjcxMQ_65037ec5-0afc-4e74-a439-0524ed90fb12">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMTItMS0xLTI3NjcxMQ_48a4354e-dfa4-44e3-a0c6-8131612fdf18">10</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjMtMi0xLTEtMjc2NzEx_051d958a-7e58-45d8-984d-ec4af5068bcc">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjMtNC0xLTEtMjc2NzEx_ca35bdc9-9172-40b1-9dcc-3c13f6fd58f0">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjMtNi0xLTEtMjc2NzEx_b467da43-feb8-4e87-b538-aca4fb820fab">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjMtOC0xLTEtMjc2NzEx_bc0e5e8e-9973-4055-9485-cd4bf1321f33">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjMtMTAtMS0xLTI3NjcxMQ_e8d39d46-6843-491a-9a86-294b3053dd9b">36</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjMtMTItMS0xLTI3NjcxMQ_7dbc5a0c-2acd-4787-a2b1-fa2a0d7f0599">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMi0xLTEtMjk5MTQ2_d6acc190-843f-4473-8d30-c3187a1c63a5">65</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItNC0xLTEtMjk5MTQ2_f0eaaf7d-927c-443a-a01f-e53a47ef2358">47</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItNi0xLTEtMjk5MTQ2_1bf0ce7a-51b4-419a-b94d-3f53b64e624a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItOC0xLTEtMjk5MTQ2_ba0e3fdc-d854-43e7-b081-7bfe6944c08a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMTAtMS0xLTI5OTE0Ng_ffce3647-e8e8-4863-b194-25c81b01386c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjItMTItMS0xLTI5OTE0Ng_2910f94a-d330-45c5-9b42-4b629e61ea5f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjUtMi0xLTEtMjc2NzEx_4a0c6430-283f-4094-a05f-fdce3ec49cf1">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjUtNC0xLTEtMjc2NzEx_7dda8942-6dea-44cc-ad7c-9fb775a3866f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjUtNi0xLTEtMjc2NzEx_762a0594-5da9-447a-bbed-9dd99990a34f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjUtOC0xLTEtMjc2NzEx_bf2e68cc-2a47-402f-9383-2bd9997d4e2e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjUtMTAtMS0xLTI3NjcxMQ_a9a1b3a1-8799-452e-84c3-763c5d193b9b">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjUtMTItMS0xLTI3NjcxMQ_5e7006b4-a069-4208-bafd-4ca2243a1e44">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjctMi0xLTEtMjc2NzEx_5d55b7af-6596-45f2-87c4-529b2b03bdfb">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjctNC0xLTEtMjc2NzEx_6f31c959-ac12-465e-ba49-1a623aa0b05f">7</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjctNi0xLTEtMjc2NzEx_5444dcb2-3e81-4161-9c84-781147396ee0">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjctOC0xLTEtMjc2NzEx_7703f89b-44a2-4c59-90dc-c40c0919e7ca">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjctMTAtMS0xLTI3NjcxMQ_b81697d7-1210-4235-ad03-7349e01ac451">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjctMTItMS0xLTI3NjcxMQ_e547c4d5-b528-437a-8a01-2bd38597264b">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjgtMi0xLTEtMjc2NzEx_0445c5cd-3172-4a43-b375-71dba04fbe1f">186</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife329842ef954edbb96697e3d8c26f84_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjgtNC0xLTEtMjc2NzEx_59a11d66-2b44-42e8-924c-2dee8b467bb9">187</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjgtNi0xLTEtMjc2NzEx_a79354ea-e045-40ba-a4b3-f148f7612489">8</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40dcac940e6847bfb8bfbe8958e5b5b3_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjgtOC0xLTEtMjc2NzEx_bedc6ffa-2520-48f6-b79c-918b051f5031">12</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjgtMTAtMS0xLTI3NjcxMQ_8a618631-bff5-4db7-8838-a86909ee9809">46</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i01e30f75113a4bb8a2ccf67ed98bd393_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RhYmxlOmI2NDZhOGJjNzA1MDRmNjU4MGM4YWU1Nzk5ZWNmNGYwL3RhYmxlcmFuZ2U6YjY0NmE4YmM3MDUwNGY2NTgwYzhhZTU3OTllY2Y0ZjBfMjgtMTItMS0xLTI3NjcxMQ_76eaadb3-e59c-4ec2-80e9-99326e9d2b4b">32</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfMTAxMQ_cdc7731d-756a-495b-a584-62d272f41c75" footnoterole="http://www.xbrl.org/2003/role/footnote">Mainly reflects interim actuarial remeasurement gains in 2022, primarily due to an increase in the discount rate.</ix:footnote></span></div></ix:nonnumeric><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i636e4555d4f44f8fb8615c83122ae685">For the three months ended April 3, 2022, we contributed $<ix:nonfraction unitref="usd" contextref="i6a94c588fe454796b51f100cf856faaa_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfMTA5OTUxMTYyOTk4OQ_569281a3-1e98-460f-b7c9-5fa389f6c161">112</ix:nonfraction> million, $<ix:nonfraction unitref="usd" contextref="ic38d60b43f5b428ca5ac124ba21ce08a_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfMTA5OTUxMTYyOTk5Ng_6e2625a7-8d7a-42b4-a86c-507e11945239">49</ix:nonfraction> million, and $<ix:nonfraction unitref="usd" contextref="i88f6b9a6ffca41a3a3150f82bdf4e675_D20220101-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl83OS9mcmFnOjJiMWNiNWUwY2MwMTRiNTBhZGJjMWNiMWM1OGM0MWY1L3RleHRyZWdpb246MmIxY2I1ZTBjYzAxNGI1MGFkYmMxY2IxYzU4YzQxZjVfMTA5OTUxMTYzMDAwNA_43e5f2d4-7407-44dc-bd97-623f1ec68ad3">3</ix:nonfraction> million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</ix:continuation></span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_82"></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RleHRyZWdpb246YzBlNjg4N2M4YzVmNDZiMmJlYTQ5MDRiZmFkOGY3NThfMjYw_526db3dc-d53d-42c8-8f4b-58b1f77faca0" continuedat="id26e017c303d476bbadb9a6161fcf590" escape="true">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonnumeric></span></div><ix:continuation id="id26e017c303d476bbadb9a6161fcf590"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RleHRyZWdpb246YzBlNjg4N2M4YzVmNDZiMmJlYTQ5MDRiZmFkOGY3NThfMjQ2_b5884931-8845-4887-8e8d-57de92c9a563" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator––Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfNi02LTEtMS0yNzY3MTE_56e68caf-6c43-40cc-88c7-a49c58de4ecf">7,872</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfNi04LTEtMS0yNzY3MTE_76693275-b869-49f9-9160-4150abe353e1">4,876</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfNy02LTEtMS0yNzY3MTE_bcc3de07-419e-4f4d-ac6f-ee59ff0b4b9e">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfNy04LTEtMS0yNzY3MTE_437f3f3e-2f06-49fe-b798-0e9655702455">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTAtNi0xLTEtMjc2NzEx_b072332e-0c5b-4df4-92c2-fba6b3ce4195">7,864</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTAtOC0xLTEtMjc2NzEx_eb091761-d3e8-4431-9a8d-c0cbbbed9d55">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator––Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTItNi0xLTEtMjc2NzEx_f825a024-656a-4a14-90c7-543b5c82299d">7,872</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTItOC0xLTEtMjc2NzEx_f531ccfa-1a67-4b3f-9a7d-71a278b82904">4,876</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTMtNi0xLTEtMjc2NzEx_367e2279-30e4-4b61-9931-6db67d42fd4c">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTMtOC0xLTEtMjc2NzEx_7e5f303f-6660-4d3c-aa20-9184cb54fb79">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTQtNi0xLTEtMjc2NzEx_74c73f69-613a-4dc3-a665-08347005a906">7,864</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTQtOC0xLTEtMjc2NzEx_71e4ee66-3efe-46ee-98aa-e95ad7a384c7">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding––Basic</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTYtNi0xLTEtMjc2NzEx_674379d7-a510-4d9a-973d-7bca5dcb49ca">5,617</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTYtOC0xLTEtMjc2NzEx_bb2d3e96-c740-4e8a-ae50-c5e3f239ea9f">5,584</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options and stock issuable under employee compensation plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTctNi0xLTEtMjc2NzEx_495702f0-61bc-454c-b707-a693f0d931a3">141</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTctOC0xLTEtMjc2NzEx_c4a33f2e-56c0-46fe-a770-71b787161a51">78</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding––Diluted</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTgtNi0xLTEtMjc2NzEx_f1a4c814-b4ca-40f6-9f00-321816d31a41">5,758</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTgtOC0xLTEtMjc2NzEx_0fe4208c-22ab-4028-a894-1ab6c3a8e1bf">5,662</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTktNi0xLTEtMjc2NzEx_fd615c2a-d6b7-49fa-9c6c-93f59cbd386f">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RhYmxlOjIxNzdhZjM2NmE3MDQ5NzJhNWZiMmYyNGI0NDYyOGZkL3RhYmxlcmFuZ2U6MjE3N2FmMzY2YTcwNDk3MmE1ZmIyZjI0YjQ0NjI4ZmRfMTktOC0xLTEtMjc2NzEx_ebecca67-12a5-4b67-ac35-1dfd4c01b804">2</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84Mi9mcmFnOmMwZTY4ODdjOGM1ZjQ2YjJiZWE0OTA0YmZhZDhmNzU4L3RleHRyZWdpb246YzBlNjg4N2M4YzVmNDZiMmJlYTQ5MDRiZmFkOGY3NThfMjQx_f4db10cf-819e-4685-a854-6257df518b15" footnoterole="http://www.xbrl.org/2003/role/footnote">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_85"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfNDI4NjE_87b40351-eeab-4c70-aa3f-35bee721ca3b" continuedat="i416e4c822fe44b16bba8753319a49fdf" escape="true">Contingencies and Certain Commitments</ix:nonnumeric></span></div><ix:continuation id="i416e4c822fe44b16bba8753319a49fdf" continuedat="iabf64df93cdc41fab9d9c74fa4a97a4a"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="iabf64df93cdc41fab9d9c74fa4a97a4a" continuedat="i23c1d69d21174f58ba20c3d5528ab6af"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-6" name="pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTEyMDMxMw_9fd340cb-7c05-47b9-9e84-c109fc806797">1</ix:nonfraction> million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings––Patent Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. BMS will seek permission to appeal the High Court’s decision. Additional challenges remain pending in other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings with respect to <ix:nonfraction unitref="patent" contextref="i98cb0e0e3bcd4d53803bacded9c4b4d9_D20170101-20171231" decimals="INF" name="pfe:GainContingencyPatentsWithoutCourtProceedingsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTEzNjY3Nw_c8caab0d-fc90-4466-bbf8-3d5c09ab51ce">two</ix:nonfraction> of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those <ix:nonfraction unitref="patent" contextref="i4cf0bc1683994dabae0b09e4f4334795_D20220101-20220403" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTEzNjgyMQ_d63c3569-180e-426b-aa79-c957fcaf2696">two</ix:nonfraction> patents, and <ix:nonfraction unitref="patent" contextref="i013e5218ec03476580132ca96892fc10_D20220101-20220403" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTEzNjgzOA_257099d7-a251-4977-a5e8-5e1444b03c52">one</ix:nonfraction> other patent, were challenged in federal court in Delaware. In September 2021, Pfizer and a challenger entered into a settlement and license agreement, resolving all worldwide legal proceedings involving that challenger, related to our pneumococcal vaccine patents. Other challenges to pneumococcal vaccine patents remain pending at the PTAB and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines into the marketplace. In the event that any of the patents are found valid and infringed, a competitor’s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i23c1d69d21174f58ba20c3d5528ab6af" continuedat="i900f3c9d0ed840ada4acf06c71d6570d"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the patent covering the active ingredient expiring in December 2025 and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets. In May 2022, we settled our action against Aurobindo on terms not material to us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we brought a separate patent-infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets. In April 2022, we settled our action against Teva on terms not material to us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we brought a separate patent-infringement action against Slayback Pharma LLC (Slayback) asserting the infringement and validity of our compound patent covering the active ingredient that was challenged by Slayback in its ANDA seeking approval to market a generic version of tofacitinib oral solution 1 mg/mL.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance capsules. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent. We have settled with certain of these generic companies on terms not material to us, and we dismissed the patent infringement actions against certain other generic companies.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. We have settled with one of these generic companies on terms not material to us, and we dismissed the patent infringement actions relating to the crystalline form of patent against certain other generic companies.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i900f3c9d0ed840ada4acf06c71d6570d" continuedat="i8dd77dd5237b4817a427aa7b4b40196d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eucrisa</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action in Which We are the Defendant</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp; Upjohn Co. LLC, our wholly owned subsidiary, alleging that Comirnaty infringes U.S. Patent No. 11,246,933, which was issued in February 2022, and seeking unspecified monetary damages. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, <ix:nonfraction unitref="defendant" contextref="i613377f8a86046149d6da3e3e6cb4bfa_D20170101-20171231" decimals="INF" name="pfe:GainContingencyNumberofDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTE2NjM0Mw_6735a8d6-9946-45ab-a268-19a93fcc7131">twenty-five</ix:nonfraction> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the <ix:nonfraction unitref="patent" contextref="i613377f8a86046149d6da3e3e6cb4bfa_D20170101-20171231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTE2NjU2Mg_3538887b-88cf-4900-a139-84fe87390934">three</ix:nonfraction> patents listed in the Orange Book for Eliquis. <ix:nonfraction unitref="patent" contextref="i613377f8a86046149d6da3e3e6cb4bfa_D20170101-20171231" decimals="INF" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTE2NjYxMw_963ea378-933c-4c83-b02e-86d3b53dd12a">One</ix:nonfraction> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all <ix:nonfraction unitref="patent" contextref="i613377f8a86046149d6da3e3e6cb4bfa_D20170101-20171231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTE2NzI4Mg_16dde118-29e7-431c-bd4a-235c42d29f70">three</ix:nonfraction> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings––Product Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div><span><br></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&nbsp;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i8dd77dd5237b4817a427aa7b4b40196d" continuedat="i612c3de73d1c42e5a203c8af7731aa0c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court’s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen (Direct Purchaser)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants’ motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i612c3de73d1c42e5a203c8af7731aa0c" continuedat="id59316c9ac9245e18f055973aee5682b"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and <ix:nonfraction unitref="manufacturer" contextref="i2621d6730855458f959b341448de9e27_D20180101-20181231" decimals="INF" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTIwNTI3MQ_73050630-e758-4ab9-bf69-97d9438f593b">eight</ix:nonfraction> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state court, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chantix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings––Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="id59316c9ac9245e18f055973aee5682b" continuedat="i7995a7a0ea9744a49aeea427a7bd842e"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we submitted a revised site-wide feasibility study with regard to the Wyeth Holdings Corporation (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the U.S. Environmental Protection Agency (EPA) with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy. In 2012, the EPA issued a final remediation plan for the Bound Brook facility’s main plant area. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for <ix:nonfraction unitref="lagoon" contextref="i9e43302017e04b1393a21ba82c9623e3_D20130101-20131231" decimals="INF" name="pfe:FeasibilityStudyNumberOfLagoons" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTIzMzE3MQ_a4f7249b-b765-4e34-a515-102838d9e5b1">two</ix:nonfraction> adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the <ix:nonfraction unitref="lagoon" contextref="i107c540186ef402d97fd5639a25a37dc_D20180101-20181231" decimals="INF" name="pfe:FeasibilityStudyNumberOfLagoons" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTIzMzYyNA_0d0c41a3-bf22-4ea6-82fc-fee5810824ed">two</ix:nonfraction> adjacent lagoons. In 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. In September 2021, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey, which the court approved in November 2021, that will allow Wyeth Holdings LLC to complete the design and implement the remedy for the <ix:nonfraction unitref="lagoon" contextref="i8b7898a9cd2641bfbff7d24c6dfad2f4_D20210901-20210930" decimals="INF" name="pfe:FeasibilityStudyNumberOfLagoons" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84NS9mcmFnOjVjODY1OTJmNGNkZDQ1NTc5ZjA1MTY1ZDJhMjUzODM1L3RleHRyZWdpb246NWM4NjU5MmY0Y2RkNDU1NzlmMDUxNjVkMmEyNTM4MzVfMjc0ODc3OTIzNDEzMA_dd30d185-e78f-4696-ba8b-52b9f763f3ac">two</ix:nonfraction> adjacent lagoons. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for the estimated costs of the site remedies for the Bound Brook facility.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. In January 2022, the Court of Appeals reversed the District Court’s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals’ decision.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Viatris Securities Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company’s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings––Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i7995a7a0ea9744a49aeea427a7bd842e" continuedat="i1f375ac878a043bbbaa951cf73a11296"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General and Multi-District Generics Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a civil investigative demand from the U.S. Attorney’s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney’s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the  U.S. Department of Justice’s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC’s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC’s FCPA Unit. We are producing records pursuant to these requests.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i1f375ac878a043bbbaa951cf73a11296"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac––State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings––Product Litigation––Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the March 2022 indemnity provided by Pfizer to GSK in connection with the issuance of notes by the Consumer Healthcare JV. Historically, we have not paid significant amounts under these provisions and, as of April&nbsp;3, 2022, the estimated fair value of these indemnification obligations is not material to Pfizer.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, each of Viatris and Pfizer has agreed to assume, and to indemnify the other for, liabilities arising out of certain matters. Also, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program, BNT162b2, aimed at preventing COVID-19 infection, includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div></ix:continuation><div id="i2d1b55fadd3b49068baa4191851d4ddf_88"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDM0NQ_1b68bd13-e823-4d84-b0f9-a007ed576697" continuedat="iee6805808de04481b6f93865b0f50d34" escape="true">Segment, Geographic and Other Revenue Information</ix:nonnumeric></span></div><ix:continuation id="iee6805808de04481b6f93865b0f50d34" continuedat="ib04495e2ffe94785981742978c1c5f69"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We manage our commercial operations through <ix:nonfraction unitref="operatingsegment" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjYzODgyNzkxMTUxMTM_c9c9c80d-6a3f-4be9-a3fb-49fa3b69c471">two</ix:nonfraction> operating segments: Biopharma and PC1. The Biopharma and PC1 segments are each led by a single manager. Biopharma is the only reportable segment. Biopharma is a science-based medicines business that includes six therapeutic areas – Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation &amp; Immunology. The Hospital therapeutic area commercializes our global portfolio of sterile injectable and anti-infective medicines, as well as an oral COVID-19 treatment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;D services from WRDM and GPD. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation.  </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Business Activities––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with: (i) R&amp;D and medical expenses managed by our WRDM and GPD organizations, (ii) corporate enabling functions and other corporate costs, (iii) overhead costs primarily associated with our manufacturing operations, (iv) our share of earnings from the Consumer Healthcare JV, as well as (v) all amortization of intangible assets, acquisition-related items, and certain significant items representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Beginning in the first quarter of 2022, acquisition-related items may now include the following purchase accounting impacts that previously would have been included as part of a reconciling item entitled “Purchase accounting adjustments” that we no longer separately present: (i) the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, (ii) depreciation related to the increase/decrease in fair value of acquired fixed assets, (iii) amortization related to the increase in fair value of acquired debt and (iv) the fair value changes for contingent </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ib04495e2ffe94785981742978c1c5f69" continuedat="id4d6ae739fc34b5288ea9c4241438bdb"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration. The operating results of PC1, our global contract development and manufacturing organization, are included in Other business activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Assets––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-9" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzODAyMw_9c1c02f8-010b-4404-ac24-5afbf6e26bd0">184</ix:nonfraction> billion as of April&nbsp;3, 2022 and $<ix:nonfraction unitref="usd" contextref="if4b7dec1e70a4dff86f95c6f3b0f03e5_I20211231" decimals="-9" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzODA0MQ_73a5cc7b-8dc0-4aed-b56d-d9b19d76cb95">181</ix:nonfraction> billion as of December 31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Income Statement Information</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTM_7cfe27f0-eaff-4fe6-9de3-b21e1962bd13" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i30a2c68c78884fae86e646356d6b9a41_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNS0yLTEtMS0yODE0NDA_b094829b-e84a-4e1b-93ab-9996815bfa04">25,323</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icaaf0596d764452bbcbac24bd260f815_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNS00LTEtMS0yODE1MTA_bf507cc8-4547-4fc9-bbcf-82a9e9e9ecb3">14,125</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i30a2c68c78884fae86e646356d6b9a41_D20220101-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNS02LTEtMS0yODE1MTM_82670197-e57c-44b2-ab10-dbb1282dc5c3">13,438</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icaaf0596d764452bbcbac24bd260f815_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNS04LTEtMS0yODE1MTc_c9eefef7-e981-429f-bc44-d3c2c87ffc81">8,383</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida5befccee2e4efa94c1a66b4baf2890_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi0yLTEtMS0yODE0NDA_ac2af997-b672-4707-8eee-66132d114f36">338</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic8bd686116ea4dac90aeec1d623a28e0_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi00LTEtMS0yODE1MTA_cfe87283-5ddd-462a-beea-7b055c8801ab">391</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ida5befccee2e4efa94c1a66b4baf2890_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi02LTEtMS0yODE1MTM_571efee2-2bbb-4760-8e1b-9226c0cbde5e">2,475</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic8bd686116ea4dac90aeec1d623a28e0_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfNi04LTEtMS0yODE1MTc_72029c23-6b87-4987-b96e-5041cc95eebf">2,048</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabc0f5e5976a4081820401402186fd35_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOC0yLTEtMS0yODE0NDA_0cc1b008-46ba-423d-b1e2-2f004936f648">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3c110eebdbb45e1a79a4c17192b29b7_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOC00LTEtMS0yODE1MTA_747997a6-b6ff-4da2-b0b9-1d2b6a228c1b">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabc0f5e5976a4081820401402186fd35_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOC02LTEtMS0yODE1MTM_7eb5963e-14fe-4480-9f88-675ff727c31e">835</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia3c110eebdbb45e1a79a4c17192b29b7_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOC04LTEtMS0yODE1MTc_f3182c25-9f3e-43cc-9b64-8459f9742e59">870</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40ed83f9e549484e847fe007ec997de8_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOS0yLTEtMS0yODE0NDA_801d3a79-f071-4d79-bde1-a617617c274e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c95d9722a724dfcb3d5eb05d4e5a3da_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOS00LTEtMS0yODE1MTA_0640e514-b568-4ce8-a8a4-f7e8a6b5e851">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40ed83f9e549484e847fe007ec997de8_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOS02LTEtMS0yODE1MTM_67508b3c-d02a-4fec-9005-02cf354f360b">187</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c95d9722a724dfcb3d5eb05d4e5a3da_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfOS04LTEtMS0yODE1MTc_4975ff5c-321c-4afc-9d7e-2c4a3a3436c1">61</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3ccec203f4144a0fb669d187f4377351_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtMi0xLTEtMjgxNDQw_d34711e7-1382-42a5-8d3c-bd024d407ca0">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3152374dfa25418595a1c0308ecc6a23_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtNC0xLTEtMjgxNTEw_6276ccc6-46a6-45c7-8189-6ed1694f8907">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3ccec203f4144a0fb669d187f4377351_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtNi0xLTEtMjgxNTEz_b209faca-c8e6-4dd7-bf6c-55eac7390da5">891</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3152374dfa25418595a1c0308ecc6a23_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTAtOC0xLTEtMjgxNTE3_edd5351b-a558-4a8b-ba0c-bdffaa44eb26">166</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTEtMi0xLTEtMjgxNDQw_a1cf6201-045f-4c03-be01-bd84c06cccbb">25,661</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTEtNC0xLTEtMjgxNTEw_8d4997b2-1b61-47ad-9059-117ea85a9338">14,516</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTEtNi0xLTEtMjgxNTEz_87fda6a1-5675-47b9-ad80-de0956176f71">9,050</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjZmMzQ4MWYwNjM4ZjRkMWQ5OTg5Zjk5OGYwNjEwOTE5L3RhYmxlcmFuZ2U6NmYzNDgxZjA2MzhmNGQxZDk5ODlmOTk4ZjA2MTA5MTlfMTEtOC0xLTEtMjgxNTE3_2812be2c-3fc6-457e-994a-cd2246c8d472">5,692</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjE_c2ea381b-8d9b-4370-9a21-42877e9195e9" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma’s earnings include dividend income from our investment in ViiV of $<ix:nonfraction unitref="usd" contextref="i41270b758c1d46fcbedebcbb44055380_D20220101-20220403" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzOTM0Ng_2af07c19-889b-4274-bab7-32eb3d9441be">56</ix:nonfraction> million in the first quarter of 2022 and $<ix:nonfraction unitref="usd" contextref="i4e7af85b3e4a4f98ad9b33d523f739d5_D20210101-20210404" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzOTM1OA_5d088935-d041-459c-809c-7f2ba7788aea">27</ix:nonfraction> million in the first quarter of 2021.</span></ix:footnote></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjI_c1290e3a-ff0c-42b1-9bca-82654dd4b085" footnoterole="http://www.xbrl.org/2003/role/footnote">Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0OTMxNjM_f33ccbd5-f25a-4a5c-bb0c-010a137a6a45" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the first quarter of 2022, includes, among other items, net losses on equity securities of $<ix:nonfraction unitref="usd" contextref="i3ccec203f4144a0fb669d187f4377351_D20220101-20220403" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjY5MzgwMzQ5Mjg3NzY_cd80968f-0fa0-4e5a-b606-dcd26a4bf65c">698</ix:nonfraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For earnings in the first quarter of 2021, includes, among other items, net gains on equity securities of $<ix:nonfraction unitref="usd" contextref="i3152374dfa25418595a1c0308ecc6a23_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTY1NTU1MA_845c1d87-f320-4f7d-b1b6-78526c5e0947">399</ix:nonfraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Geographic Information</span></div><div style="margin-bottom:3pt"><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDM1MQ_efc09e8a-d677-4604-855c-9565fa4acd6d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00164188d3ab4ba0a6525f0333129fd3_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfMy0yLTEtMS0yNzY3MTE_3db6c87c-cb54-46ee-9b0a-e7e1d862795e">8,918</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i43cf026e4ceb4512aeca1360388ccd6c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfMy00LTEtMS0yNzY3MTE_b9877188-3dca-4d7b-92ae-17ec70cab452">7,530</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i00164188d3ab4ba0a6525f0333129fd3_D20220101-20220403" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfMy02LTEtMS0yNzY3MTE_093b8773-4f44-4ba0-b0ef-0c1beba51152">18</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11e19e5bb8cc49a6b0070c913874a10c_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNC0yLTEtMS0yNzY3MTE_10a6a19f-b958-41b0-b309-2021141fb960">6,090</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if5b9e8ab6e0d4cd1a5f8c0a2743cefd4_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNC00LTEtMS0yNzY3MTE_92dff38d-a920-453b-ba8b-1fe651bc733b">3,038</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i11e19e5bb8cc49a6b0070c913874a10c_D20220101-20220403" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNC02LTEtMS0yNzY3MTE_c017ccf2-8b6e-48be-a77e-e547f4b2f0d3">100</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i87530cb66c58474f807cb29294dbcd86_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNS0yLTEtMS0yNzY3MTE_1d93447f-9e03-42bd-b060-11b01ab11210">3,286</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2d629aca7a2449a96eeb492739ebc60_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNS00LTEtMS0yNzY3MTE_21398990-f0c2-4b4d-9fef-bed189437c6a">1,123</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i87530cb66c58474f807cb29294dbcd86_D20220101-20220403" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNS02LTEtMS0yNzY3MTE_8cd9465e-f97f-41ef-8568-bd84b628da52">193</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c07ff391c6949e49366878bf9642489_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNi0yLTEtMS0yNzY3MTE_b685eac2-3073-478c-8044-7b0b0f7cf03d">7,367</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i29a3b2c8b1c7462d9fa379cbb7056d6a_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNi00LTEtMS0yNzY3MTE_d8102610-58b3-4b4e-9c26-8d887ac12809">2,824</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i2c07ff391c6949e49366878bf9642489_D20220101-20220403" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNi02LTEtMS0yNzY3MTE_e66c9787-f71c-40e8-8902-5d8d23fc21e7">161</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNy0yLTEtMS0yNzY3MTE_c42f4a01-9d72-4164-b60b-7c87beffa357">25,661</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNy00LTEtMS0yNzY3MTE_9c4db021-6ebd-42ba-86c5-f413b432092a">14,516</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjU2NmE0ZDg4MDE5ODRmYzlhZjRmYTdlYmZlYWFlYTVjL3RhYmxlcmFuZ2U6NTY2YTRkODgwMTk4NGZjOWFmNGZhN2ViZmVhYWVhNWNfNy02LTEtMS0yNzY3MTE_d1400420-7834-43f1-a9b3-b944d0f8d38f">77</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Other Revenue Information</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K. Additionally, revenues from the U.S. government represented <ix:nonfraction unitref="number" contextref="id921a82c38464bd88b73da3115bf2b7c_D20220101-20220403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfOTU1_62f84061-a73c-4ed8-887b-cd1500eaa968">19</ix:nonfraction>% of total revenues for the three months ended April&nbsp;3, 2022, and primarily represent sales of Comirnaty and Paxlovid. Accounts receivable from the U.S. government represented <ix:nonfraction unitref="number" contextref="i8a707be866f14de18ce2230a729d8119_D20220101-20220403" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTExOQ_fad12657-258d-4e8b-91ae-136e63fbb9b2">11</ix:nonfraction>% of total trade accounts receivable as of April&nbsp;3, 2022, and primarily relate to sales of Comirnaty and Paxlovid.</span></div></ix:continuation><div><span><br></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="id4d6ae739fc34b5288ea9c4241438bdb" continuedat="i67231c9123514b59bf28799fa778de5e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><ix:nonnumeric contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMzOQ_0faeeaf2-3414-4f0c-8b28-dca400fa56e6" continuedat="i8726b40def804c6f8864731a6b637a23" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMi00LTEtMS0yNzY3MTE_855e2e97-d90a-4fcd-ab23-213c92d6eaef">25,661</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4741d6ead6b45d59abb5f6187403c12_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMi02LTEtMS0yNzY3MTE_7e1e8b5a-5ea4-4ad6-973e-b65316f17d96">14,516</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i374d2afe98284addbca9020d145b8a8e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy00LTEtMS0yODUyMTI_c7677d98-5c35-43dd-9e2e-5976d93ff2df">25,323</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e75354e487a4dc8af572674dfc8737a_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy02LTEtMS0yODUyMTU_ea296c5f-91bd-4fcd-b3bd-c9370e55bbbb">14,125</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Vaccines</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e80a0ae2b3a4bb58d29d5a14a0e3758_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy00LTEtMS0yNzY3MTE_0b515d0b-0af2-4883-a22d-e8ea42bbf96d">14,941</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i68a8d6e882a7477db4bdef5ada229a8a_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMy02LTEtMS0yNzY3MTE_a583a377-72fb-408a-83c1-7f9179d9ed20">4,894</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i23b05a2dee4141d8aafbaece3b0f2a9e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNC00LTEtMS0yNzY3MTE_4d7f0b79-8604-4bb0-96d0-9260cae36412">13,227</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i26c29fc52df0492d8adf588dd23eacd3_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNC02LTEtMS0yNzY3MTE_86d74ac6-8978-4698-a560-75d4b07e85a1">3,462</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar family</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">   </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c98ee0bda8749e4bb5bc3deb581e80f_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNS00LTEtMS0yNzY3MTE_803a47fb-7358-49c3-ac1a-82abccf579d7">1,565</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib200840a55b74a4ba250410b4d846b8d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNS02LTEtMS0yNzY3MTE_197965ee-9a64-4a8a-b9a2-93d7276c1e25">1,284</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2da31f898f4d467bacc0fb123da37640_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNy00LTEtMS0zMjM5NzI_013b2ab1-757c-4f48-bf63-1d7eb1148b89">77</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i20d0a20745c14c1281a88f27d679e887_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNy02LTEtMS0zMjM5NzI_6978f8c9-1f8e-4339-b3e3-7e9e948cd05a">46</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id3f74c09f5f0465f90b6c2736b56e403_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNi00LTEtMS0yNzY3MTE_e785ebcd-4703-49a8-ae33-5f43fb95281b">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3622ef3f518d42449c5e4f3423f0bd86_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNi02LTEtMS0yNzY3MTE_35ed2f05-03f6-498e-8785-4802694acec2">53</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Vaccines</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f203f618b4944d3928f406d4d9b3c09_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfOS00LTEtMS0yNzY3MTE_c54d30f1-3cc0-4d39-851a-ab42e88e2424">29</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie8e0583d1d904a65afac1e36a704af68_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfOS02LTEtMS0yNzY3MTE_679e8557-0e2c-436c-ade8-96c5a3911d12">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i03bff54ac3e3492b941cf2880c0b04a1_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTAtNC0xLTEtMzI2Mzcw_f7f369f9-1f89-4ae7-bfe1-c338d38308cf">3,191</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i480524826e154d858ceed97bf478569b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTAtNi0xLTEtMzI2Mzcw_688175bf-d067-49fa-abe6-e27106330922">1,886</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Paxlovid</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia79b5ae25b904f9c9489c79a05f8ac5e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTEtNC0xLTEtMzI2Mzcw_42f8a37d-d88a-4a15-a0ad-230c2b7fcfe5">1,470</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie1572b96b6bd44e18e5b7de528a81eef_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTEtNi0xLTEtMzI2Mzcw_588da332-073e-491b-910c-54ac8de4d6bb">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i56b6f4110e334aaca34cf65b91803525_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTItNC0xLTEtMzI2Mzcw_c2792cab-3350-4ef9-8658-b491f98fd990">210</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4aa8e10486f14cc9929e3f515e497185_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTItNi0xLTEtMzI2Mzcw_f938a786-3a47-426f-944b-592a3e8ae68d">192</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5761dda6d0904083928fc3e4dd368990_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTMtNC0xLTEtMzI2Mzcw_fbfdc85e-e9e2-41ff-8766-4007bc9913b1">125</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa747d7722c0451cbf43d5994c727bd2_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTMtNi0xLTEtMzI2Mzcw_cad1e1d2-c248-4c9d-b10c-38664fac17b5">89</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ig Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i20367294350841ff8f8d103f66b27128_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNC0xLTEtMzI2Mzcw_16435377-2cfa-4aaf-a4e4-cc6f4f7dfa2c">107</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic6f25f2250e04c79959c22e7d8dd40b7_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNi0xLTEtMzI2Mzcw_167b2ce4-4354-4d76-b319-f853d63a4b84">105</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0a7e1209b9654b42884a80f3cbc035b6_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTUtNC0xLTEtMzI2Mzcw_5294990f-b1cd-46b2-bb6e-d5e94db697f9">104</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa38542696af49449bec808dec503c3e_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTUtNi0xLTEtMzI2Mzcw_9347f46a-98e3-413a-bb18-4791de771054">94</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22329063ffca434184f5e54477c37d27_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTYtNC0xLTEtMzI2Mzcw_c2062e0a-954c-42e5-981a-4cd6fdfec93c">76</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibfc2f94d96c6497186ed529e92425b1b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTYtNi0xLTEtMzI2Mzcw_bd8086e6-555e-4723-85e4-0bd582f582da">99</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13c3eeafa900479da2138733992b2636_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTctNC0xLTEtMzI2Mzcw_254d0acd-4b0f-47a4-84fe-7b9affff2745">70</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i464f59429cf449a1ab096ee576bda4ba_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTctNi0xLTEtMzI2Mzcw_fa1671a4-1c59-499f-8aea-9c631dd0e7ff">71</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4247fd55c65047fa90eb67e8ca54f06e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTgtNC0xLTEtMzI2Mzcw_a1f2936b-4adb-4e3c-8f37-a45ee056f57b">65</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3825cc8f059a48539bf52a46a8495f99_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTgtNi0xLTEtMzI2Mzcw_408c789e-b5e4-4ade-848d-9f642fe00afa">80</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibbc4e0bd2ad1456c9f2a7fad2803084b_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTktNC0xLTEtMzI2Mzcw_cd1fc9ac-eb5b-4a68-af5f-c46c7b815782">381</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6e4a1b1e4c04856a3682021abfdb171_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTktNi0xLTEtMzI2Mzcw_0066ea76-6684-4b75-b039-26dae6af9dd2">455</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Hospital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67bb24f4746c4b9c8c51bb10c4620be7_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjAtNC0xLTEtMzI2Mzcw_df5a289c-2d01-407e-9cc5-aaca50c32ada">583</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="ifd4ce5f051904dbf9441d4269e7cef9c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjAtNi0xLTEtMzI2Mzcw_0228b6c6-d67f-4189-b926-6d7350f7be32">700</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea5e5c69dedf462fb8e78af7eef609f1_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTAtNC0xLTEtMjc2NzEx_7dd638f5-332e-4d0e-9acc-01de4f48a997">2,967</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b6086c49fc047a19b337a5f6904926b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTAtNi0xLTEtMjc2NzEx_dba34916-1003-4a56-8357-91798709ea70">2,862</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1a9cfec816743ccae7e7ddee1817fd7_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTEtNC0xLTEtMjc2NzEx_f3451f30-f9f7-433c-8e82-ad9e1c1773d8">1,237</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1180d8a0bb09417bbf62af96856e9382_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTEtNi0xLTEtMjc2NzEx_f8ded316-7f45-4fbb-8f91-78ed99f6273a">1,254</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d35a5f7d57744e4913402ae016b2d68_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTItNC0xLTEtMjc2NzEx_a4acf4c5-3525-49d1-954a-6194940c9c79">268</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i38b77cd344ef43889d191a17740ccf7c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTItNi0xLTEtMjc2NzEx_c3e3f959-9c65-4fc0-9169-314ffacc4507">267</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i312153f7ba1f479ab467c39b2c5d2ff9_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTMtNC0xLTEtMjc2NzEx_b9f459f5-d194-44da-9c7a-90e72785a877">234</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i858b30e3471f40f3b0715d2260ee4fc3_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTMtNi0xLTEtMjc2NzEx_1932d2e1-67eb-4314-93eb-9839706ac7ff">229</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22b45f70d46c44fab93b6cb968fde7d6_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNC0xLTEtMzI0ODM3_45b0a2bd-e97e-48b8-b21a-7c6bc37f33da">147</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i167c294d808a4baea160301675828860_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTQtNi0xLTEtMzI0ODM3_efa2a47f-256b-4dcc-b7a4-96c2504a45d6">86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&nbsp;chromosome–positive&nbsp;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2edaf2e90e324125ba42d8cdb377ddb7_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTUtNC0xLTEtMjc2NzEx_0159f6a2-88f0-42a6-ab66-37ed1a1d31b0">128</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibf1e8f7edde548a1a8c88f472551ca96_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTUtNi0xLTEtMjc2NzEx_e144daf0-b7fe-4242-9e25-90dd1b5b7fc0">123</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82bd332b07504350a19fb5ca2c765f9b_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTYtNC0xLTEtMjc2NzEx_fe7552b8-63ca-495d-81d0-aeed1d33deaf">127</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07167b12cbf3406b95c38cb9916a2809_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTYtNi0xLTEtMjc2NzEx_16416e53-db26-4469-8d83-316dcd012c76">134</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i73e290283edb4f8abb2b3dd3fa118093_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTctNC0xLTEtMjc2NzEx_d00f9623-48c1-480d-be2e-93a7718416ec">124</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i763e39ccea79436fb64fa76bdcf1a286_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTctNi0xLTEtMjc2NzEx_52203469-5687-4bd4-9249-d6233cfb6e81">98</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if6c58f343d9e4021b80feae0e6071b8c_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTgtNC0xLTEtMjc2NzEx_1e62bc50-a0e6-41c4-b80a-09b474ff7476">115</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4db19eac381483a93032d162775f7c0_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMTgtNi0xLTEtMjc2NzEx_3ac30c5b-00f8-4696-a5ee-b42e244d9a76">109</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id4f5a7ba34e2472f801d20af2cc481dd_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjAtNC0xLTEtMzI0ODUw_a80abc96-8ad8-437b-9c0b-07f5d7ac53ff">114</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaa09128622de4a3ba3052989631fee82_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjAtNi0xLTEtMzI0ODUw_fade7220-d807-40c0-9c21-852ffb7453ff">200</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d34083b3baf463c820a2523f4b71ffa_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjAtNC0xLTEtMjc2NzEx_c7b6885e-7f64-4f8b-97ae-83a54a5b8617">72</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfeea77fd8044250b9a58e054b46d17e_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjAtNi0xLTEtMjc2NzEx_8a19c753-aab2-4c74-aa73-3fb023e5f33b">60</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0002a141088e488aae7dc3008321793f_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjEtNC0xLTEtMzI0ODcw_5aa9e715-79b5-4dc0-acad-fbc0332106ed">67</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88ff63e57253422498c526a43b85c2e1_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjEtNi0xLTEtMzI0ODcw_4f3f0b60-43d5-4765-8fc3-accd666ace3a">32</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9831594f3d4d47f5a86f5fd43c2d2dc9_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjEtNC0xLTEtMjc2NzEx_0ec5b574-f637-4d79-9101-0c1ee301d3bf">62</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i644e06c55f674618a3cf4b635f1b8793_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjEtNi0xLTEtMjc2NzEx_c44ded44-f749-479f-a5cd-f0bf6d5ffb6c">52</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trazimera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HER-positive breast cancer and metastatic stomach cancers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i17e1cf89c4ca4291b45b31f62c95dbd3_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjMtNC0xLTEtMzI0OTE3_ce72a88a-cf8a-42fa-a0f7-4354d39e5389">52</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i75ed4cf33ca34e4a9bc6aa4d73178459_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjMtNi0xLTEtMzI0OTI0_5cd81174-83bf-484e-a172-9439d0f07e61">45</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b793d79c5ed44c38384530e981002e6_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjItNC0xLTEtMjc2NzEx_448e6855-f200-4d80-bc6a-49694b82d75c">51</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc838b33cbd049e3866a6be07c55b9ef_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjItNi0xLTEtMjc2NzEx_36345b1f-0f9e-4661-899a-0033be1530ca">50</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i730e7608c5d041de8a09917c7ea6b1b0_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjMtNC0xLTEtMjc2NzEx_865322c3-24b8-4c4d-9e52-646f824c2902">48</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i069a55b784a5444facc987514dfcbf0e_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjMtNi0xLTEtMjc2NzEx_3cd8ceec-9dda-49f4-9f07-09bd76d577ad">47</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92eccd20d0d240fdba4fdcc076a3bd8e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjUtNC0xLTEtMjc2NzEx_14977717-37aa-4191-b8cb-31bb201288a0">40</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic1ebbc94721f4b3d9729bb2e84e63849_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjUtNi0xLTEtMjc2NzEx_caec1abd-f100-466a-a2ba-f7cdc4f0ffcd">35</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id80bcaaa63c94b439df9c4d2c987d05d_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjYtNC0xLTEtMjc2NzEx_91a9834e-71ae-46e7-903e-eaab86381069">81</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c258487c37448c7a5f7865c46dd6667_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjYtNi0xLTEtMjc2NzEx_54d2be27-b0cf-440c-b834-f9ab0e94400e">41</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Internal Medicine</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94b27e5834be4ed095ab7e46579bc9f6_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjctNC0xLTEtMjc2NzEx_17691a83-d0a8-4380-9613-3e36cc29e1af">2,440</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iecde536e0bdc4a9298033ca562d335bb_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjctNi0xLTEtMjc2NzEx_e8aa0c4c-6cb1-40df-ae12-329add992018">2,594</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2390737b19a14f2394dd4c7d06346f87_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjgtNC0xLTEtMjc2NzEx_d2725d74-58b6-4d26-a6d2-74f2a6b10d92">1,793</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ec1c6f5bd01474ca2851d3875cc2812_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjgtNi0xLTEtMjc2NzEx_1f322611-bd58-4cba-9f29-d24413d2f8ec">1,643</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i946d879e581c4bd98bb69c1c12d158bf_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjktNC0xLTEtMjc2NzEx_7a095ab7-22ea-4e72-b9c2-f48c234e7d2a">102</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="if91945f6ed7240bfb57ae5a7c3c3eb2c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMjktNi0xLTEtMjc2NzEx_9dac7231-f5f4-41de-92fa-bc5e0ac0918e">143</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BMP2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b33eb0b0c274277a6b11939ae2f5e4e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzAtNC0xLTEtMzI0Nzg5_8b4422b1-2190-4046-9e06-512a9aa6a42a">67</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id7f9aa1074494b13b06bf4e30d1eab74_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzAtNi0xLTEtMzI0Nzg5_c9e1df51-45e9-4aca-840a-a95490805ea0">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7cbfaeeefa6743e6bd89506f62c4f5ba_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzItNC0xLTEtMzI2MTIw_24ee16ec-a482-4750-acd1-59db9e292311">54</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa5f87e4a8144775961301d9c4da571c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzItNi0xLTEtMzI2MTIw_c6c58daf-660c-4d84-8e06-a6077b6d3e25">57</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22eb186593d943b0a83b5a158a5c4bbf_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzAtNC0xLTEtMjc2NzEx_f3a78fe7-5f30-42f8-a77a-e89e5d57964e">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7647ea6b84924a64a6d35398e085a719_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzAtNi0xLTEtMjc2NzEx_546cb3e7-7217-4a66-9503-fa7528523177">217</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13fdcef05287493ab8780f56121b4a9f_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzQtNC0xLTEtMjc2NzEx_77b9436f-4de3-46ed-a439-8a73f0662707">423</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="i75ac7c13b90b4b42b2f32593d8f144ea_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfMzQtNi0xLTEtMjc2NzEx_88afd334-0b97-4cc1-889b-6d8349499bb6">484</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Rare Disease</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i131c61a3ac5f4e1fa3614c3292ba145e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTUtNC0xLTEtMjc2NzEx_8c24429d-d722-4c72-bf0d-c691cfd9e02c">963</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia73c1afe171e45c883095fc4903b9d02_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTUtNi0xLTEtMjc2NzEx_8df06433-5043-4d9f-9fac-f9a39c4a0751">824</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf6831f047364b47a19a28060648adc1_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTYtNC0xLTEtMjc2NzEx_4a363411-6a9f-4a2d-908e-8a0ec102eace">612</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i17ec224b285a408aab25ad7aa49baa92_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTYtNi0xLTEtMjc2NzEx_2e03e958-660b-44f0-bf34-43593b57edca">453</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9331f572dca54312812dab029d25d4b6_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTctNC0xLTEtMjc2NzEx_7286e257-243b-4e6f-8982-15e314d383fb">112</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i80f8caf5dc454967b79771f3ed2a1a1c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTctNi0xLTEtMjc2NzEx_d6a2cda6-5d23-46cc-9cf2-f6586d19c05c">112</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i67231c9123514b59bf28799fa778de5e"><ix:continuation id="i8726b40def804c6f8864731a6b637a23"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i84f7316209254d369b391702633ea27d_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTgtNC0xLTEtMjc2NzEx_1fa541dd-2ea6-43d3-b966-5049c5ba6a40">80</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib9e387a17a3e4284b4330917883bb632_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTgtNi0xLTEtMjc2NzEx_5ec2c6af-1ee9-4aac-9c67-c7f5580223c3">80</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i933eefba8db34a6fb618d8eba93c2999_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTYtNC0xLTEtMzI2MTI3_e3075668-af89-4928-85c8-1efcf3be1c9d">68</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia9adaa23531147e385a170b2f139531d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTYtNi0xLTEtMzI2MTI3_4d168392-8668-4343-a5f8-2fc93222e481">65</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee7ae2a9acec4754a261164669b76ae9_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTktNC0xLTEtMjc2NzEx_951e7f54-83b2-4527-9060-7baf0b46551f">66</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b63f86bb6a74083bf90380872a01bd7_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTktNi0xLTEtMjc2NzEx_34116534-f874-44fe-b919-9a0589651e52">89</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7ad61ebd0f7420ca92d477dbc2f9b9c_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjEtNC0xLTEtMjc2NzEx_61b7a5f8-b3ed-4a5a-8929-739e15681de7">25</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6734edd6cb5f4663a2779a9e64e461b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjEtNi0xLTEtMjc2NzEx_bf669126-b435-4a76-aae9-bb0873211093">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16409719261f43008f5bbaf2c0fa7843_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTktNC0xLTEtMzI2MTQ4_e28af65f-f920-4c90-a63c-3b449e249f4a">821</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i893dd0e0ba9b4b7e9ba0fbb6cb8c0ab6_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNTktNi0xLTEtMzI2MTQ4_95b4972b-d0d7-445b-a0d3-dee3fb6a9412">1,065</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></div></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6e5f91c4c4c493986eda62f0c5b60a9_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjAtNC0xLTEtMzI2MTQ4_a080826a-8fab-4ffa-8f84-d0006a4817d5">372</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia128c50ff4df4ed894d90e14461dab94_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjAtNi0xLTEtMzI2MTQ4_c05be906-82de-4cb3-90f0-2cb2baf0f99b">538</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8483472faf6c4201a992e4609257452d_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjEtNC0xLTEtMzI2MTQ4_63f8ec01-506c-48cc-aeae-3eb322e616e7">280</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63e93084b61840a29a027fd45290e750_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjEtNi0xLTEtMzI2MTQ4_9254cf42-4ce3-44ba-bffd-54a2195309d5">319</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0956b534d13549b39a4f4c82c07de287_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjItNC0xLTEtMzI2MTQ4_d751a480-5b26-4783-96ae-3684cefc9fda">135</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b1b7d3d21084227bad2e6d857b8691f_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjItNi0xLTEtMzI2MTQ4_d9a0d048-174c-40e8-af5c-323e1e691b49">177</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other I&amp;I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib44fa39bb6d5456caeb94fff03f512b2_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNC0xLTEtMzI2MTQ4_e996bf77-f8d6-47bc-b6a6-d04a98a895f8">35</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc9f8478410041109d88625f91cf1fdd_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNi0xLTEtMzI2MTQ4_79d501b3-7733-40a7-a433-56615b480d86">31</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d61326b704944419cce3fce1cebfeb6_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNC0xLTEtMjg1MjI2_7e11c141-ce07-44b3-9ab4-13794adb9c23">338</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia27c207acad449e7a064045a163e1d07_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNi0xLTEtMjg1MjI5_c4a96786-467c-4aef-9742-15f3f32e11de">391</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5a7505f413e4b6b87c5d8d59c07cc8c_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjItNC0xLTEtMjc2NzEx_5ea9a4b5-cb07-45bf-857f-4e9120a03c81">2,314</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8b4a02c10854ad0a881ad1c41403bbf_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjItNi0xLTEtMjc2NzEx_bcabc466-f1a0-4eae-b0ea-3c3971f23070">1,770</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic6bf0e1bdd7b4de695e41c0d1403502a_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNC0xLTEtMjc2NzEx_24622a70-1c32-4753-8e56-b3766a257cff">605</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ec0d207102a4ba3a04c43550b49d460_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjMtNi0xLTEtMjc2NzEx_668dca05-7cd7-4aff-bd62-a96c7ab4f45b">530</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c4fd02f8da94946bbd28441ccf00831_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjQtNC0xLTEtMjc2NzEx_6e353de4-2668-43b8-bd03-bbedc389d306">1,331</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6540f0b3a8d347bb8a81e0000e47d62d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RhYmxlOjYxODc0YTg1Mzk2MzQ2NjQ5M2IwNTNiNDZmY2MxZmQ5L3RhYmxlcmFuZ2U6NjE4NzRhODUzOTYzNDY2NDkzYjA1M2I0NmZjYzFmZDlfNjQtNi0xLTEtMjc2NzEx_1e1c035a-9a27-420b-9fe1-55b2e791b25b">1,482</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTk_0f0d2b9f-4fc4-408d-b35b-92f657ae7162" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTc_c165efd6-604d-44b8-9c0a-9003848351e6" footnoterole="http://www.xbrl.org/2003/role/footnote">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of <ix:nonfraction unitref="operatingsegment" contextref="ibae7c039b14641f6a5659fcc4dbe0587_D20220101-20220403" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjYzODgyNzkxMTUxNDg_c9c9c80d-6a3f-4be9-a3fb-49fa3b69c471">two</ix:nonfraction> operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($<ix:nonfraction unitref="usd" contextref="i522df390299349d98c16cb7286a06a1e_D20220101-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTY1MzUyNQ_5416ddc8-efb5-407a-8cda-28f5e82d8b0e">47</ix:nonfraction>&nbsp;million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMzMQ_7c368f4b-d77c-42ed-920c-158e8df2d670" footnoterole="http://www.xbrl.org/2003/role/footnote">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTY0OTI2NzQ0NjUxNTg_ac6803fb-ec6d-447e-b765-42254754a809" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Immunoglobulin (Ig) portfolio includes the revenues from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig. </span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMyNw_be1a8271-a2c8-4eec-93a2-3001ad08e395" footnoterole="http://www.xbrl.org/2003/role/footnote">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Zirabev, Inflectra, Ruxience, Retacrit, and Trazimera.</ix:footnote></span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNDMwNw_95743234-3c54-4c2b-ac3c-691f38de9eec" footnoterole="http://www.xbrl.org/2003/role/footnote">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</ix:footnote></span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $<ix:nonfraction unitref="usd" contextref="i4e9531c688ae4b31893b5f87a304c2d9_I20220403" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTY1NDI4MQ_40e4b2b9-c724-4553-8956-2fb57b254107">30</ix:nonfraction>&nbsp;billion as of April&nbsp;3, 2022, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, we expect to recognize revenue of approximately $<ix:nonfraction unitref="usd" contextref="i1398ecf2c42643d5b2dd9bcf4fff0b09_I20220403" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzODY1Mw_c358b7fa-c357-4b64-bbe2-d6463c00e49d">18</ix:nonfraction> billion in 2022, $<ix:nonfraction unitref="usd" contextref="i450d5b616e06425ebaaee6005832c8fc_I20220403" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzODY2Ng_94916045-21fd-49b1-a98d-dfd4cefbd29b">12</ix:nonfraction> billion in 2023 and $<ix:nonfraction unitref="usd" contextref="i5e9ce103164c49ccb09b4c678fcffc2d_I20220403" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMTA5OTUxMTYzODY4Mg_de8c0a3c-6d57-4baf-8c8b-07ad7053dfbb">300</ix:nonfraction> million in 2024. Remaining performance obligations exclude arrangements with an original expected contract duration of less than one year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2022 and 2021 with various government or government sponsored customers in international markets for supply of Comirnaty and Paxlovid. The deferred revenues associated with the advance payments related to Comirnaty and Paxlovid total $<ix:nonfraction unitref="usd" contextref="i25f04f53b93c4f7d85d0d00977069a9e_I20220403" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjY5MzgwMzQ5MzYzNjY_9eaa4a8c-ceb7-4835-b1db-be6ee11cfc9d">3.3</ix:nonfraction> billion as of April&nbsp;3, 2022 and the deferred revenues associated with the advance payments of Comirnaty total $<ix:nonfraction unitref="usd" contextref="i9d528d42f6414b6dae3a8bb680aeb22c_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjY5MzgwMzQ5MzYzNzk_12b219b6-0d59-40e8-bec8-4f19a7b096f4">3.3</ix:nonfraction> billion as of December 31, 2021, with $<ix:nonfraction unitref="usd" contextref="i25f04f53b93c4f7d85d0d00977069a9e_I20220403" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNjU5NzA2OTgyNTQ5Ng_7d57e7f3-3142-499f-b722-6b75c2386e6b">3.0</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i25f04f53b93c4f7d85d0d00977069a9e_I20220403" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNjU5NzA2OTgyNTUwNA_6813cf47-c519-4b5d-a8df-7eccd3e0100a">258</ix:nonfraction> million recorded in current liabilities and noncurrent liabilities, respectively, as of April&nbsp;3, 2022, and $<ix:nonfraction unitref="usd" contextref="i9d528d42f6414b6dae3a8bb680aeb22c_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNjU5NzA2OTgyNTY0Ng_2a02bfbc-f33f-4059-a1f9-5b41aea3be32">3.0</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i9d528d42f6414b6dae3a8bb680aeb22c_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfNjU5NzA2OTgyNTY1NA_22c0d201-4e92-4762-a541-ed45127464df">249</ix:nonfraction> million recorded in current liabilities and noncurrent liabilities, respectively, as of December 31, 2021. There were <ix:nonfraction unitref="usd" contextref="i7af3306ed56345c389e398557df7f547_I20211231" decimals="INF" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjYzODgyNzkxMzk5NTU_8065bf30-9432-4b46-b395-23d748a8288a">no</ix:nonfraction> deferred revenues associated with Paxlovid as of December 31, 2021. The Comirnaty and Paxlovid deferred revenue balances were effectively unchanged during the first three months of 2022 as amounts recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as we delivered the products to our customers were offset by additional advance payments received as we entered into new or amended contracts, including new advance payments received for Paxlovid contracts, and additional advance payments received as we invoiced customers in advance of product deliveries. During the first quarter of 2022, we recognized revenue of $<ix:nonfraction unitref="usd" contextref="i475612619a5342b28380c77a81b499d6_D20220101-20220403" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJkMWI1NWZhZGQzYjQ5MDY4YmFhNDE5MTg1MWQ0ZGRmL3NlYzoyZDFiNTVmYWRkM2I0OTA2OGJhYTQxOTE4NTFkNGRkZl84OC9mcmFnOmM2NmVmZWIwNGFhYTQ1ZGRhOTM1NTU3MWRiMzNmM2VhL3RleHRyZWdpb246YzY2ZWZlYjA0YWFhNDVkZGE5MzU1NTcxZGIzM2YzZWFfMjgwMzc1NDY1NjQwNzg_cd34e4d4-d98a-4f1f-9926-2c735ea25923">1.6</ix:nonfraction> billion that was included in the balance of Comirnaty deferred revenues as of December 31, 2021. The Comirnaty and Paxlovid deferred revenues as of April&nbsp;3, 2022 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we transfer control of the products to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of April&nbsp;3, 2022 or December 31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_94"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF<br> OPERATIONS</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_97"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and since they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business and Strategy</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments: Biopharma and PC1. Biopharma is the only reportable segment. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which, approximately 80% has been incurred since inception and through the first quarter of 2022. These charges include costs and expenses related to separation of legal entities and transaction costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our business, strategy and operating environment, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2021 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant recent business development activities include the transactions discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the following:</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Biohaven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––In May 2022, we and Biohaven announced that the companies entered into an agreement under which we will acquire Biohaven, the maker of Nurtec® ODT (rimegepant), an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Under the terms of the agreement, we will acquire all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash. The proposed transaction includes the acquisition of Biohaven’s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical CGRP assets. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline compounds, per Biohaven common share. Pfizer will pay transaction consideration totaling approximately $11.6 billion in cash. Pfizer will also make payments at closing to settle Biohaven’s third party debt and for the redemption of all outstanding shares of Biohaven’s redeemable preferred stock.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This agreement follows on the November 2021 collaboration for the commercialization of rimegepant and zavegepant outside the U.S., in connection with which Pfizer acquired 2.6% of Biohaven’s common stock. New Biohaven will also have the right to receive tiered royalties from Pfizer on any annual net sales of rimegepant and zavegepant in the U.S. in excess of $5.25 billion. The proposed transaction is subject to the completion of the New Biohaven spin-off transaction and other customary closing conditions, including receipt of regulatory approvals and approval by Biohaven’s shareholders. The companies expect the transaction to close by early 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of ReViral</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––In April 2022, we and ReViral announced that the companies entered into an agreement under which we will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus. Under the terms of the agreement, we will acquire ReViral for a total consideration of up to $525 million, including upfront and development milestones, subject to customary closing conditions, including receipt of regulatory approvals.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the more significant recent transactions through February&nbsp;24, 2022, the filing date of our 2021 Form 10-K, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our First Quarter 2022 Performance</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $11.1 billion, or 77%, in the first quarter of 2022 to $25.7 billion from $14.5 billion in the first quarter of 2021, reflecting an operational increase of $11.9 billion, or 82%, as well as an unfavorable impact of foreign exchange of $778 million, or 5%. Excluding direct sales and alliance revenues of Comirnaty and sales of Paxlovid, revenues increased 2% operationally, reflecting strong growth in the Prevnar family in the U.S., Eliquis, Vyndaqel/Vyndamax, Oncology biosimilars and Ibrance internationally, partially offset by declines in Chantix/Champix, Xeljanz and Ibrance in the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues in the first quarter of 2022 were unfavorably impacted by approximately $200 million as a result of the first quarter of 2022 having one fewer selling day in the U.S. and one fewer selling day in international markets as compared to the first quarter of 2021. This unfavorable impact is expected to reverse in the fourth quarter of 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geography</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections for more information, including a discussion of key drivers of our revenue performance. For information regarding the primary indications or class of certain products, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $3.4&nbsp;billion in the first quarter of 2022, compared to the same period in 2021, was primarily attributable to higher revenues, partially offset by an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net losses on equity securities in the first quarter of 2022 versus net gains on equity securities in the first quarter of 2021, and increases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our tax provision and effective tax rate, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operating Environment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below, as well as in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business––Government Regulation and Price Constraints </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Operating Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our 2021 Form 10-K.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2022 through 2025. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant in relation to our business as a whole, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business––Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K. For a discussion of recent developments with respect to patent litigation, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A1.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and Access––Government and Other Payer Group Pressures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––Governments globally, as well as private third-party payers in the U.S., may use a variety of measures to control costs, including, among others, proposing pricing reform or legislation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mploying formularies to control costs, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. We anticipate that these and similar initiatives will continue to increase pricing pressures globally. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Pressures and Managed Care Organizations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections in our 2021 Form 10-K and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Supply</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines. This has led to recalls, including our voluntary recall of Chantix in 2021 and additional voluntary recalls initiated for other products in 2022 due to the presence of nitrosamines above the applicable acceptable intake limit, and may lead to additional recalls or other market actions for Pfizer products. For information on our Chantix recall in 2021 and risks related to product manufacturing, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors––Product Manufacturing, Sales and Marketing Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Global Economic Environment</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2021 Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Russia/Ukraine Conflict</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––Our global operations may be impacted by certain factors in the global economic environment including impacts of political or civil unrest or military action, including the conflict between Russia and Ukraine. To date, the financial impacts of the conflict have not been material to our consolidated financial statements. For both the fiscal year ended December 31, 2021 and the fiscal quarter ended April 3, 2022, the business of our Russia and Ukraine subsidiaries represented less than 1% of our consolidated revenues and assets. In March 2022, we announced certain steps we are taking in response to the conflict, which are being taken in addition to the company’s adherence to global sanctions. Consistent with our commitment to putting patients first, we are maintaining the supply of medicines to Russia, including the provision of needed medicines to patients already enrolled in clinical trials. Effective March 14, 2022, Pfizer is donating all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine, in addition to the company’s ongoing efforts to support the humanitarian response in the region. Additionally, we will no longer initiate new clinical trials in Russia, will stop recruiting new patients in our ongoing clinical trials in the country, and will cease all future investments with local suppliers intended to build manufacturing capacity in Russia. While we are monitoring the effects of the armed conflict between Russia and Ukraine, the broader economic consequences of the conflict, including its potential future impact on our business, are currently difficult to predict. Regional instability, geopolitical shifts, potential additional sanctions and other restrictive measures against Russia, neighboring countries or allies of Russia, and any retaliatory measures taken by Russia, neighboring countries or allies of Russia, in response to such measures could adversely affect the global macroeconomic environment, our operations, currency exchange rates and financial markets, which could in turn adversely impact our business.</span></div><div><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––The COVID-19 pandemic has impacted our business, operations and financial condition and results. </span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Response to COVID-19</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has helped lead the global effort to confront the COVID-19 pandemic by advancing a vision for industry-wide collaboration while making significant investments in breakthrough science and global manufacturing.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Comirnaty/BNT162b2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">We have collaborated with BioNTech to jointly develop Comirnaty/BNT162b2, a mRNA-based coronavirus vaccine to help prevent COVID-19. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Developments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of this MD&amp;A. We continue to evaluate our vaccine, including for additional pediatric indications, and the short- and long-term efficacy of Comirnaty. We are also studying vaccine candidates to potentially prevent COVID-19 caused by new and emerging variants or an updated vaccine as needed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">The companies have entered into agreements to supply pre-specified doses of Comirnaty in 2022 with multiple developed and emerging countries around the world and are continuing to deliver doses of Comirnaty to governments under such agreements. We also signed agreements with multiple countries to supply Comirnaty doses in 2023 and are currently negotiating similar potential agreements with multiple other countries. We anticipate delivering at least two billion doses to low- and middle-income countries by the end of 2022—one billion that was delivered in 2021 and one billion expected to be delivered in 2022, with the possibility to increase those deliveries if more orders are placed by these countries for 2022. One billion of the aforementioned doses to low- and middle-income countries are being supplied to the U.S. government at a not-for-profit price to be donated to the world’s poorest nations at no charge to those countries.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.59pt">As of May 3, 2022, we forecasted approximately $32&nbsp;billion in revenues for Comirnaty in 2022, with gross profit to be split evenly with BioNTech, which includes doses expected to be delivered in fiscal 2022 under contracts signed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of mid-April 2022. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Paxlovid</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">In December 2021, the FDA authorized the emergency use of Paxlovid, a novel oral COVID-19 treatment, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid has been granted an authorization or approval in many other countries. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Developments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of this MD&amp;A.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">We continue to evaluate Paxlovid in other populations, including in patients with a confirmed diagnosis of SARS-CoV-2 infection who are at standard risk (i.e., low risk of hospitalization or death) (Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard Risk Patients)) and in non-hospitalized, symptomatic, pediatric patients with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease (Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients)). In April 2022, Pfizer announced that the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met in the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">We have entered into agreements with multiple countries to supply pre-specified courses of Paxlovid, such as the U.S. and U.K. Additionally, we have signed a voluntary non-exclusive license agreement with the Medicines Patent Pool (MPP) to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share intellectual property related to our oral COVID-19 treatment to enable qualified generic medicine manufacturers worldwide to manufacture and supply generic versions of this treatment to 95 low- and middle-income countries, pending authorization or approval, covering up to approximately 53% of the world’s population. MPP has entered into sublicense agreements with 36 generic manufacturers. In addition, in March 2022, Pfizer entered into an agreement with UNICEF to supply up to 4 million treatment courses of Paxlovid to 95 low- and middle-income countries, pending authorization or approval. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.25pt">Pfizer has capacity to manufacture up to 120 million treatment courses by the end of 2022 (and is on track to produce 30 million courses in the first half of 2022 with the ability to produce the remaining 90 million courses in the second half of 2022), depending on the global need, which will be driven by purchase agreements.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">As of May 3, 2022, we forecasted approximately $22&nbsp;billion of revenues for Paxlovid in 2022, which includes treatment courses expected to be delivered in fiscal 2022, primarily relating to supply contracts signed or committed as of mid-April 2022.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of COVID-19 on Our Business and Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our on-going monitoring and assessment, we have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration, severity and the global macroeconomic impact of the pandemic, as well as COVID-19 vaccine and oral COVID-19 treatment revenues, supply and contracts, which remain dynamic. Despite careful tracking and planning, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&amp;D and corporate enabling functions globally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our 2021 Form 10-K, apart from our introduction of Comirnaty/BNT162b2 and Paxlovid, our business and operations were impacted by the pandemic in various ways; certain of those impacts have continued in 2022. For additional detail and discussion on the impact of the COVID-19 pandemic on certain of our products, sales and marketing, supply chain and clinical trials, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income—Revenues by Geography </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenues—Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections within this MD&amp;A and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook—The Global Economic Environment—COVID-19 Pandemic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2021 Form 10-K. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the pandemic. Future developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, if demand for our products is significantly reduced as a result of the COVID-19 pandemic, or if demand for our COVID-19 vaccine or oral COVID-19 treatment is reduced or no longer exists, we could experience a material adverse impact on our business, operations and financial condition and results. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors—COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2021 Form 10-K.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_100"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Fair Value (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Asset Impairments (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Tax Assets and Liabilities and Income Tax Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Pension and Postretirement Benefit Plans (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2021 Form 10-K. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K for a discussion about the risks associated with estimates and assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of a recently adopted accounting standard, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of presentation changes for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_103"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_106"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues by Geography</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents worldwide revenues by geography:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">World-wide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inter-national</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">% Change in Revenues</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating segments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,323&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,125&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,816&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,378&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,507&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,747&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer CentreOne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,661&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,516&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,918&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,530&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,743&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,985&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">First Quarter of 2022 vs. First Quarter of 2021</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following provides an analysis of the change in worldwide revenues by geographic areas in the first quarter of 2022:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended April 3, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Growth from Comirnaty, Paxlovid, Prevnar family, Eliquis, Vyndaqel/Vyndamax, Biosimilars, Ibrance and Inlyta, partially offset by a decline from Xeljanz, while Xtandi was flat. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within MD&amp;A for additional analysis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,367&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,603&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Decline from PC1. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> within MD&amp;A for additional analysis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lower revenues for Chantix/Champix, Sutent and Enbrel: </span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">The decrease in Chantix/Champix was driven by the ongoing global pause in shipments of Chantix due to the presence of N-nitroso-varenicline above an acceptable level of intake set by various global regulators, the ultimate timing for resolution of which may vary by country</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">The decrease for Sutent primarily reflects lower volume demand in the U.S. resulting from its loss of exclusivity in August 2021, as well as continued erosion as a result of increased competition in certain international developed markets</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">The decrease for Enbrel internationally primarily reflects continued biosimilar competition, which is expected to continue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(204)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operational growth, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,923&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,387&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,536&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,145&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,387&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,758&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets revenues increased $4.5 billion, or 161%, in the first quarter of 2022 to $7.4 billion from $2.8 billion in the first quarter of 2021, reflecting an operational increase of $4.8 billion, or 169%, and an unfavorable impact from foreign exchange of approximately 8%. The operational increase in emerging markets was primarily driven by growth from Comirnaty and revenues from Paxlovid.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents information about revenue deductions:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns and cash discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,458&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our accruals for revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_109"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues––Selected Product Discussion</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biopharma</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.328%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="27" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$13,227</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></div></td><td colspan="3" rowspan="27" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,314&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,038&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Driven by global uptake including pediatric and booster doses following a growing number of regulatory approvals and temporary authorizations.  </span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,913&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,424&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,227&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,462&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliquis</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,793</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 12%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,080&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">981&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Global growth driven primarily by continued oral anti-coagulant adoption and market share gains in non-valvular atrial fibrillation, partially offset by the non-recurrence of an $80 million favorable adjustment related to the Medicare “coverage gap” provision recorded in the first quarter of 2021.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">713&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">662&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,793&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,643&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Prevnar family</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,565</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up 23% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,014&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Growth driven by strong retail and wholesaler stocking in the U.S. of Prevnar 20 for the adult indication and favorable timing of government purchases of Prevnar 13 for the pediatric indication, partially offset by declines in the Prevnar 13 adult indication internationally due to disruptions to healthcare activity related to COVID-19, including the continued prioritization of COVID-19 vaccinations and booster doses. </span></div></td></tr><tr style="height:18pt"><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,284&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paxlovid</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,470</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;* </span></div><div style="text-align:center"><span><br></span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,015&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Driven by the U.S. launch in December 2021 and international launches in late 2021 and early 2022 following regulatory approvals or temporary authorizations.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">455&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ibrance</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,237</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 1%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">753&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth driven primarily by accelerating demand internationally as the delays in diagnosis and treatment initiations caused by the COVID-19 pandemic show signs of recovery across several international markets, partially offset by a decline in the U.S., primarily driven by an increase in the proportion of patients accessing Ibrance through our Patient Assistance Program.</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">484&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">460&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,237&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,254&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vyndaqel/ <br>Vyndamax</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$612</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 41%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">265&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily driven by continued strong uptake of the ATTR-CM indication in developed Europe, the U.S. and Japan.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">612&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xeljanz</span></td><td colspan="3" rowspan="34" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$372</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Down 29% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" rowspan="34" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Decline driven primarily by decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to JAK class label changes and, to a lesser extent, unfavorable wholesaler inventory buying patterns and declines in net price in the U.S. due to unfavorable changes in channel mix.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">372&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">538&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$268</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Flat  </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance driven by consistent demand across the mCRPC, nmCRPC and mCSPC indications, offset primarily by a lag in new patient starts as a consequence of delays in diagnosis and treatment due to COVID-19.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inlyta</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$234</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 4% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily reflects continued adoption in emerging markets and developed Europe of combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$605</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 16% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Growth mainly driven by oncology biosimilars primarily due to strong U.S. growth of Zirabev, Ruxience and Retacrit, partially offset by decreases in Inflectra globally as a result of competitive pressures for certain biosimilars.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">605&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">530&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer CentreOne</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Segment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April. 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PC1</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$338</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Down 11%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Decline is driven by lower manufacturing of divested products under manufacturing and supply agreements and COVID-19 manufacturing activities performed on behalf of customers, partially offset by timing of Comirnaty supply to BioNTech.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">338&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Comirnaty includes direct sales and alliance revenues related to sales of the Pfizer-BioNTech COVID-19 vaccine, which are recorded within our Vaccines therapeutic area. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the Pfizer CentreOne contract development and manufacturing operation. Revenues related to these manufacturing activities totaled $47&nbsp;million for the first quarter of 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&nbsp;&nbsp;&nbsp;&nbsp;Calculation is not meaningful or results are equal to or greater than 100%.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K for information regarding the expiration of various patent rights, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the primary indications or class of the selected products discussed.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_112"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Developments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comprehensive update of Pfizer’s development pipeline was published as of May&nbsp;3, 2022 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes only approvals for products that have occurred in the last twelve months and generally does not include approvals that may have occurred prior to that time. The table includes filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.796%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DISEASE AREA</span></td><td colspan="9" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">APPROVED/FILED*</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">JAPAN</span></td></tr><tr style="height:27pt"><td colspan="3" rowspan="4" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comirnaty/BNT162b2</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(PF-07302048)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (16 years of age and older)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">BLA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Aug. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dec. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (12-15 years of age)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">EUA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&nbsp;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">CMA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&nbsp;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (booster)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">EUA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&nbsp;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (5-11 years of age)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">CMA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&nbsp;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2022</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cibinqo<br>(abrocitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Atopic dermatitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Xeljanz <br>(tofacitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ankylosing spondylitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Myfembree</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(relugolix fixed dose combination)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Uterine fibroids (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Endometriosis (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Lorbrena/Lorviqua </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(lorlatinib)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">First-line ALK-positive NSCLC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Ngenla</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(somatrogon)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pediatric growth hormone deficiency</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Prevnar 20/Apexxnar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Vaccine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent invasive and non-invasive pneumococcal infections (adults)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">TicoVac<br>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent tick-borne encephalitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;Aug. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">Paxlovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">(nirmatrelvir [PF-07321332]; ritonavir)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EUA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">Vydura</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">(rimegepant)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Acute migraine</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:27pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Migraine prevention</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Apr. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:5.25pt">For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with BioNTech. Prior to BLA, Comirnaty/BNT162b2 for ages 16 and up was available in the U.S. pursuant to an EUA from the FDA on December 11, 2020. In December 2021, a supplemental BLA was submitted to the FDA requesting to expand the approval of Comirnaty to include individuals ages 12 through 15 years. In February 2022, following a request from the FDA, a rolling submission seeking to amend the EUA to include children 6 months through 4 years of age (6 months to &lt;5 years of age) was initiated as we wait for data evaluating a third 3 µg dose given at least two months after the second dose of the two-dose series in this age group. A booster dose received EUA from the FDA on September 22, 2021 for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. In addition, in October 2021, the FDA authorized for emergency use a booster dose to eligible individuals who have completed primary vaccination with a different authorized </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">COVID-19 vaccine. Subsequently, the FDA expanded the booster EUA: (i) in November 2021 to include individuals 18 years of age and older, (ii) in December 2021 to include individuals 16 years of age and older, (iii) in January 2022 to include individuals 12 years of age and older as well as individuals 5 through 11 years of age who have been determined to have certain kinds of immunocompromise and (iv) in March 2022 to include a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine and a second booster dose for individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine. A booster dose received conditional marketing authorization from the EMA in October 2021 for individuals 18 years of age and older and may be given to individuals 5 years and older with a severely weakened immune system, at least 28 days after their second dose. Subsequently, the EMA expanded the booster CMA in February 2022 to include individuals 12 years of age and older. A booster dose received approval in Japan in November 2021 for 18 years of age and older. In April 2022, we and BioNTech submitted an application to the FDA for EUA of a booster dose for children 5 through 11 years of age.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with Myovant. In May 2022, the FDA extended the review period for the sNDA for Myfembree (relugolix fixed dose combination) for the management of moderate to severe pain associated with endometriosis. The FDA requires extended time to review additional information requested by the FDA from the companies regarding bone mineral density. The extended Prescription Drug User Fee Act goal date is August 6, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with OPKO. In January 2022, Pfizer and OPKO received a Complete Response Letter (CRL) from the FDA for the BLA for somatrogon. Discussions are ongoing with the FDA regarding the CRL and how to best address their concerns.  </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">In October 2021, the CDC’s ACIP voted to recommend Prevnar 20 for routine use in adults. Specifically, the ACIP voted to recommend the following: (i) adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either pneumococcal 20-valent conjugate vaccine (PCV20) or pneumococcal 15-valent conjugate vaccine (PCV15)). If PCV15 is used, this should be followed by a dose of pneumococcal polysaccharide vaccine (PPSV23); and (ii) adults aged 19 years of age or older with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23. The recommendations were published in the Morbidity and Mortality Weekly Report on January 28, 2022. The publication also notes “for adults who have received pneumococcal conjugate vaccine (PCV13) but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of Prevnar 20 may be used if PPSV23 is not available.”</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">In December 2021, the FDA authorized the emergency use of Paxlovid for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. In January 2022, the EMA approved the CMA of Paxlovid for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.14pt">Under a commercialization arrangement with Biohaven.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, in light of the results from the completed required postmarketing safety study of Xeljanz, ORAL Surveillance (A3921133), the U.S. label for Xeljanz was revised. In addition, at the request of the EC, the PRAC of the EMA has adopted a referral procedure under Article 20 of Regulation (EC) No 726/2004 to assess safety information relating to oral JAK inhibitors authorized for inflammatory diseases, including Xeljanz and Cibinqo, which is ongoing. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors—Post-Authorization/Approval Data </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> the Product Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections of our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the following products received regulatory approvals in the last twelve months: Cresemba for fungal infection and Besponsa for second line acute lymphoblastic leukemia, both in December 2021; Paxlovid for COVID-19 infection in February 2022; Cibinqo for atopic dermatitis in April 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="14" style="border-left:0.5pt solid #000;border-right:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:7.2pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-metastatic high-risk castration sensitive prostate cancer</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for first-line mCRPC</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for DNA Damage Repair (DDR)-deficient mCSPC</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06482077 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunization to prevent invasive and non-invasive pneumococcal infections (pediatric)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">somatrogon (PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Adult growth hormone deficiency</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">First-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">-mutant mCRC</span></div></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Myfembree</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(relugolix fixed dose combination)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with estradiol and norethindrone acetate for contraceptive efficacy</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> (pembrolizumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">-mutant metastatic or unresectable locally advanced melanoma</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BNT162b2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(PF-07302048)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (children 2 to &lt;5 years of age)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (infants 6 months to &lt;24 months)</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Paxlovid (nirmatrelvir [PF-07321332]; ritonavir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">COVID-19 infection (standard</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> risk population)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">COVID-19 infection (</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">post exposure prophylaxis)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">COVID-19 infection (</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">pediatric)</span></div></td></tr><tr style="height:21pt"><td colspan="3" rowspan="15" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">aztreonam-avibactam<br>(PF-06947387)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Treatment of infections caused by Gram-negative bacteria</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">fidanacogene elaparvovec (PF-06838435)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Hemophilia B</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">giroctocogene fitelparvovec </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(PF-07055480)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Hemophilia A</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06425090 (Vaccine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(k)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent primary clostridioides difficile infection</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06886992 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent serogroups meningococcal infection (adolescent and young adults)</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06928316 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent respiratory syncytial virus infection (maternal)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent respiratory syncytial virus infection (older adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-07265803</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dilated cardiomyopathy due to Lamin A/C gene mutation</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Alopecia areata</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">fordadistrogene movaparvovec (PF-06939926)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Duchenne muscular dystrophy</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">marstacimab (PF-06741086)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Hemophilia</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">elranatamab (PF-06863135)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Multiple myeloma, double-class exposed</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Omicron-based mRNA vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(l)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Immunization to prevent COVID-19 (adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Etrasimod (PF-07915503)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Ulcerative colitis (moderately to severely active)</span></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with The Alliance Foundation Trials, LLC.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with OPKO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.14pt">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with BioNTech.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:112%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:112%;padding-left:3.33pt">In April 2022, Pfizer shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study in adults living in the same household as someone with a confirmed COVID-19 infection observing a risk reduction of 32% and 37% in adults who received Paxlovid for five and ten days, respectively, to prevent infection. These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met. For additional information on Paxlovid, please see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:112%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:112%"> section of this MD&amp;A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with Spark Therapeutics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with Sangamo Therapeutics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">In March 2022, Pfizer announced results from the CLOVER trial, a pivotal Phase 3 study evaluating its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> (C. difficile) vaccine candidate (PF-06425090) in the prevention of C. difficile infection (CDI). Initial analyses of two protocol defined secondary endpoints indicated a favorable benefit in reducing CDI severity and 100% vaccine efficacy in preventing medically attended CDI, although the trial did not meet its pre-specified primary endpoint of prevention of primary CDI. Safety reviews indicated that the investigational vaccine was safe and well tolerated. Pfizer is evaluating next steps for the program in coordination with regulatory agencies.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with BioNTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_115"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COSTS AND EXPENSES</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.835%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br>&nbsp;Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,984&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,157&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Percentage of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38.9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28.6&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,777&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,301&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,994&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">355&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">835&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">858&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">192&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions—net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">350&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="21" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></td></tr></tbody></table></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $5.8 billion, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of Comirnaty, which includes a charge for the 50% gross profit split with BioNTech and applicable royalty expenses; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of Paxlovid,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the favorable impact of foreign exchange rates.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percentage of revenues was primarily due to the impact of Comirnaty as discussed above, partially offset by the favorable impact of Paxlovid, foreign exchange rates, and an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Informational and Administrative (SI&amp;A) Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI&amp;A expenses decreased $184 million, mostly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower spending for corporate enabling functions;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a decrease in our liability to be paid to participants of our supplemental savings plan;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower spending within the Biopharma segment, excluding COVID-19 products; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the favorable impact of foreign exchange,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increased spending on Paxlovid and Comirnaty.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased $307 million primarily driven by increased investments across multiple late-stage clinical programs, as well as additional spending on programs to prevent and treat COVID-19.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development (IPR&amp;D) Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses increased $336 million largely due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an upfront payment to Biohaven and a premium paid on our equity investment in Biohaven; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a premium paid on our equity investment in BioNTech to develop a potential mRNA vaccine against shingles.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets decreased $24 million, primarily as a result of lower amortization of Comirnaty sales milestones to BioNTech.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Transforming to a More Focused Company Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––For a description of our program, as well as the anticipated and actual costs, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program savings discussed below may be rounded and represent approximations. In connection with restructuring our corporate enabling functions, we expect gross cost savings of $1.0&nbsp;billion, or net cost savings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, to be achieved primarily from 2021 through 2022. In connection with transforming our marketing strategy, we expect net cost savings of $1.3&nbsp;billion, to be achieved primarily from 2022 through 2024. In connection with manufacturing network optimization, we expect net cost savings of $550 million to be achieved primarily from 2020 through 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain qualifying costs for this program were recorded in the first quarters of 2022 and 2021 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of this MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to this program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Deductions—Net </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period-over-period change was primarily driven by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">net losses on equity securities in the first quarter of 2022 versus net gains recognized in the first quarter of 2021; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower income from collaborations, out-licensing arrangements and sales of compound/product rights.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_118"></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROVISION/(BENEFIT) FOR TAXES ON INCOME</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br>Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,172&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">808&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate on continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.9&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.2&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_1632"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCONTINUED OPERATIONS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our discontinued operations, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_121"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP reported performance measures. As such, we believe that investors’ understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations––the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide––prior to considering certain income statement elements as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relevance of Metrics to Our Business Performance</span></td></tr><tr style="height:101pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">before the impact of amortization of intangible assets, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors useful information to:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">assist in modeling expected future performance on a normalized basis</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:66pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, each before the impact of amortization of intangible assets, acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders––diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> before the impact of amortization of intangible assets, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part versus three budgeted metrics, one of which is Adjusted diluted EPS (as defined for annual incentive compensation purposes), which is derived from Adjusted income and accounts for 40% of the bonus pool funding tied to financial performance. Additionally, the payout for performance share awards is determined in part by Adjusted net income, which is derived from Adjusted income. Beginning in the first quarter of 2022, we no longer exclude any expenses for acquired IPR&amp;D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">annual incentive compensation purposes. The bonus pool funding, which is largely based on financial performance, will be modified by our R&amp;D performance as measured by four metrics relating to our pipeline and performance against our environmental, social and governance (ESG) metrics and may be further modified by our Compensation Committee’s assessment of other factors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders—diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first quarter of 2022, our reconciliation of certain GAAP reported to non-GAAP adjusted information is updated to reflect the following, and prior period information has been revised to conform to the current period presentation:</span></div><div><span><br></span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjusted Income and Adjusted Diluted EPS</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Non-GAAP Adjusted financial measures include expenses for all acquired IPR&amp;D costs incurred in connection with upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities, as well as asset acquisitions of acquired IPR&amp;D. Previously, certain of these items were excluded from our non-GAAP adjusted results. Acquired IPR&amp;D expenses that previously would have been excluded from non-GAAP Adjusted income but are now included in both GAAP Reported income and non-GAAP Adjusted income were approximately $339&nbsp;million pre-tax ($276&nbsp;million, net of tax), or $0.05 per share, in the first quarter of 2022, and had no impact in the first quarter of 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—We began excluding all amortization of intangibles from non-GAAP Adjusted income, compared to excluding only amortization of intangibles related to large mergers or acquisitions under the prior methodology, and presenting it as a separate reconciling line. Previously, the adjustment under the prior methodology was included as part of a reconciling line entitled “Purchase accounting adjustments” that we no longer separately present. The impact of this policy change resulted in benefits of $0.01 on Adjusted diluted EPS in the first quarter of 2022 and $0.02 in the first quarter of 2021.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Adjusted income continues to exclude acquisition-related items, which are comprised of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies. Beginning in the first quarter of 2022, acquisition-related items may now include the following purchase accounting impacts that previously would have been included as part of a reconciling line entitled “Purchase accounting adjustments” that we no longer separately present: (i) the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, (ii) depreciation related to the increase/decrease in fair value of acquired fixed assets, (iii) amortization related to the increase in fair value of acquired debt and (iv) the fair value changes for contingent consideration. </span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Adjusted income continues to exclude the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our therapeutic areas and product lines for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Adjusted income continues to exclude certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Gains and losses on equity securities, and pension and postretirement actuarial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remeasurement gains and losses have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of GAAP Reported to Non-GAAP Adjusted information—Certain Line Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a non-inclusive list of certain significant items and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2021 Annual Report on Form 10-K for additional information.</span></div><div><span><br></span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Three Months Ended April 3, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders––diluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">350</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">835&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(698)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">698&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">72&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision—non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,958&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,496&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(406)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,338&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.62&nbsp;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="48" style="padding:0 1pt"></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.403%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Three Months Ended April 4, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders––diluted</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,004)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">870&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">105&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(399)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">167&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision—non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(159)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,127&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,643&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(601)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,351&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.95&nbsp;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP reported income from continuing operations were: 12.9% in the three months ended April 3, 2022 and 14.2% in the three months ended April 4, 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our effective tax rates on non-GAAP adjusted income were: 14.8% in the three months ended April 3, 2022 and 15.4% in the three months ended April 4, 2021.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Acquisition-related items in the three months ended April 3, 2022 primarily represent integration and other costs for the acquisition of Arena in March 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Relates to the previously divested Meridian subsidiary, Mylan-Japan collaboration and Upjohn Business. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">For the three months ended April 3, 2022, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $104&nbsp;million primarily includes charges for certain legal matters of $79&nbsp;million. For the first quarter of 2021, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $87&nbsp;million primarily includes charges of $49&nbsp;million representing our equity-method accounting pro rata share of restructuring charges and costs of preparing for separation from GSK recorded by the GSK Consumer Healthcare JV. The first quarters of 2022 and 2021 include insignificant reconciling amounts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="51" style="padding:0 1pt"></td></tr></tbody></table></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_124"></div><div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Continuing Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:49.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drivers of change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,541&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The change was driven primarily by (i) higher net income adjusted for non-cash items, including an increase from non-cash unrealized losses on equity securities recognized in the first quarter of 2022, compared to unrealized gains recognized in the first quarter of 2021, partially offset by (ii) a decrease in the change in amounts due to BioNTech for the gross profit split for Comirnaty and a decrease in the change in deferred revenues. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Notes 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,746)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change was driven mainly by an $8.0&nbsp;billion increase in redemptions of short-term investments with original maturities of greater than three months and a $4.4&nbsp;billion increase in net proceeds from short-term investments with original maturities of three months or less, partially offset by $6.2 billion cash paid for the acquisition of Arena, net of cash acquired, and a $2.7&nbsp;billion increase in purchases of short-term investments with original maturities of greater than three months.</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities from continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,578)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,807)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change was driven mostly by $2.0 billion purchases of the Company’s common stock and a $1.6&nbsp;billion increase in repayments of long-term debt.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Discontinued Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from discontinued operations primarily relate to the previously divested Meridian subsidiary, Mylan-Japan collaboration and Upjohn Business (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_127"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our significant operating cash flows, which is a key strength of our liquidity and capital resources and our primary funding source, as well as our financial assets, access to capital markets, revolving credit agreements, and available lines of credit, we believe that we have, and will maintain, the ability to meet our liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future. For additional information, including information about off-balance sheet arrangements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2021 Form 10-K. For information about the sources and uses of our funds, as well as our operating cash flows, see our condensed consolidated statements of cash flows, condensed consolidated balance sheets, condensed consolidated statements of equity, and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A. For information on our money market funds, available-for sale-debt securities and long-term debt, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Capacity––Lines of Credit</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&nbsp;3, 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we had access to a $7 billion committed U.S. revolving credit facility expiring in 2026, which may be used for general corporate purposes including to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have provided us an additional $348 million in lines of credit, of which $319 million expire within one year. Essentially all lines of credit were unused as of April&nbsp;3, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Allocation Framework</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation framework is devised to facilitate (i) the achievement of medical breakthroughs through R&amp;D investments and business development activities and (ii) returning capital to shareholders through dividends and share repurchases. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our 2021 Form 10-K. In April 2022, our BOD declared a dividend of $0.40 per share, payable on June 10, 2022, to shareholders of record at the close of business on May 13, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we purchased 39&nbsp;million shares of our common stock at a cost of $2.0 billion under our</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">publicly announced share purchase plan. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 2 for more information. At April&nbsp;3, 2022, our remaining share-purchase authorization was approximately $3.3 billion. </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about off-balance sheet arrangements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2021 Form 10-K. For more information on guarantees and indemnifications, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2022, in connection with GSK’s previously announced planned demerger, the Consumer Healthcare JV issued notes of $8.75 billion, €2.35 billion and £700 million with various maturities. GSK has guaranteed the notes and we have agreed to indemnify GSK for 32% of any amount payable by GSK. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Conditions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in our second quarter of 2022, our operations in Turkey function in a hyperinflationary economy. The impact to Pfizer is not considered material. For more information about global economic conditions, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook—The Global Economic Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within this MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our diverse sources of funds, global economic conditions, and information about credit ratings, market risk and LIBOR, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within MD&amp;A in our 2021 Form 10-K.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_130"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Standard, Not Adopted as of April&nbsp;3, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect on the Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reference rate reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> provides temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The new guidance provides the following optional expedients: </span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.25pt">Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.25pt">Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.25pt">Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elections can be adopted prospectively at any time through December 31, 2022.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We are assessing the impact, but currently do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr></tbody></table></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_133"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity and potential benefits;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-Q includes statements relating to specific future actions and effects, including, among others, our efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty and Paxlovid, and any potential future vaccines or treatments; the forecasted revenue, demand, manufacturing and supply of Comirnaty and Paxlovid; our expectations regarding the impact of COVID-19 on our business; the expected impact of patent expiries and competition from generic manufacturers; the expected pricing pressures on our products and the anticipated impact to our business; the availability of raw materials for 2022; the expected charges and/or costs in connection with the spin-off of the Upjohn Business and its combination with Mylan; the benefits expected from our business development transactions; our anticipated liquidity position; the anticipated costs and savings from certain of our initiatives, including our Transforming to a More Focused Company program; and our planned capital spending.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2021 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form  10-Q. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2021 Form 10-K and within this MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below or in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2021 Form 10-K, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business, Industry and Operations, and Business Development</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of R&amp;D activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; the impact of recommendations by technical or advisory committees; and the timing of pricing approvals and product launches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or actions by regulatory authorities based on analysis of ORAL Surveillance or other data, including on other JAK inhibitors in our portfolio;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic), including the impact of vaccine mandates where applicable, on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&amp;D and clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to develop and commercialize a vaccine to help prevent COVID-19 and an oral COVID-19 treatment, as well as challenges related to their manufacturing, supply and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks related to our ability to achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments, including, among other things, whether and when additional supply or purchase agreements will be reached, the risk that demand for any products may be reduced or no longer exist and the possibility that COVID-19 will diminish in severity or prevalence or disappear entirely, which may lead to reduced revenues or excess inventory;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines or vaccines in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; and any significant issues related to our JVs and other third-party business arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, civil unrest or military action;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as the impact of political unrest or civil unrest or military action, including the ongoing conflict between Russia and Ukraine and the related economic consequences, unstable governments and legal systems and inter-governmental disputes;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and the adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation;</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., including, among others, potential adoption of global minimum taxation requirements and potential changes to existing tax law by the current U.S. Presidential administration and Congress;</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property, Technology and Security</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any business disruption, theft of confidential or proprietary information, extortion or integrity compromise resulting from a cyber-attack or other malfeasance by third parties, including, but not limited to, nation states, employees, business partners or others;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and</span></div><div style="margin-bottom:8pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to protect our patents and other intellectual property, such as against claims of invalidity that could result in LOE, including challenges faced by our collaboration or licensing partners to the validity of their patent rights, unasserted intellectual property claims and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products, including our vaccine to help prevent COVID-19 and our oral COVID-19 treatment.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_136"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item is incorporated by reference from the discussion in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2021 Form 10-K.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_139"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_142"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART II.&nbsp; OTHER INFORMATION</span></td></tr></tbody></table></div><div><span><br></span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_148"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Operating Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Information and Factors That May Affect Future Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A of this Form 10-Q and of our 2021 Form 10-K and to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the first quarter of 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Paid per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:700;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Approximate Value of Shares That May Yet Be Purchased Under the Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 1 through January 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,741&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58.40&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 31 through February 27, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,581,474&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">46.91&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">February 28 through April&nbsp;3, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,650,890&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">50.86&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,139,431&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">51,246,105&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">50.12&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,139,431&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In addition to amounts purchased under our share repurchase program, these columns represent (i) 12,104,268 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 2,406 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_163"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh311x0403202210q.htm">Exhibit 31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh312x0403202210q.htm">Exhibit 31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh321x0403202210q.htm">Exhibit 32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh322x0403202210q.htm">Exhibit 32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EX-101.SCH<br>EX-101.CAL<br>EX-101.LAB<br>EX-101.PRE<br>EX-101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema<br>Inline XBRL Taxonomy Extension Calculation Linkbase<br>Inline XBRL Taxonomy Extension Label Linkbase<br>Inline XBRL Taxonomy Extension Presentation Linkbase<br>Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></tbody></table></div><div id="i2d1b55fadd3b49068baa4191851d4ddf_166"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer B. Damico</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer B. Damico<br>Senior Vice President and Controller<br>(Principal Accounting Officer and<br>Duly Authorized Officer)</span></td></tr></tbody></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div>
</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>